



(43) International Publication Date
19 October 2017 (19.10.2017)

- (51) **International Patent Classification:**
C07D 413/12 (2006.01) C07D 271/06 (2006.01)
- (21) **International Application Number:**
PCT/EP2017/058839
- (22) **International Filing Date:**
12 April 2017 (12.04.2017)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
2016 11012875 12 April 2016 (12.04.2016) IN
- (71) **Applicant:** SYNGENTA PARTICIPATIONS AG
[CH/CH]; Schwarzwaldallee 215, 4058 Basel (CH).
- (72) **Inventors:** STIERLI, Daniel; Syngenta Crop Protection
AG Schaffhauserstrasse, 4332 Stein (CH). HOFFMAN,
Thomas, James; Syngenta Crop Protection AG Schaff-
hauserstrasse, 4332 Stein (CH). POULIOT, Martin; Syn-
genta Crop Protection AG Schaffhauserstrasse, 4332 Stein
(CH). RAJAN, Ramya; Syngenta Biosciences Private
Limited Santa Monica Works, Corlim Ilhas, Goa 403 110
(IN).
- (74) **Agent:** SYNGENTA INTERNATIONAL AG; Schwar-
zwaldallee 215 (WRO B8-Z1-30), 4058 Basel (CH).
- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,
TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) **Title:** MICROBICIDAL OXADIAZOLE DERIVATIVES




(57) **Abstract:** Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially fungicides.

Microbiocidal Oxadiazole Derivatives

The present invention relates to microbiocidal oxadiazole derivatives, e.g., as active ingredients, which have microbiocidal activity, in particular, fungicidal activity. The invention also relates to 5 agrochemical compositions which comprise at least one of the oxadiazole derivatives, to processes of preparation of these compounds and to uses of the oxadiazole derivatives or compositions in agriculture or horticulture for controlling or preventing infestation of plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, preferably fungi.

10 Phenyl oxadiazole derivatives are known from WO 1994/05153 and EP 0 276 432. WO 2015/185485 describes the use of substituted oxadiazoles for combating phytopathogenic fungi.

According to the present invention, there is provided a compound of formula (I):



15 wherein

A^1 represents N or CR^1 , wherein R^1 represents hydrogen, halogen, methyl, ethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, or difluoromethoxy;

20 A^2 represents N or CR^2 , wherein R^2 represents hydrogen, halogen, methyl, ethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, or difluoromethoxy;

A^3 represents N or CR^3 , wherein R^3 represents hydrogen or fluoro;

25 A^4 represents N or CR^4 , wherein R^4 represents hydrogen or fluoro; and

wherein no more than two of A^1 to A^4 are N;

R^5 and R^6 are independently selected from hydrogen, halogen, cyano, methyl, ethyl, methoxy or 30 Ci-2haloalkyl; or

R^5 and R^6 together with the carbon atom to which they are attached form a C_{3-6} cycloalkyl ring;

n is 1 or 2;

35

L^1 represents -O-, -C(O)O-, -(R^8)NC(O)O- or -(R^{10})C=N-O-;

R^7 represents Ci-ealkyl, C₃-ealkenyl, C₃-ealkynyl, cyanoCi -ealkyl, C₁-ehaloalkyl, C₃-ehaloalkenyl, hydroxyCi -ealkyl, Ci-4alkoxyCi-6alkyl, Ci-4alkoxyCi-6alkoxy, Ci-2haloalkoxyCi-6alkyl or -CH=N-O-C₁₋₄alkyl; or

5

R^7 represents C₃-scycloalkyl wherein the cycloalkyl moiety is optionally partially unsaturated, phenyl, heteroaryl bonded to L¹ through a carbon atom wherein the heteroaryl moiety is a 5- or 6-membered monocyclic aromatic ring which comprises 1, 2, 3 or 4 heteroatoms individually selected from N, O and S, heterocyclyl bonded to L¹ through a carbon atom wherein the heterocyclyl moiety is 10 a 4- to 6-membered non-aromatic ring which comprises 1, 2 or 3 heteroatoms individually selected from N, O and S, and wherein C₃-scycloalkyl, phenyl, heteroaryl, and heterocyclyl are optionally substituted by 1, 2, or 3 substituents, which may be the same or different, selected from R⁹;

wherein when R^7 represents C₃-scycloalkyl or heterocyclyl, the C₃-scycloalkyl moiety or the 15 heterocyclyl moiety is optionally substituted by 1 or 2 oxo groups;

R^8 represents hydrogen, Ci-4alkyl, Ci-4alkoxy or methylcarbonyl;

R^9 represents cyano, halogen, hydroxy, Ci-4alkyl, Ci-4haloalkyl, Ci-4alkoxy, Ci-4haloalkoxy, Ci- 20 4alkylcarbonyl, Ci-4alkoxycarbonyl, aminocarbonyl, C₁₋₄alkylaminocarbonyl, diCi-4alkylaminocarbonyl; and

R^{10} is C₁₋₄alkyl; or

when L¹ is -C(O)O- or -(R¹⁰)C=N-O-, R^7 may be a heterocyclyl ring comprising a nitrogen atom, wherein the heterocyclyl is bonded to L¹ through the nitrogen atom, and wherein the heterocyclyl moiety is a 4- to 6-membered non-aromatic ring which optionally comprises an additional heteroatom selected from N, O or S, and wherein the heterocyclyl is optionally substituted by 1, 2, or 3 25 substituents, which may be the same or different, selected from R⁹; or

30

when L¹ is -(R¹⁰)C=N-O-, R^7 may be a heteroaryl ring comprising a nitrogen atom, wherein the heteroaryl is bonded to L¹ through the nitrogen atom, and wherein the heteroaryl moiety is a 5- or 6-membered monocyclic aromatic ring which optionally comprises an additional 1 or 2 nitrogen atoms, and wherein the heteroaryl is optionally substituted by 1, 2, or 3 substituents, which may be the same 35 or different, selected from R⁹; or

when L¹ is -(R¹⁰)C=N-O-, R^7 and R¹⁰, together with the carbon atom to which they are bonded, may form a 4-, 5- or 6-membered cycle, optionally partially unsaturated or fully unsaturated, and optionally containing 1 or 2 nitrogen atoms, wherein the the cycle is optionally substituted by 1, 2, or 3 40 substituents, which may be the same or different, selected from R⁹ and may optionally further contain 1 group selected from C(O) or S(O)₂; or

a salt or an N-oxide thereof.

Surprisingly, it has been found that the novel compounds of formula (I) have, for practical
5 purposes, a very advantageous level of biological activity for protecting plants against diseases that
are caused by fungi.

According to a second aspect of the invention, there is provided an agrochemical composition
comprising a fungicidally effective amount of a compound of formula (I). Such an agricultural
10 composition may further comprise at least one additional active ingredient and/or an agrochemically-
acceptable diluent or carrier.

According to a third aspect of the invention, there is provided a method of controlling or
preventing infestation of useful plants by phytopathogenic microorganisms, wherein a fungicidally
15 effective amount of a compound of formula (I), or a composition comprising this compound as active
ingredient, is applied to the plants, to parts thereof or the locus thereof.

According to a fourth aspect of the invention, there is provided the use of a compound of
formula (I) as a fungicide. According to this particular aspect of the invention, the use may exclude
20 methods for the treatment of the human or animal body by surgery or therapy.

As used herein, the term "halogen" or "halo" refers to fluorine (fluoro), chlorine (chloro), bromine
(bromo) or iodine (iodo), preferably fluorine, chlorine or bromine.

As used herein, cyano means a -CN group.

25 As used herein, hydroxy means an -OH group.

As used herein, oxo means a =O group (eg, as in a carbonyl (C=O) group).

As used herein, acyl means a -C(O)CH₃ group.

As used herein, the term "C_i-alkyl" refers to a straight or branched hydrocarbon chain radical
consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to six
30 carbon atoms, and which is attached to the rest of the molecule by a single bond. C_i-alkyl and C_i-
3alkyl are to be construed accordingly. Examples of C₁-alkyl include, but are not limited to, methyl,
ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl, and 1-dimethylethyl (i-butyl). A "C_i-alkylene" group
refers to the corresponding definition of C_i-alkyl (and C_i-alkyl and C_i-alkyl), except that such radical
is attached to the rest of the molecule by two single bonds. Examples of C₁-alkylene, include, but are
35 not limited to, -CH₂-, -CH₂CH₂- and -(CH₂)₃-.

As used herein, the term "C_i-alkoxy" refers to a radical of the formula -OR_a where R_a is a C_i-
Calkyl radical as generally defined above. C_i-alkoxy and C_i-alkoxy are to be construed accordingly.
Examples of C₁-alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, iso-propoxy, *t*-
butoxy.

40 As used herein, the term "C_i-haloalkyl" refers to a C₁-alkyl radical as generally defined above
substituted by one or more of the same or different halogen atoms. Examples of *d*-haloalkyl include,

but are not limited to chloromethyl, fluoromethyl, fluoroethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl. Ci-4haloalkyl and Ci-2haloalkyl are to be construed accordingly.

As used herein, the term "C₃-6alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond that can be of either the (E)- or (Z)-configuration, having from three to six carbon atoms, which is attached to the rest of the molecule by a single bond. Examples of C₃-ealkenyl include, but are not limited to, prop-1-enyl, allyl (prop-2-enyl), but-1-enyl.

As used herein, the term "C₃-6haloalkenyl" refers to a C₃-ealkenyl radical as generally defined above substituted by one or more of the same or different halogen atoms. Examples of C₃-ehaloalkenyl include, but are not limited to chloroethylene, fluoroethylene, 1,1-difluoroethylene, 1,1-dichloroethylene, 1,1,2-trichloroethylene.

As used herein, the term "C₃-6alkynyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having from three to six carbon atoms, and which is attached to the rest of the molecule by a single bond. Examples of C₃-ealkynyl include, but are not limited to, prop-1-ynyl, propargyl (prop-2-ynyl), but-1-ynyl.

As used herein, the term "Ci-4haloalkoxy" refers to a Ci-4alkoxy group as defined above substituted by one or more of the same or different halogen atoms. Ci-2haloalkoxy (including Ci-2fluoroalkoxy) is to be construed accordingly. Examples of Ci-4haloalkoxy include, but are not limited to, fluoromethoxy, difluoromethoxy, fluoroethoxy, trifluoromethoxy, trifluoroethoxy.

As used herein, the term "Ci-4alkoxyCi-6alkyl" refers to radical of the formula R_b-O-R_a where R_b is a Ci-4alkyl radical as generally defined above, and R_a is a C₁-ealkylene radical as generally defined above.

As used herein, the term "Ci-4alkoxyCi-6alkoxy" refers to a radical of the formula R_b-O-R_a where R_b is a Ci-4alkyl radical as generally defined above, and R_a is a C₁-ealkoxy radical as generally defined above.

As used herein, the term "Ci-2haloalkoxyCi-6alkyl" refers to radical of the formula R_b-O-R_a where R_b is a Ci-2haloalkyl radical as generally defined above, and R_a is a C₁-ealkylene radical as generally defined above.

As used herein, the term "hydroxyCi-6alkyl" refers to a C₁-ealkyl radical as generally defined above substituted by one or more hydroxyl groups.

As used herein, the term "cyanod-6alkyl" refers to a d-ealkyl radical as generally defined above substituted by one or more cyano groups.

As used herein, the term "d-4alkylcarbonyl" refers to a radical of the formula -C(0)R_a where R_a is a Ci-4 alkyl radical as generally defined above.

As used herein, the term "d-4alkoxycarbonyl" refers to a radical of the formula -C(0)OR_a where R_a is a d-4 alkyl radical as generally defined above.

As used herein, the term "aminocarbonyl" refers to a radical of the formula -C(0)NH₂.

As used herein, the term "d-4alkylaminocarbonyl" refers to a radical of the formula -C(0)NHR_a where R_a is a d-4 alkyl radical as generally defined above.

As used herein, the term "did-4alkylaminocarbonyl" refers to a radical of the formula -C(0)NR_a(R_a) where each R_a is a d-4 alkyl radical as generally defined above.

As used herein, the term " C_{3-8} -cycloalkyl" refers to a stable, monocyclic ring radical which is saturated or partially unsaturated and contains 3 to 8 carbon atoms. C_{3-6} -cycloalkyl is to be construed accordingly. Examples of C_{3-8} -cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

5 As used herein, the term "heteroaryl" refers to a 5- or 6-membered monocyclic aromatic ring, or a 7- to 11-membered aromatic fused ring radical which comprises 1, 2, 3 or 4 heteroatoms individually selected from nitrogen, oxygen and sulfur. The heteroaryl radical may be bonded to the rest of the molecule *via* a carbon atom or heteroatom. Examples of heteroaryl include, furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazinyl, 10 pyridazinyl, pyrimidyl, pyridyl, or indolyl.

As used herein, the term "heterocyclyl" or "heterocyclic" refers to a stable 4- to 6-membered non-aromatic monocyclic ring, or a 7- to 11-membered non-aromatic fused ring radical which comprises 1, 2, or 3 heteroatoms individually selected from nitrogen, oxygen and sulfur. The heterocyclyl radical may be bonded to the rest of the molecule *via* a carbon atom or heteroatom. 15 Examples of heterocyclyl include, but are not limited to, pyrrolinyl, pyrrolidyl, tetrahydrofuryl, tetrahydrothienyl, tetrahydrothiopyranyl, piperidyl, piperazinyl, tetrahydropyranyl, dihydroisoxazolyl, dioxolanyl, morpholinyl, δ -lactamyl, perhydroazepinyl, indolinyl, or benzimidazole.

The presence of one or more possible asymmetric carbon atoms in a compound of formula (I) 20 means that the compounds may occur in chiral isomeric forms, i.e., enantiomeric or diastereomeric forms. Also atropisomers may occur as a result of restricted rotation about a single bond. Formula (I) is intended to include all those possible isomeric forms and mixtures thereof. The present invention includes all those possible isomeric forms and mixtures thereof for a compound of formula (I). Likewise, formula (I) is intended to include all possible tautomers (including lactam-lactim tautomerism 25 and keto-enol tautomerism) where present. The present invention includes all possible tautomeric forms for a compound of formula (I).

In each case, the compounds of formula (I) according to the invention are in free form, in oxidized form as an N-oxide, in covalently hydrated form, or in salt form, e.g., an agronomically usable 30 or agrochemically acceptable salt form.

N-oxides are oxidized forms of tertiary amines or oxidized forms of nitrogen containing heteroaromatic compounds. They are described for instance in the book "Heterocyclic N-oxides" by A. Albini and S. Pietra, CRC Press, Boca Raton 1991 .

35

The following list provides definitions, including preferred definitions, for substituents n , A^1 , A^2 , A^3 , A^4 , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} and L^1 , with reference to the compounds of formula (I) according to the invention. For any one of these substituents, any of the definitions given below may be combined with any definition of any other substituent given below or elsewhere in this document.

40

n is 1 or 2. In some embodiments of the invention, n is 1. In other embodiments of the invention, n is 2.

A¹ represents N or CR¹, wherein R¹ is hydrogen, halogen, methyl, ethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, or difluoromethoxy. Preferably, A¹ represents N or CR¹, wherein R¹ is selected from hydrogen, halogen or methyl. More preferably, R¹ is hydrogen, chloro, fluoro or methyl. More preferably still, R¹ is hydrogen, fluoro or methyl, and most preferably, R¹ is hydrogen.

A² represents N or CR², wherein R² represents hydrogen, halogen, methyl, ethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, or difluoromethoxy. Preferably, A² represents N or CR², wherein R² is selected from hydrogen, halogen or methyl. More preferably, R² is hydrogen, fluoro or methyl. More preferably still, R² is hydrogen or fluoro, and most preferably, R² is hydrogen.

A³ represents N or CR³, wherein R³ represents hydrogen or fluoro. Preferably, R³ is hydrogen.

A⁴ represents N or CR⁴, wherein R⁴ represents hydrogen or fluoro. Preferably, R⁴ is hydrogen.

In a further embodiment of the invention, R³ and R⁴ are hydrogen.

In one embodiment of the invention, A¹ represents CR¹, A² represents CR², and 0, 1 or 2 of R¹, R², R³ and R⁴ are fluorine, wherein when any of R¹, R², R³ and R⁴ is not fluorine, it is hydrogen.

In one embodiment of the invention, A² and A⁴ are C-H and A¹ and A³ are C-F. In another embodiment of the invention A¹, A², and A⁴ are C-H and A³ is C-F. In another embodiment of the invention, A¹, A², A³, and A⁴ are C-H.

R⁵ and R⁶ are independently selected from hydrogen, halogen, cyano, methyl, ethyl, methoxy or Ci-2haloalkyl; or R⁵ and R⁶ together with the carbon atom to which they are attached form a C3-6cycloalkyl ring (eg, cyclopropyl). Preferably, R⁵ and R⁶ are independently selected from hydrogen, methyl, methoxy or Ci-2haloalkyl. More preferably, R⁵ and R⁶ are independently selected from hydrogen or methyl. More preferably still, R⁵ and R⁶ are both hydrogen.

L¹ represents -O-, -C(O)O-, -(R⁸)NC(O)O- or -(R¹⁰)C=N-O-. In some embodiments of the invention, L¹ is -O-. In other embodiments of the invention, L¹ is -C(O)O-. In other embodiments of the invention, L¹ is -(R⁸)NC(O)O-. In other embodiments of the invention, L¹ is -(R¹⁰)C=N-O-.

Preferably, L¹ is -O- or -C(O)O-, more preferably, L¹ is -O-.

R⁷ represents C₁-ealkyl, C₃-ealkenyl, C₃-ealkynyl, cyanoCi-ealkyl, C₁-ehaloalkyl, C₃-ehaloalkenyl, hydroxyCi-ealkyl, Ci-4alkoxyCi-6alkyl, Ci-4alkoxyCi-6alkoxy, Ci-2haloalkoxyCi-6alkyl or -CH=N-O-C₁-4alkyl; or R⁷ represents C3-scycloalkyl wherein the cycloalkyl moiety is optionally partially unsaturated,

phenyl, heteroaryl bonded to L¹ through a carbon atom wherein the heteroaryl moiety is a 5- or 6-membered monocyclic aromatic ring which comprises 1, 2, 3 or 4 heteroatoms individually selected from N, O and S, heterocyclyl bonded to L¹ through a carbon atom wherein the heterocyclyl moiety is a 4- to 6-membered non-aromatic ring which comprises 1, 2 or 3 heteroatoms individually selected
5 from N, O and S, and wherein C₃-scycloalkyl, phenyl, heteroaryl, and heterocyclyl are optionally substituted by 1, 2, or 3 substituents, which may be the same or different, selected from R⁹;

and wherein when R⁷ represents C₃-scycloalkyl or heterocyclyl, the C₃-scycloalkyl moiety or the heterocyclyl moiety is optionally substituted by 1 or 2 oxo groups.

Preferably, R⁷ represents C₁-alkyl, C₁-haloalkyl, C₃₋₆cycloalkyl, phenyl, heteroaryl or
10 heterocyclyl, wherein phenyl, heteroaryl, and heterocyclyl are optionally substituted by 1, 2, or 3 substituents, which may be the same or different, selected from R⁹. More preferably, R⁷ represents C₁₋₆alkyl, C₁₋₄haloalkyl, C₃₋₆cycloalkyl, phenyl, heteroaryl, or heterocyclyl, wherein the heterocyclyl moiety is a 5-membered non-aromatic ring which comprises 1, 2 or 3 heteroatoms individually selected from N, O and S, and wherein phenyl, heteroaryl, and heterocyclyl are optionally substituted by 1, 2, or 3
15 substituents, which may be the same or different, selected from R⁹. Even more preferably, R⁷ represents methyl, ethyl, isopropyl, i-butyl, 2,2,2-trifluoroethyl, cyclopropyl, phenyl, pyridinyl, pyridazinyl, isoxazolyl, dihydroisoxazolyl, tetrazolyl, pyrazolyl, oxadiazolyl, or mopholinyl, wherein each phenyl, pyridinyl, pyridazinyl, isoxazolyl, dihydroisoxazolyl, tetrazolyl, pyrazolyl, and oxadiazolyl, is optionally substituted by 1, 2, or 3 substituents, which may be the same or different, selected from R⁹.

20

In some embodiments of the invention, R⁷ represents phenyl which may be optionally substituted by 1 or 2 R⁹, which is independently selected from methyl, fluoro, or cyano. In other embodiments, R⁷ represents pyridinyl which may be optionally substituted by a single R⁹ selected from methyl, fluoro, cyano, or trifluoromethyl. In further embodiments, R⁷ represents isoxazolyl, dihydroisoxazolyl, or tetrazolyl which may be optionally substituted by 1 or 2 R⁹, wherein each R⁹ is
25 methyl.

Where R⁷ represents C₃₋₆cycloalkyl or heterocyclyl, the C₃₋₆cycloalkyl moiety or the heterocyclyl moiety may optionally be substituted by 1 or 2 oxo groups.

30

Particularly preferred groups representing R⁷ are methyl, isopropyl, t-butyl, cyclopropyl, phenyl, 2-methylphenyl, 2-fluorophenyl, 4-fluorophenyl, 2,6-difluorophenyl, 4-cyanophenyl, 2-pyridyl, 5-methyl-2-pyridyl, 5-fluoro-2-pyridyl, 5-trifluoromethyl-2-pyridyl, 6-cyano-2-pyridyl, 4-cyano-2-pyridyl, isoxazol-3-yl, 5-methoxyisoxazol-3-yl, 4,5-dihydroisoxazol-3-yl, 4,4-dimethyl-5H-isoxazol-3-yl, and 5,5-
35 dimethyl-4H-isoxazol-3-yl, 1-methylpyrazol-3-yl, 1-methyltetrazol-5-yl, 5-methyl-1H-pyrazol-3-yl, 1-methylcarbonylpyrazol-1-yl, and imidazole-1-yl.

Even more particularly preferred groups representing R⁷ are methyl, cyclopropyl, 2-fluorophenyl, 5-methoxyisoxazol-3-yl, 4,5-dihydroisoxazol-3-yl, 4,4-dimethyl-5H-isoxazol-3-yl, 5,5-
40 dimethyl-4H-isoxazol-3-yl, 1-methylpyrazol-3-yl, 1-methyltetrazol-5-yl, 5-methyl-1H-pyrazol-3-yl, 1-methylcarbonylpyrazol-1-yl, and imidazole-1-yl.

R⁸ represents hydrogen, Ci-4alkyl, Ci-4alkoxy or methylcarbonyl. Preferably, R⁸ represents
5 hydrogen, methyl, methoxy or methylcarbonyl.

R⁹ represents cyano, halogen, hydroxy, Ci-4alkyl, Ci-4haloalkyl, Ci-4alkoxy, Ci-4haloalkoxy, Ci-
4alkylcarbonyl, Ci-4alkoxycarbonyl, aminocarbonyl, d⁴alkylaminocarbonyl, diCi-4alkylaminocarbonyl.
Preferably, R⁹ represents cyano, halogen, Ci-4alkyl, or Ci-4haloalkyl. More preferably, R⁹ represents
10 cyano, chloro, bromo, fluoro, iodo, methyl, isopropyl, i-butyl, difluoromethyl or trifluoromethyl. More
preferably still, R⁹ represents cyano, fluoro, methyl, and trifluoromethyl.

R¹⁰ is C₁₋₄alkyl. Preferably, R¹⁰ is methyl.

15 When L¹ is -C(0)0- or -(R¹⁰)C=N-O-, R⁷ may be a heterocyclyl ring comprising a nitrogen atom,
wherein the heterocyclyl is bonded to L¹ through the nitrogen atom, and wherein the heterocyclyl
moiety is a 4- to 6-membered non-aromatic ring which optionally comprises an additional heteroatom
selected from N, O or S, and wherein the heterocyclyl is optionally substituted by 1, 2, or 3
substituents, which may be the same or different, selected from R⁹; or

20 when L¹ is -(R¹⁰)C=N-O-, R⁷ may be a heteroaryl ring comprising a nitrogen atom, wherein the
heteroaryl is bonded to L¹ through the nitrogen atom, and wherein the heteroaryl moiety is a 5- or 6-
membered monocyclic aromatic ring which optionally comprises an additional 1 or 2 nitrogen atoms,
and wherein the heteroaryl is optionally substituted by 1, 2, or 3 substituents, which may be the same
or different, selected from R⁹; or

25 when L¹ is -(R¹⁰)C=N-O-, R⁷ and R¹⁰, together with the carbon atom to which they are bonded,
may form a 4-, 5- or 6-membered cycle, optionally partially unsaturated or fully unsaturated, and
optionally containing 1 or 2 nitrogen atoms, wherein the the cycle is optionally substituted by 1, 2, or 3
substituents, which may be the same or different, selected from R⁹ and may optionally further contain
1 group selected from C(O) or S(0)2.

30

Preferably, the compound according to Formula (I) is selected from compound 1.1 to 1.27 listed
in Table T 1 (below), or compound 2.1 to 2.3 listed in Table T2 (below), or compound 3.1 to 3.1 1 listed
in Table T3 (below) or compound 4.1 to 4.4 listed in Table T4 (below).

35 Preferably, in a compound according to formula (I) of the invention, n is 1 or 2;

A¹ represents N or CR¹, wherein R¹ is selected from hydrogen, halogen or methyl;

A² represents N or CR², wherein R² is selected from hydrogen, halogen or methyl;

A³ represents CR³, wherein R³ is hydrogen or fluoro;

A⁴ represents CR⁴, wherein R⁴ is hydrogen or fluoro;

40 R⁵ and R⁶ are independently selected from hydrogen or methyl; or

L¹ represents -0-;

R⁷ represents Ci-ealkyl, C₃-scycloalkyl, phenyl, heteroaryl or heterocyclyl, wherein C₃-scycloalkyl, phenyl, heteroaryl, and heterocyclyl are optionally substituted by 1, 2, or 3 substituents, which may be the same or different, selected from R⁹; and

R⁹ represents cyano, halogen, hydroxy, Ci-4alkyl, Ci-4haloalkyl, Ci-4alkoxy, or Ci-4haloalkoxy.

5

More preferably, n is 1;

A¹ represents N or CR¹, wherein R¹ is selected from hydrogen, halogen or methyl;

A² represents N or CR², wherein R² is selected from hydrogen, halogen or methyl;

A³ represents CR³, wherein R³ is hydrogen or fluoro;

10

A⁴ represents CR⁴, wherein R⁴ is hydrogen or fluoro;

R⁵ and R⁶ are independently selected from hydrogen and methyl; or

L¹ represents -O-;

R⁷ represents Ci-ealkyl, phenyl, heteroaryl or heterocyclyl, wherein phenyl, heteroaryl, and heterocyclyl are optionally substituted by 1, 2, or 3 substituents, which may be the same or different, selected from R⁹;

15

R⁹ represents cyano, halogen, Ci-4alkyl, and Ci-4haloalkyl.

Even more preferably, n is 1;

A¹ represents CR¹, wherein R¹ is hydrogen;

20

A² represents CR², wherein R² is hydrogen;

A³ represents CR³, wherein R³ is hydrogen;

A⁴ represents CR⁴, wherein R⁴ is hydrogen;

R⁵ and R⁶ both represent hydrogen;

L¹ represents -O-;

25

R⁷ is represents Ci-ealkyl, phenyl, heteroaryl or heterocyclyl, wherein phenyl, heteroaryl, and heterocyclyl are optionally substituted by 1, 2, or 3 substituents, which may be the same or different, selected from R⁹; and

R⁹ represents cyano, halogen, Ci-4alkyl, and Ci-4haloalkyl.

30

Preferably, in a compound according to formula (I) of the invention, n is 1;

A¹ represents CR¹, wherein R¹ is hydrogen;

A² represents CR², wherein R² is hydrogen;

A³ represents CR³, wherein R³ is hydrogen;

A⁴ represents CR⁴, wherein R⁴ is hydrogen;

35

R⁵ and R⁶ are independently selected from hydrogen and methyl; or

L¹ represents -C(O)O-; and

R⁷ represents Ci-ealkyl, cyanoCi-ealkyl, C₁-ehaloalkyl or hydroxyCi-ealkyl.

Preferably, in a compound according to formula (I) of the invention, n is 1;

40

A¹ represents CR¹, wherein R¹ is hydrogen;

A² represents CR², wherein R² is hydrogen;

A^3 represents CR^3 , wherein R^3 is hydrogen;

A^4 represents CR^4 , wherein R^4 is hydrogen;

R^5 and R^6 both represent hydrogen;

L^1 represents $-(R^{10})C=N-O-$;


5 R^7 represents C₁-alkyl;

R^{10} represents C₁-alkyl, heteroaryl or heterocyclyl; or

R^7 and R^{10} , together with the carbon atom to which they are bonded, may form a 6-membered cycle, optionally partially unsaturated or fully unsaturated, and optionally containing 1 or 2


10 nitrogen atoms, wherein the the cycle is optionally substituted by 1 or 2 substituents, which may be the same or different, selected from R^9 and may optionally contain 1 C(O) group; and R^9 represents cyano, halogen, Ci-4alkyl, and Ci-4haloalkyl.

The compounds of the present invention may be enantiomers of the compound of Formula (I) as represented by a Formula (Ia) or a Formula (Ib), wherein R^5 and R^6 are different.




It is understood that when in aqueous media, the compounds of Formula (I) according to the invention may be present in a reversible equilibrium with the corresponding covalently hydrated forms (i.e., the compounds of Formula (I-I) and Formula (I-II) as shown below which may exist in tautomeric form as the compounds of formula (I-Ia) and formula (I-IIa)) at the CF₃-oxadiazole motif. This dynamic equilibrium may be important for the biological activity of the compounds of Formula (I). The designations of n, A¹, A², A³, A⁴, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰ and L¹, with reference to the compounds of Formula (I) of the present invention apply generally to the compounds of Formulae (I-I), (I-II), (I-Ia) and (I-IIa), as do the specific disclosures of combinations of n, A¹, A², A³, A⁴, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰ and L¹, as represented in Tables 1.1 to 1.12 or the compounds 1.1 to 1.27 described in Table T1 (below); Tables 2.1 to 2.4 or the compounds 2.1 to 2.3 described in Table T2 (below); Tables 3.1 to 3.6 or the compounds 3.1 to 3.11 described in Table T3 (below); or the compounds 4.1 to 4.4 described in Table T4 (below).

30



Compounds of the present invention can be made as shown in the following schemes 1 to 13, in which, unless otherwise stated, the definition of each variable is as defined above for a compound of 5 formula (I).

The compounds of formula (I), wherein L¹ is -N(R⁸)C(O)O⁻ and n is 1 or 2; can be obtained by an ester coupling transformation with compounds of formula (II) and compounds of formula (III), preferably in a suitable solvent (eg, dimethylformamide, dichloromethane or tetrahydrofuran), preferably at a temperature of between 25°C and 100°C, and optionally in the presence of a base 10 such as triethylamine or pyridine. Compounds of formula (III) are commercially available or prepared using known methods. For related examples, see: Hoppe, D., Bronneke, A. *Synthesis* (1982), 1045; and Yamagami, C. et al *Chem. & Pharm. Bull.*, (1982), 30, 4175. This reaction is shown in Scheme 1.




Scheme 1

5 The compounds of formula (I), wherein L^1 is $-C(O)O-$ and n is 1 or 2, can be obtained by an ester coupling transformation with a compound of formula (II) and a compound of formula (IV) by activating the carboxylic acid function of the compound of formula (IV), a process that usually takes place by converting the $-OH$ of the carboxylic acid into a good leaving group, such as a chloride group, for example by using $(COCl)_2$ or $SOCl_2$, prior to treatment with the compounds of formula (II),

10 preferably in a suitable solvent (eg, dimethylformamide, dichloromethane or tetrahydrofuran), preferably at a temperature of between $25^\circ C$ and $100^\circ C$, and optionally in the presence of a base such as triethylamine or *N,N*-diisopropylethylamine, or under conditions described in the literature for an ester coupling. For related examples, see: WO 2013/066835 and Dao, H. T. et al *J. Am. Chem. Soc.* (2015), 137, 8046. Compounds of formula (IV) are commercially available or prepared using


15 known methods. This reaction is shown in Scheme 2.



Scheme 2

20 Alternatively, compounds of formula (I), wherein L^1 is $-O-$ and n is 1 or 2, can be prepared from compounds of formula (V), wherein X is Cl , Br or I , via treatment with alcohols of formula (II), in the presence of a suitable base, such as NaH , in a suitable solvent, such as dimethylformamide or tetrahydrofuran, at a temperature between $0^\circ C$ and $100^\circ C$. In some cases, a better reaction performance may be gained from the use of a catalyst (eg, NaI or 4-dimethylaminopyridine) and with


25 microwaves irradiation. For related examples, see, WO2011/0021482. Compounds of formula (V) are commercially available. This reaction is shown in Scheme 3.



Scheme 3

5 Additionally, compounds of formula (I), wherein L¹ is -O-, -C(O)O- or -(R¹⁰)C=N-O- and n is preferably 1, can be prepared from compounds of formula (VI), wherein X is a halogen, preferably Cl, Br, I or -OSchOMe, via treatment with compounds of formula (VII), in the presence of a base (e.g. K₂CO₃, CS₂CO₃, KOAc, or NaH) in a suitable solvent (e.g. dimethylformamide or tetrahydrofuran) at a temperature between 25°C and 110°C. In some cases, a better reaction performance may be gained

10 from the use of a catalyst (eg, NaI or 4-dimethylaminopyridine) and with microwave irradiation. For related examples, see: Patrick, D. A. et al *Eur. J. Med. Chem.* (2013) 67, 310 or WO2008/1 36324. Compounds of formula (VII) are commercially available. This reaction is shown in Scheme 4.




Scheme 4

15


Furthermore, compounds of formula (I) can be prepared from compounds of formula (VIII) by treatment with trifluoroacetic anhydride in the presence of a base (eg, pyridine or 4-dimethylaminopyridine) in a suitable solvent, such as tetrahydrofuran or ethanol, at a temperature between 25°C and 75°C. For related examples, see WO 2003/028729 and WO 2010/045251. This

20 reaction is shown in Scheme 5.




Scheme 5

Compounds of formula (VIII) can be prepared from compounds of formula (IX) by treatment with a hydroxylamine hydrochloride salt in the presence of a base, such as triethylamine, in a suitable solvent, such as methanol, at a temperature between 0°C and 100°C. For related examples, see
 5 Kitamura, S. *et al Chem. Pharm. Bull.* (2001), 49, 268 and WO 2013/066838. This reaction is shown in Scheme 6.



Scheme 6


10 Compounds of formula (II) can be prepared from compounds of formula (VI), wherein X is -OC(0)CF₃ or -OC(0)CH₃, via saponification of the ester using a suitable base, such as Na₂CO₃ or K₂CO₃, in a suitable solvent, such as methanol, at 25°C. For related examples, see: Kawate, T. *et al Bioorg. & Med. Chem. Lett.*, (2013), 23, 6052. This reaction is shown in Scheme 7.



Scheme 7


15

Compounds of formula (VI), wherein X is Cl or Br and n is 1, can be prepared from compounds of formula (X) by treatment with a halogen source (eg, N-bromosuccinimide (NBS) or N-chlorosuccinimide (NCS)) and a radical initiator (eg, (PhCO₂)₂ or azobisisobutyronitrile (AIBN)) in a
 20 suitable solvent, such as tetrachloromethane, at temperatures between 55° and 100°C in the presence of ultraviolet light. For related examples, see Liu, S. *et al Synthesis* (2001), 14, 2078 and Kompella, A. *et al Org. Proc. Res. Dev.* (2012), 16, 1794. This reaction is shown in Scheme 8.



Scheme 8


Alternatively, compounds of formula (VI), wherein X is halogen, -OC(O)CH₃, -OC(O)CF₃ can be prepared from compounds of formula (XII), wherein X is halogen, -OH, -OC(O)CF₃ by treatment with trifluoroacetic anhydride in the presence of a base (eg, pyridine or 4-dimethylaminopyridine) in a suitable solvent, such as tetrahydrofuran or ethanol, at a temperature between 25°C and 75°C. For related examples, see WO 2003/028729 and WO 2010/045251. This reaction is shown in Scheme 9.



Scheme 9

10

Compounds of formula (XII) can be prepared from compounds of formula (XIII) by treatment with a hydroxylamine hydrochloride salt in the presence of a base, such as triethylamine, in a suitable solvent, such as methanol, at a temperature between 0°C and 100°C. For related examples, see Kitamura, S. *et al Chem. Pharm. Bull.* (2001), 49, 268 and WO 2013/066838. This reaction is shown in Scheme 10.




Scheme 10

20

Compounds of formula (XIII) can be prepared from compounds of formula (XIV), wherein Y is Br or I, via metal-promoted reaction with a suitable cyanide reagent, such as Pd(0)/Zn(CN)₂ or CuCN, in


a suitable solvent (eg, dimethylformamide or N-methylpyrrolidone) at elevated temperatures between 100°C and 120°C. For related examples, see US 2007/01 55739 and WO 2009/022746. This reaction is shown in Scheme 11.



5

Scheme 11

Compounds of formula (XIV), wherein Y is Br, I or CN and X is Cl, Br or I and n is 1, are either commercially available or can be prepared from compounds of formula (XV), by treatment with a halogen source, (eg, N-bromosuccinimide (NBS) or N-chlorosuccinimide (NCS)) and a radical initiator, such as (PhCO₂)₂ or azobisisobutyronitrile (AIBN), in the presence of ultraviolet light, in a suitable solvent, such as tetrachloromethane, at temperatures between 55°C and 100°C. For related examples, see Liu, S. *et al Synthesis* (2001), 14, 2078 and Kompella, A. *et al Org. Proc. Res. Dev.* (2012), 16, 1794. Compounds of formula (XV) are commercially available. This reaction is shown in Scheme 12.




15

Scheme 12

Alternatively, compounds of formula (XIV), wherein X is Cl, Br, I, -OSO₂CH₃, or -OC(O)CH₃ and Y is Br, I or CN, are either commercially available or can be prepared from compounds of formula (XVI), by treatment with a halogen source (eg, CCl₃Br, CCl₄ or I₂) in the presence of triphenylphosphine, or with methanesulfonyl chloride (ClSO₂Me), or with CH₃C(O)Cl, in a suitable solvent, (eg, dichloromethane) at a temperature between 0°C and 100°C. For related examples, see Liu, H. *et al Bioorg. & Med. Chem.* (2008), 16, 10013, WO 2014/020350 and Kompella, A. *et al Bioorg. & Med. Chem. Lett.* (2001), 1, 3161. Compounds of formula (XVI) are commercially available. This reaction is shown in Scheme 13.

25



Scheme 13

As already indicated, surprisingly, it has now been found that the novel compounds of formula (I) of the present invention have, for practical purposes, a very advantageous level of biological activity for protecting plants against diseases that are caused by fungi.

The compounds of formula (I) can be used in the agricultural sector and related fields of use, e.g., as active ingredients for controlling plant pests or on non-living materials for the control of spoilage microorganisms or organisms potentially harmful to man. The novel compounds are distinguished by excellent activity at low rates of application, by being well tolerated by plants and by being environmentally safe. They have very useful curative, preventive and systemic properties and can be used for protecting numerous cultivated plants. The compounds of formula (I) can be used to inhibit or destroy the pests that occur on plants or parts of plants (fruit, blossoms, leaves, stems, tubers, roots) of different crops of useful plants, while at the same time protecting also those parts of the plants that grow later, e.g., from phytopathogenic microorganisms.

The present invention further relates to a method for controlling or preventing infestation of plants or plant propagation material and/or harvested food crops susceptible to microbial attack by treating plants or plant propagation material and/or harvested food crops wherein an effective amount of a compound of formula (I) is applied to the plants, to parts thereof or the locus thereof.

It is also possible to use compounds of formula (I) as fungicide. The term "fungicide" as used herein means a compound that controls, modifies, or prevents the growth of fungi. The term "fungicidally effective amount" where used means the quantity of such a compound or combination of such compounds that is capable of producing an effect on the growth of fungi. Controlling or modifying effects include all deviation from natural development, such as killing, retardation and the like, and prevention includes barrier or other defensive formation in or on a plant to prevent fungal infection.

It may also be possible to use compounds of formula (I) as dressing agents for the treatment of plant propagation material, e.g., seed, such as fruits, tubers or grains, or plant cuttings, for the protection against fungal infections as well as against phytopathogenic fungi occurring in the soil. The propagation material can be treated with a composition comprising a compound of formula (I) before planting: seed, for example, can be dressed before being sown. The active compounds of formula (I) can also be applied to grains (coating), either by impregnating the seeds in a liquid formulation or by coating them with a solid formulation. The composition can also be applied to the planting site when

the propagation material is being planted, for example, to the seed furrow during sowing. The invention relates also to such methods of treating plant propagation material and to the plant propagation material so treated.

5 Furthermore, the compounds of formula (I) can be used for controlling fungi in related areas, for example in the protection of technical materials, including wood and wood related technical products, in food storage, in hygiene management.

In addition, the invention could be used to protect non-living materials from fungal attack, e.g.
10 lumber, wall boards and paint.

The compounds of formula (I) are for example, effective against fungi and fungal vectors of disease as well as phytopathogenic bacteria and viruses. These fungi and fungal vectors of disease as well as phytopathogenic bacteria and viruses are for example:

15 *Absidia corymbifera*, *Alternaria* spp, *Aphanomyces* spp, *Ascochyta* spp, *Aspergillus* spp. including *A. flavus*, *A. fumigatus*, *A. nidulans*, *A. niger*, *A. terreus*, *Aureobasidium* spp. including *A. pullulans*, *Blastomyces dermatitidis*, *Blumeria graminis*, *Bremia lactucae*, *Botryosphaeria* spp. including *B. dothidea*, *B. obtusa*, *Botrytis* spp. including *B. cinerea*, *Candida* spp. including *C. albicans*, *C. glabrata*, *C. krusei*, *C. lusitanae*, *C. parapsilosis*, *C. tropicalis*, *Cephalosporium fragrans*, *Ceratocystis*
20 spp, *Cercospora* spp. including *C. arachidicola*, *Cercosporidium personatum*, *Cladosporium* spp, *Claviceps purpurea*, *Coccidioides immitis*, *Cochliobolus* spp, *Colletotrichum* spp. including *C. musae*, *Cryptococcus neoformans*, *Diaporthe* spp, *Didymella* spp, *Drechslera* spp, *Elsinoe* spp, *Epidermophyton* spp, *Erwinia amylovora*, *Erysiphe* spp. including *E. cichoracearum*, *Eutypa lata*, *Fusarium* spp. including *F. culmorum*, *F. graminearum*, *F. langsethiae*, *F. moniliforme*, *F. oxysporum*,
25 *F. proliferatum*, *F. subglutinans*, *F. solani*, *Gaeumannomyces graminis*, *Gibberella fujikuroi*, *Gloeodes pomigena*, *Gloeosporium musarum*, *Glomerella cingulate*, *Guignardia bidwellii*, *Gymnosporangium juniperi-virginianae*, *Helminthosporium* spp, *Hemileia* spp, *Histoplasma* spp. including *H. capsulatum*, *Laetisaria fuciformis*, *Leptographium lindbergii*, *Leveillula taurica*, *Lophodermium seeditiosum*, *Microdochium nivale*, *Microsporium* spp, *Monilinia* spp, *Mucor* spp, *Mycosphaerella* spp. including *M.*
30 *graminicola*, *M. pomi*, *Oncobasidium theobromaeon*, *Ophiostoma piceae*, *Paracoccidioides* spp, *Penicillium* spp. including *P. digitatum*, *P. italicum*, *Petriellidium* spp, *Peronosclerospora* spp. Including *P. maydis*, *P. philippinensis* and *P. sorghi*, *Peronospora* spp, *Phaeosphaeria nodorum*, *Phakopsora pachyrhizi*, *Phellinus igniarius*, *Phialophora* spp, *Phoma* spp, *Phomopsis viticola*, *Phytophthora* spp. including *P. infestans*, *Plasmopara* spp. including *P. halstedii*, *P. viticola*, *Pleospora* spp.,
35 *Podosphaera* spp. including *P. leucotricha*, *Polymyxa graminis*, *Polymyxa betae*, *Pseudocercospora herpotrichoides*, *Pseudomonas* spp, *Pseudoperonospora* spp. including *P. cubensis*, *P. humuli*, *Pseudopeziza tracheiphila*, *Puccinia* Spp. including *P. hordei*, *P. recondita*, *P. striiformis*, *P. triticina*, *Pyrenopeziza* spp, *Pyrenophora* spp, *Pyricularia* spp. including *P. oryzae*, *Pythium* spp. including *P.*
40 *ultimum*, *Ramularia* spp, *Rhizoctonia* spp, *Rhizomucor pusillus*, *Rhizopus arrhizus*, *Rhynchosporium* spp, *Scenedosporium* spp. including *S. apiospermum* and *S. prolificans*, *Schizothyrium pomi*, *Sclerotinia* spp, *Sclerotium* spp, *Septoria* spp, including *S. nodorum*, *S. tritici*, *Sphaerotheca macularis*,

Sphaerotheca fusca (Sphaerotheca fuliginea), Sporothrix spp, Stagonospora nodorum, Stemphylium spp, . Stereum hirsutum, Thanatephorus cucumeris, Thielaviopsis basicola, Tilletia spp, Trichoderma spp. including T. harzianum, T. pseudokoningii, T. viride, Trichophyton spp, Typhula spp, Uncinula necator, Urocystis spp, Ustilago spp, Venturia spp. including V. inaequalis, Verticillium spp, and
5 Xanthomonas spp.

The compounds of formula (I) may be used for example on turf, ornamentals, such as flowers, shrubs, broad-leaved trees or evergreens, for example conifers, as well as for tree injection, pest management and the like.

10 Within the scope of present invention, target crops and/or useful plants to be protected typically comprise perennial and annual crops, such as berry plants for example blackberries, blueberries, cranberries, raspberries and strawberries; cereals for example barley, maize (corn), millet, oats, rice, rye, sorghum triticale and wheat; fibre plants for example cotton, flax, hemp, jute and sisal; field crops
15 for example sugar and fodder beet, coffee, hops, mustard, oilseed rape (canola), poppy, sugar cane, sunflower, tea and tobacco; fruit trees for example apple, apricot, avocado, banana, cherry, citrus, nectarine, peach, pear and plum; grasses for example Bermuda grass, bluegrass, bentgrass, centipede grass, fescue, ryegrass, St. Augustine grass and Zoysia grass; herbs such as basil, borage, chives, coriander, lavender, lovage, mint, oregano, parsley, rosemary, sage and thyme; legumes for
20 example beans, lentils, peas and soya beans; nuts for example almond, cashew, ground nut, hazelnut, peanut, pecan, pistachio and walnut; palms for example oil palm; ornamentals for example flowers, shrubs and trees; other trees, for example cacao, coconut, olive and rubber; vegetables for
example asparagus, aubergine, broccoli, cabbage, carrot, cucumber, garlic, lettuce, marrow, melon, okra, onion, pepper, potato, pumpkin, rhubarb, spinach and tomato; and vines for example grapes.

The term "useful plants" is to be understood as also including useful plants that have been
25 rendered tolerant to herbicides like bromoxynil or classes of herbicides (such as, for example, HPPD inhibitors, ALS inhibitors, for example primisulfuron, prosulfuron and trifloxysulfuron, EPSPS (5-enol-pyrovyl-shikimate-3-phosphate-synthase) inhibitors, GS (glutamine synthetase) inhibitors or PPO (protoporphyrinogen-oxidase) inhibitors) as a result of conventional methods of breeding or genetic engineering. An example of a crop that has been rendered tolerant to imidazolinones, e.g. imazamox,
30 by conventional methods of breeding (mutagenesis) is Clearfield® summer rape (Canola). Examples of crops that have been rendered tolerant to herbicides or classes of herbicides by genetic engineering methods include glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names Round upReady®, Herculex I® and LibertyLink®.

The term "useful plants" is to be understood as also including useful plants which have been so
35 transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus Bacillus.

Examples of such plants are: YieldGard® (maize variety that expresses a CryIA(b) toxin); YieldGard Rootworm® (maize variety that expresses a CryIIIB(bl) toxin); YieldGard Plus® (maize
40 variety that expresses a CryIA(b) and a CryIIIB(bl) toxin); Starlink® (maize variety that expresses a

Cry9(c) toxin); Herculex I® (maize variety that expresses a CryIF(a2) toxin and the enzyme phosphinothricine N-acetyltransferase (PAT) to achieve tolerance to the herbicide glufosinate ammonium); NuCOTN 33B® (cotton variety that expresses a CryIA(c) toxin); Bollgard I® (cotton variety that expresses a CryIA(c) toxin); Bollgard II® (cotton variety that expresses a CryIA(c) and a
5 CryIIA(b) toxin); VIPCOT® (cotton variety that expresses a VIP toxin); NewLeaf® (potato variety that expresses a CryIIIA toxin); NatureGard® Agrisure® GT Advantage (GA21 glyphosate-tolerant trait), Agrisure® CB Advantage (Bt1 1 corn borer (CB) trait), Agrisure® RW (corn rootworm trait) and Protecta®.

The term "crops" is to be understood as including also crop plants which have been so
10 transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus *Bacillus*.

Toxins that can be expressed by such transgenic plants include, for example, insecticidal proteins from *Bacillus cereus* or *Bacillus popilliae*; or insecticidal proteins from *Bacillus thuringiensis*,
15 such as δ -endotoxins, e.g. CryIAb, CryIAc, CryIF, Cry1Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), e.g. Vip1, Vip2, Vip3 or Vip3A; or insecticidal proteins of bacteria colonising nematodes, for example *Photorhabdus* spp. or *Xenorhabdus* spp., such as *Photorhabdus luminescens*, *Xenorhabdus nematophilus*; toxins produced by animals, such as scorpion toxins, arachnid toxins, wasp toxins and other insect-specific neurotoxins; toxins produced by fungi, such as
20 *Streptomyces* toxins, plant lectins, such as pea lectins, barley lectins or snowdrop lectins; agglutinins; proteinase inhibitors, such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin, papain inhibitors; ribosome-inactivating proteins (RIP), such as ricin, maize-RIP, abrin, luffin, saporin or bryodin; steroid metabolism enzymes, such as 3-hydroxysteroidoxidase, ecdysteroid-UDP-glycosyl-transferase, cholesterol oxidases, ecdysone inhibitors, HMG-COA-reductase, ion channel blockers,
25 such as blockers of sodium or calcium channels, juvenile hormone esterase, diuretic hormone receptors, stilbene synthase, bibenzyl synthase, chitinases and glucanases.

Further, in the context of the present invention there are to be understood by δ -endotoxins, for example CryIAb, CryIAc, CryIF, Cry1Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), for example Vip1, Vip2, Vip3 or Vip3A, expressly also hybrid toxins,
30 truncated toxins and modified toxins. Hybrid toxins are produced recombinantly by a new combination of different domains of those proteins (see, for example, WO 02/15701). Truncated toxins, for example a truncated CryIAb, are known. In the case of modified toxins, one or more amino acids of the naturally occurring toxin are replaced. In such amino acid replacements, preferably non-naturally present protease recognition sequences are inserted into the toxin, such as, for example, in the case
35 of Cry3A055, a cathepsin-G-recognition sequence is inserted into a Cry3A toxin (see WO 03/018810).

Examples of such toxins or transgenic plants capable of synthesising such toxins are disclosed, for example, in EP-A-0 374 753, WO93/07278, W095/34656, EP-A-0 427 529, EP-A-451 878 and WO 03/052073.

The processes for the preparation of such transgenic plants are generally known to the person
40 skilled in the art and are described, for example, in the publications mentioned above. CryI-type

deoxyribonucleic acids and their preparation are known, for example, from WO 95/34656, EP-A-0 367 474, EP-A-0 401 979 and WO 90/1 3651 .

The toxin contained in the transgenic plants imparts to the plants tolerance to harmful insects. Such insects can occur in any taxonomic group of insects, but are especially commonly found in the
5 beetles (Coleoptera), two-winged insects (Diptera) and butterflies (Lepidoptera).

Transgenic plants containing one or more genes that code for an insecticidal resistance and express one or more toxins are known and some of them are commercially available. Examples of such plants are: YieldGard® (maize variety that expresses a CryIAb toxin); YieldGard Rootworm®
10 (maize variety that expresses a Cry3Bb1 toxin); YieldGard Plus® (maize variety that expresses a CryIAb and a Cry3Bb1 toxin); Starlink® (maize variety that expresses a Cry9C toxin); Herculex I® (maize variety that expresses a Cry1 Fa2 toxin and the enzyme phosphinothricine N-acetyltransferase (PAT) to achieve tolerance to the herbicide glufosinate ammonium); NuCOTN 33B® (cotton variety that expresses a CryIAC toxin); Bollgard I® (cotton variety that expresses a CryIAC toxin); Bollgard
15 II® (cotton variety that expresses a CryIAC and a Cry2Ab toxin); VipCot® (cotton variety that expresses a Vip3A and a CryIAb toxin); NewLeaf® (potato variety that expresses a Cry3A toxin); NatureGard®, Agrisure® GT Advantage (GA21 glyphosate-tolerant trait), Agrisure® CB Advantage (Bt1 1 corn borer (CB) trait) and Protecta®.

20 Further examples of such transgenic crops are:

1. **Bt1 1 Maize** from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/1 0. Genetically modified *Zea mays* which has been rendered resistant to attack by the European corn borer (*Ostrinia nubilalis* and *Sesamia nonagrioides*) by transgenic
25 expression of a truncated CryIAb toxin. Bt1 1 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.

2. **Bt1 76 Maize** from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur, France, registration number C/FR/96/05/1 0. Genetically modified *Zea mays* which has been rendered
30 resistant to attack by the European corn borer (*Ostrinia nubilalis* and *Sesamia nonagrioides*) by transgenic expression of a CryIAb toxin. Bt1 76 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.

3. **MIR604 Maize** from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790 St. Sauveur,
35 France, registration number C/FR/96/05/1 0. Maize which has been rendered insect-resistant by transgenic expression of a modified Cry3A toxin. This toxin is Cry3A055 modified by insertion of a cathepsin-G-protease recognition sequence. The preparation of such transgenic maize plants is described in WO 03/01 881 0.

4. **MON 863 Maize** from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1 150 Brussels, Belgium, registration number C/DE/02/9. MON 863 expresses a Cry3Bb1 toxin and has resistance to certain Coleoptera insects.

5 5. **IPC 531 Cotton** from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1 150 Brussels, Belgium, registration number C/ES/96/02.

6. **1507 Maize** from Pioneer Overseas Corporation, Avenue Tedesco, 7 B-1 160 Brussels, Belgium, registration number C/NL/00/10. Genetically modified maize for the expression of the protein
10 Cryl F for achieving resistance to certain Lepidoptera insects and of the PAT protein for achieving tolerance to the herbicide glufosinate ammonium.

7. **NK603 × MON 810 Maize** from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1 150 Brussels, Belgium, registration number C/GB/02/M3/03. Consists of conventionally bred hybrid maize
15 varieties by crossing the genetically modified varieties NK603 and MON 810. NK603 × MON 810 Maize transgenically expresses the protein CP4 EPSPS, obtained from *Agrobacterium sp.* strain CP4, which imparts tolerance to the herbicide Roundup® (contains glyphosate), and also a CryIAb toxin obtained from *Bacillus thuringiensis subsp. kurstaki* which brings about tolerance to certain
20 Lepidoptera, include the European corn borer.

The term "locus" as used herein means fields in or on which plants are growing, or where seeds of cultivated plants are sown, or where seed will be placed into the soil. It includes soil, seeds, and seedlings, as well as established vegetation.

The term "plants" refers to all physical parts of a plant, including seeds, seedlings, saplings,
25 roots, tubers, stems, stalks, foliage, and fruits.

The term "plant propagation material" is understood to denote generative parts of the plant, such as seeds, which can be used for the multiplication of the latter, and vegetative material, such as cuttings or tubers, for example potatoes. There can be mentioned for example seeds (in the strict sense), roots, fruits, tubers, bulbs, rhizomes and parts of plants. Germinated plants and young plants
30 which are to be transplanted after germination or after emergence from the soil, may also be mentioned. These young plants can be protected before transplantation by a total or partial treatment by immersion. Preferably "plant propagation material" is understood to denote seeds.

The compounds of formula I may be used in unmodified form or, preferably, together with the adjuvants conventionally employed in the art of formulation. To this end they may be conveniently
35 formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions or suspensions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations e.g. in polymeric substances. As with the type of the compositions, the methods of application, such as spraying, atomising, dusting, scattering, coating or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances. The
40 compositions may also contain further adjuvants such as stabilizers, antifoams, viscosity regulators,

binders or tackifiers as well as fertilizers, micronutrient donors or other formulations for obtaining special effects.

Suitable carriers and adjuvants, e.g. for agricultural use, can be solid or liquid and are substances useful in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, thickeners, binders or fertilizers. Such carriers are for example described in WO 97/33890.

Suspension concentrates are aqueous formulations in which finely divided solid particles of the active compound are suspended. Such formulations include anti-settling agents and dispersing agents and may further include a wetting agent to enhance activity as well an anti-foam and a crystal growth inhibitor. In use, these concentrates are diluted in water and normally applied as a spray to the area to be treated. The amount of active ingredient may range from 0.5% to 95% of the concentrate.

Wettable powders are in the form of finely divided particles which disperse readily in water or other liquid carriers. The particles contain the active ingredient retained in a solid matrix. Typical solid matrices include fuller's earth, kaolin clays, silicas and other readily wet organic or inorganic solids. Wettable powders normally contain from 5% to 95% of the active ingredient plus a small amount of wetting, dispersing or emulsifying agent.

Emulsifiable concentrates are homogeneous liquid compositions dispersible in water or other liquid and may consist entirely of the active compound with a liquid or solid emulsifying agent, or may also contain a liquid carrier, such as xylene, heavy aromatic naphthas, isophorone and other non-volatile organic solvents. In use, these concentrates are dispersed in water or other liquid and normally applied as a spray to the area to be treated. The amount of active ingredient may range from 0.5% to 95% of the concentrate.

Granular formulations include both extrudates and relatively coarse particles and are usually applied without dilution to the area in which treatment is required. Typical carriers for granular formulations include sand, fuller's earth, attapulgitic clay, bentonite clays, montmorillonite clay, vermiculite, perlite, calcium carbonate, brick, pumice, pyrophyllite, kaolin, dolomite, plaster, wood flour, ground corn cobs, ground peanut hulls, sugars, sodium chloride, sodium sulphate, sodium silicate, sodium borate, magnesia, mica, iron oxide, zinc oxide, titanium oxide, antimony oxide, cryolite, gypsum, diatomaceous earth, calcium sulphate and other organic or inorganic materials which absorb or which can be coated with the active compound. Granular formulations normally contain 5% to 25% of active ingredients which may include surface-active agents such as heavy aromatic naphthas, kerosene and other petroleum fractions, or vegetable oils; and/or stickers such as dextrans, glue or synthetic resins.

Dusts are free-flowing admixtures of the active ingredient with finely divided solids such as talc, clays, flours and other organic and inorganic solids which act as dispersants and carriers.

Microcapsules are typically droplets or granules of the active ingredient enclosed in an inert porous shell which allows escape of the enclosed material to the surroundings at controlled rates. Encapsulated droplets are typically 1 to 50 microns in diameter. The enclosed liquid typically constitutes 50 to 95% of the weight of the capsule and may include solvent in addition to the active compound. Encapsulated granules are generally porous granules with porous membranes sealing the granule pore openings, retaining the active species in liquid form inside the granule pores. Granules

typically range from 1 millimetre to 1 centimetre and preferably 1 to 2 millimetres in diameter. Granules are formed by extrusion, agglomeration or prilling, or are naturally occurring. Examples of such materials are vermiculite, sintered clay, kaolin, attapulgite clay, sawdust and granular carbon. Shell or membrane materials include natural and synthetic rubbers, cellulosic materials, styrene-
5 butadiene copolymers, polyacrylonitriles, polyacrylates, polyesters, polyamides, polyureas, polyurethanes and starch xanthates.

Other useful formulations for agrochemical applications include simple solutions of the active ingredient in a solvent in which it is completely soluble at the desired concentration, such as acetone, alkylated naphthalenes, xylene and other organic solvents. Pressurised sprayers, wherein the active
10 ingredient is dispersed in finely-divided form as a result of vaporisation of a low boiling dispersant solvent carrier, may also be used.

Suitable agricultural adjuvants and carriers that are useful in formulating the compositions of the invention in the formulation types described above are well known to those skilled in the art.

Liquid carriers that can be employed include, for example, water, toluene, xylene, petroleum
15 naphtha, crop oil, acetone, methyl ethyl ketone, cyclohexanone, acetic anhydride, acetonitrile, acetophenone, amyl acetate, 2-butanone, chlorobenzene, cyclohexane, cyclohexanol, alkyl acetates, diacetonol, 1,2-dichloropropane, diethanolamine, p-diethylbenzene, diethylene glycol, diethylene glycol abietate, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, N,N-dimethyl formamide, dimethyl sulfoxide, 1,4-dioxane, dipropylene glycol, dipropylene glycol
20 methyl ether, dipropylene glycol dibenzoate, diproxitol, alkyl pyrrolidinone, ethyl acetate, 2-ethyl hexanol, ethylene carbonate, 1,1,1-trichloroethane, 2-heptanone, alpha pinene, d-limonene, ethylene glycol, ethylene glycol butyl ether, ethylene glycol methyl ether, gamma-butyrolactone, glycerol, glycerol diacetate, glycerol monoacetate, glycerol triacetate, hexadecane, hexylene glycol, isoamyl acetate, isobornyl acetate, isooctane, isophorone, isopropyl benzene, isopropyl myristate, lactic acid,
25 laurylamine, mesityl oxide, methoxy-propanol, methyl isoamyl ketone, methyl isobutyl ketone, methyl laurate, methyl octanoate, methyl oleate, methylene chloride, m-xylene, n-hexane, n-octylamine, octadecanoic acid, octyl amine acetate, oleic acid, oleylamine, o-xylene, phenol, polyethylene glycol (PEG400), propionic acid, propylene glycol, propylene glycol monomethyl ether, p-xylene, toluene, triethyl phosphate, triethylene glycol, xylene sulfonic acid, paraffin, mineral oil, trichloroethylene,
30 perchloroethylene, ethyl acetate, amyl acetate, butyl acetate, methanol, ethanol, isopropanol, and higher molecular weight alcohols such as amyl alcohol, tetrahydrofurfuryl alcohol, hexanol, octanol, etc., ethylene glycol, propylene glycol, glycerine and N-methyl-2-pyrrolidinone. Water is generally the carrier of choice for the dilution of concentrates.

Suitable solid carriers include, for example, talc, titanium dioxide, pyrophyllite clay, silica,
35 attapulgite clay, kieselguhr, chalk, diatomaceous earth, lime, calcium carbonate, bentonite clay, fuller's earth, cotton seed hulls, wheat flour, soybean flour, pumice, wood flour, walnut shell flour and lignin.

A broad range of surface-active agents are advantageously employed in both said liquid and solid compositions, especially those designed to be diluted with carrier before application. These agents, when used, normally comprise from 0.1% to 15% by weight of the formulation. They can be
40 anionic, cationic, non-ionic or polymeric in character and can be employed as emulsifying agents, wetting agents, suspending agents or for other purposes. Typical surface active agents include salts

of alkyl sulfates, such as diethanolammonium lauryl sulphate; alkylarylsulfonate salts, such as calcium dodecylbenzenesulfonate; alkylphenol-alkylene oxide addition products, such as nonylphenol-C.sub. 18 ethoxylate; alcohol-alkylene oxide addition products, such as tridecyl alcohol-C.sub. 16 ethoxylate; soaps, such as sodium stearate; alkylnaphthalenesulfonate salts, such as sodium
5 dibutylnaphthalenesulfonate; dialkyi esters of sulfosuccinate salts, such as sodium di(2-ethylhexyl) sulfosuccinate; sorbitol esters, such as sorbitol oleate; quaternary amines, such as lauryl trimethylammonium chloride; polyethylene glycol esters of fatty acids, such as polyethylene glycol stearate; block copolymers of ethylene oxide and propylene oxide; and salts of mono and dialkyi phosphate esters.

10 Other adjuvants commonly utilized in agricultural compositions include crystallisation inhibitors, viscosity modifiers, suspending agents, spray droplet modifiers, pigments, antioxidants, foaming agents, anti-foaming agents, light-blocking agents, compatibilizing agents, antifoam agents, sequestering agents, neutralising agents and buffers, corrosion inhibitors, dyes, odorants, spreading agents, penetration aids, micronutrients, emollients, lubricants and sticking agents.

15 In addition, further, other biocidally active ingredients or compositions may be combined with the compositions of the invention and used in the methods of the invention and applied simultaneously or sequentially with the compositions of the invention. When applied simultaneously, these further active ingredients may be formulated together with the compositions of the invention or mixed in, for example, the spray tank. These further biocidally active ingredients may be fungicides, herbicides,
20 insecticides, bactericides, acaricides, nematocides and/or plant growth regulators.

Pesticidal agents are referred to herein using their common name are known, for example, from "The Pesticide Manual", 15th Ed., British Crop Protection Council 2009.

In addition, the compositions of the invention may also be applied with one or more systemically acquired resistance inducers ("SAR" inducer). SAR inducers are known and described in, for
25 example, United States Patent No. US 6,919,298 and include, for example, salicylates and the commercial SAR inducer acibenzolar-S-methyl.

The compounds of formula (I) are normally used in the form of agrochemical compositions and can be applied to the crop area or plant to be treated, simultaneously or in succession with further
30 compounds. These further compounds can be e.g. fertilizers or micronutrient donors or other preparations, which influence the growth of plants. They can also be selective herbicides or non-selective herbicides as well as insecticides, fungicides, bactericides, nematocides, molluscicides or mixtures of several of these preparations, if desired together with further carriers, surfactants or application promoting adjuvants customarily employed in the art of formulation.

35 The compounds of formula (I) may be used in the form of (fungicidal) compositions for controlling or protecting against phytopathogenic microorganisms, comprising as active ingredient at least one compound of formula (I) or of at least one preferred individual compound as defined herein, in free form or in agrochemically usable salt form, and at least one of the above-mentioned adjuvants.

The invention therefore provides a composition, preferably a fungicidal composition, comprising
40 at least one compound formula (I) an agriculturally acceptable carrier and optionally an adjuvant. An agricultural acceptable carrier is for example a carrier that is suitable for agricultural use. Agricultural

carriers are well known in the art. Preferably said composition may comprise at least one or more pesticidally-active compounds, for example an additional fungicidal active ingredient in addition to the compound of formula (I).

5 The compound of Formula (I) may be the sole active ingredient of a composition or it may be admixed with one or more additional active ingredients such as a pesticide, fungicide, synergist, herbicide or plant growth regulator where appropriate. An additional active ingredient may, in some cases, result in unexpected synergistic activities.

Examples of suitable additional active ingredients include the following: acycloamino acid
 10 fungicides, aliphatic nitrogen fungicides, amide fungicides, anilide fungicides, antibiotic fungicides, aromatic fungicides, arsenical fungicides, aryl phenyl ketone fungicides, benzamide fungicides, benzanilide fungicides, benzimidazole fungicides, benzothiazole fungicides, botanical fungicides, bridged diphenyl fungicides, carbamate fungicides, carbanilate fungicides, conazole fungicides, copper fungicides, dicarboximide fungicides, dinitrophenol fungicides, dithiocarbamate fungicides,
 15 dithiolane fungicides, furamide fungicides, furanilide fungicides, hydrazide fungicides, imidazole fungicides, mercury fungicides, morpholine fungicides, organophosphorous fungicides, organotin fungicides, oxathiin fungicides, oxazole fungicides, phenylsulfamide fungicides, polysulfide fungicides, pyrazole fungicides, pyridine fungicides, pyrimidine fungicides, pyrrole fungicides, quaternary ammonium fungicides, quinoline fungicides, quinone fungicides, quinoxaline fungicides, strobilurin
 20 fungicides, sulfonanilide fungicides, thiadiazole fungicides, thiazole fungicides, thiazolidine fungicides, thiocarbamate fungicides, thiophene fungicides, triazine fungicides, triazole fungicides, triazolopyrimidine fungicides, urea fungicides, valinamide fungicides, and zinc fungicides.

Examples of suitable additional active ingredients also include the following: 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylene-1,2,3,4-tetrahydro-1,4-methano-
 25 naphthalen-5-yl)-amide, 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid methoxy-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-amide, 1-methyl-3-difluoromethyl-1H-pyrazole-4-carboxylic acid (2-dichloromethylene-3-ethyl-1-methyl-indan-4-yl)-amide (1072957-71-1), 1-methyl-3-difluoromethyl-1H-pyrazole-4-carboxylic acid (4'-methylsulfanyl-biphenyl-2-yl)-amide, 1-methyl-3-difluoromethyl-4H-pyrazole-4-carboxylic acid [2-(2,4-dichloro-phenyl)-2-methoxy-1-methyl-ethyl]-amide, (5-Chloro-2,4-dimethyl-pyridin-3-yl)-(2,3,4-trimethoxy-6-methyl-phenyl)-methanone, (5-Bromo-4-chloro-2-methoxy-pyridin-3-yl)-(2,3,4-trimethoxy-6-methyl-phenyl)-methanone, 2-{2-[(E)-3-(2,6-Dichloro-phenyl)-1-methyl-prop-2-en-(E)-ylideneaminooxymethyl]-phenyl}-2-[(Z)-methoxyimino]-N-methyl-acetamide, 3-[5-(4-Chloro-phenyl)-2,3-dimethyl-isoxazolidin-3-yl]-pyridine, (E)-N-methyl-2-[2-(2,5-dimethylphenoxy)methyl]phenyl]-2-methoxy-iminoacetamide, 4-bromo-2-cyano-N,N-dimethyl-6-trifluoromethylbenzimidazole-1-sulphonamide, a- [N-(3-chloro-2,6-xylyl)-2-methoxyacetamido]-γ-butyrolactone, 4-chloro-2-cyano-N,N-dimethyl-5-p-tolylimidazole-1-sulfonamide, N-allyl-4,5-dimethyl-2-trimethylsilylthiophene-3-carboxamide, N-(1-cyano-1,2-dimethylpropyl)-2-(2,4-dichlorophenoxy)propionamide, N-(2-methoxy-5-pyridyl)-cyclopropane carboxamide, (+,-)-cis-1-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)-cycloheptanol, 2-(1-tert-butyl)-1-(2-chlorophenyl)-3-(1,2,4-triazol-1-yl)-propan-2-ol, 2',6'-dibromo-2-methyl-4-trifluoromethoxy-4'-trifluoromethyl-1,3-thiazole-5-carboxanilide, 1-imidazolyl-1-(4'-chlorophenoxy)-3,3-dimethylbutan-2-one, methyl (E)-2-[2-[6-(2-

cyanophenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[6-(2-
 thioamidophenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[6-(2-
 fluorophenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[6-(2,6-
 difluorophenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[3-(pyrimidin-2-
 5 yloxy)phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[3-(5-methylpyrimidin-2-yloxy)-
 phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[3-(phenyl-sulphonyloxy)phenoxy]phenyl]-3-
 methoxyacrylate, methyl (E)-2-[2-[3-(4-nitrophenoxy)phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-
 [2-phenoxyphenyl]-3-methoxyacrylate, methyl (E)-2-[2-(3,5-dimethyl-benzoyl)pyrrol-1-yl]-3-
 methoxyacrylate, methyl (E)-2-[2-(3-methoxyphenoxy)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(2-
 10 phenylethen-1-yl)-phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(3,5-dichlorophenoxy)pyridin-3-yl]-3-
 methoxyacrylate, methyl (E)-2-(2-(3-(1,1,2,2-tetrafluoroethoxy)phenoxy)phenyl)-3-methoxyacrylate,
 methyl (E)-2-(2-[3-(alpha-hydroxybenzyl)phenoxy]phenyl)-3-methoxyacrylate, methyl (E)-2-(2-(4-
 phenoxy)pyridin-2-yloxy)phenyl)-3-methoxyacrylate, methyl (E)-2-[2-(3-n-propyloxy-phenoxy)phenyl]-3-
 methoxyacrylate, methyl (E)-2-[2-(3-isopropyloxyphenoxy)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-
 15 [3-(2-fluorophenoxy)phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(3-ethoxyphenoxy)phenyl]-3-
 methoxyacrylate, methyl (E)-2-[2-(4-tert-butyl-pyridin-2-yloxy)phenyl]-3-methoxyacrylate, methyl (E)-2-
 [2-[3-(3-cyanophenoxy)phenoxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[(3-methyl-pyridin-2-
 yloxymethyl)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[6-(2-methyl-phenoxy)pyrimidin-4-
 20 yloxy]phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(5-bromo-pyridin-2-yloxymethyl)phenyl]-3-
 methoxyacrylate, methyl (E)-2-[2-(3-(3-iodopyridin-2-yloxy)phenoxy)phenyl]-3-methoxyacrylate, methyl
 (E)-2-[2-[6-(2-chloropyridin-3-yloxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E),(E)-2-[2-
 (5,6-dimethylpyrazin-2-ylmethylloximinomethyl)phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[6-(6-
 methylpyridin-2-yloxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E),(E)-2-[2-(3-
 methoxyphenyl)methylloximinomethyl]-phenyl]-3-methoxyacrylate, methyl (E)-2-[2-(6-(2-
 25 azidophenoxy)-pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E),(E)-2-[2-[6-phenylpyrimidin-4-
 yl)-methylloximinomethyl]phenyl]-3-methoxyacrylate, methyl (E),(E)-2-[2-[(4-chlorophenyl)-
 methylloximinomethyl]-phenyl]-3-methoxyacrylate, methyl (E)-2-[2-[6-(2-n-propylphenoxy)-1,3,5-
 triazin-4-yloxy]phenyl]-3-methoxyacrylate, methyl (E),(E)-2-[2-[(3-
 nitrophenyl)methylloximinomethyl]phenyl]-3-methoxyacrylate, 3-chloro-7-(2-aza-2,7,7-trimethyl-oct-3-
 30 en-5-ine), 2,6-dichloro-N-(4-trifluoromethylbenzyl)-benzamide, 3-iodo-2-propinyl alcohol, 4-
 chlorophenyl-3-iodopropargyl formal, 3-bromo-2,3-diiodo-2-propenyl ethylcarbamate, 2,3,3-triiodoallyl
 alcohol, 3-bromo-2,3-diiodo-2-propenyl alcohol, 3-iodo-2-propinyl n-butylcarbamate, 3-iodo-2-propinyl
 n-hexylcarbamate, 3-iodo-2-propinyl cyclohexyl-carbamate, 3-iodo-2-propinyl phenylcarbamate;
 phenol derivatives, such as tribromophenol, tetrachlorophenol, 3-methyl-4-chlorophenol, 3,5-dimethyl-
 35 4-chlorophenol, phenoxyethanol, dichlorophene, o-phenylphenol, m-phenylphenol, p-phenylphenol, 2-
 benzyl-4-chlorophenol, 5-hydroxy-2(5H)-furanone; 4,5-dichlorodithiazolinone, 4,5-benzodithiazolinone,
 4,5-trimethylenedithiazolinone, 4,5-dichloro-(3H)-1,2-dithiol-3-one, 3,5-dimethyl-tetrahydro-1,3,5-
 thiadiazine-2-thione, N-(2-p-chlorobenzoyl)ethyl)-hexaminium chloride, acibenzolar, acypetacs,
 alanycarb, albendazole, aldimorph, allacin, allyl alcohol, ametoctradin, amisulbrom, amobam,
 40 ampropylfos, anilazine, asomate, aureofungin, azaconazole, azafendin, azithiram, azoxystrobin,
 barium polysulfide, benalaxyl, benalaxyl-M, benodanil, benomyl, benquinox, bentaluron,

benthiavalicarb, benthiazole, benzalkonium chloride, benzamacril, benzamorf, benzohydroxamic acid, benzovindiflupyr, berberine, bethoxazin, biloxazol, binapacryl, biphenyl, bitertanol, bithionol, bixafen, blasticidin-S, boscalid, bromothalonil, bromuconazole, bupirimate, buthiobate, butylamine calcium polysulfide, captafol, captan, carbamorph, carbendazim, carbendazim chlorhydrate, carboxin, 5 carpropamid, carvone, CGA41396, CGA41397, chinomethionate, chitosan, chlobenthiazone, chloraniformethan, chloranil, chlorfenazole, chloroneb, chloropicrin, chlorothalonil, chlorozolate, chlozolate, climbazole, clotrimazole, clozylacon, copper containing compounds such as copper acetate, copper carbonate, copper hydroxide, copper naphthenate, copper oleate, copper oxychloride, copper oxyquinolate, copper silicate, copper sulphate, copper tallate, copper zinc chromate and 10 Bordeaux mixture, cresol, cufraneb, cuprobam, cuprous oxide, cyazofamid, cyclafuramid, cycloheximide, cyflufenamid, cymoxanil, cypendazole, cyproconazole, cyprodinil, dazomet, debacarb, decafentin, dehydroacetic acid, di-2-pyridyl disulphide 1, 1'-dioxide, dichlofluanid, diclomezine, dichlone, dicloran, dichlorophen, dichlozoline, diclobutrazol, diclocymet, diethofencarb, difenoconazole, difenzoquat, diflumerimol, O, O-di-iso-propyl-S-benzyl thiophosphate, dimefluazole, 15 dimetachlone, dimetconazole, dimethomorph, dimethirimol, diniconazole, diniconazole-M, dinobuton, dinocap, dinocton, dinopenton, dinosulfon, dinoterbon, diphenylamine, dipyrithione, disulfiram, ditalimfos, dithianon, dithioether, dodecyl dimethyl ammonium chloride, dodemorph, dodicin, dodine, doguadine, drazoxolon, edifenphos, enestroburin, epoxiconazole, etaconazole, etem, ethaboxam, ethirimol, ethoxyquin, ethilicin, ethyl (Z)-N-benzyl-N [(methyl (methyl-thioethylideneamino- 20 oxycarbonyl) amino] thio)-alaninate, etridiazole, famoxadone, fenamidone, fenaminosulf, fenapanil, fenarimol, fenbuconazole, fenfuram, fenhexamid, fenitropan, fenoxanil, fencpiclonil, fencpicoxamid, fenpropidin, fenpropimorph, fenpyrazamine, fentin acetate, fentin hydroxide, ferbam, ferimzone, fluazinam, fludioxonil, flumetover, flumorph, flupicolide, fluopyram, fluoroimide, fluotrimazole, fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutanil, flutolanil, flutriafol, fluxapyroxad, folpet, 25 formaldehyde, fosetyl, fuberidazole, furalaxyl, furametpyr, furcarbanil, furconazole, furfural, furnecyclox, furophanate, glyodin, griseofulvin, guazatine, halacrinat, hexa chlorobenzene, hexachlorobutadiene, hexachlorophene, hexaconazole, hexylthiofos, hydrargaphen, hydroxyisoxazole, hymexazole, imazalil, imazalil sulphate, imibenconazole, iminoctadine, iminoctadine triacetate, inezin, iodocarb, ipconazole, ipfentrifluconazole, iprobenfos, iprodione, iprovalicarb, isopropanil butyl 30 carbamate, isoprothiolane, isopyrazam, isotianil, isovalledione, izopamfos, kasugamycin, kresoxim-methyl, LY186054, LY21 1795, LY248908, mancozeb, mandipropamid, maneb, mebenil, mecarbinzid, mefenoxam, mefentrifluconazole, mepanipyrim, mepronil, mercuric chloride, mercurous chloride, meptyldinocap, metalaxyl, metalaxyl-M, metam, metazoxolon, metconazole, methasulfocarb, methfuroxam, methyl bromide, methyl iodide, methyl isothiocyanate, metiram, metiram-zinc, 35 metominostrobin, metrafenone, metsulfovax, milneb, moroxydine, myclobutanil, myclozolin, nabam, natamycin, neoasozin, nickel dimethyldithiocarbamate, nitrostyrene, nitrothal-iso- propyl, nuarimol, octhilonone, ofurace, organomercury compounds, oryastrobin, osthol, oxadixyl, oxasulfuron, oxathiapiprolin, oxine-copper, oxolinic acid, oxpoconazole, oxycarboxin, parinol, pefurazoate, penconazole, pencycuron, penflufen, pentachlorophenol, penthiopyrad, phenamacril, phenazin oxide, 40 phosdiphen, phosetyl-Al, phosphorus acids, phthalide, picoxystrobin, piperalin, polycarbamate, polyoxin D, polyoxrim, polyram, probenazole, prochloraz, procymidone, propamidine, propamocarb,

propiconazole, propineb, propionic acid, proquinazid, prothiocarb, prothioconazole, pydiflumetofen, pyracarbolid, pyraclostrobin, pyrametrostrobin, pyraoxystrobin, pyrazophos, pyribencarb, pyridinitril, pyrifenox, pyrimethanil, pyriofenone, pyroquilon, pyroxychlor, pyroxyfur, pyrrolnitrin, quaternary ammonium compounds, quinacetol, quinazamid, quinconazole, quinomethionate, quinoxifen, 5 quintozene, rabenzazole, santonin, sedaxane, silthiofam, simeconazole, sipconazole, sodium pentachlorophenate, spiroxamine, streptomycin, sulphur, sultropen, tebuconazole, tebfloquin, tecloftalam, tecnazene, tecoram, tetraconazole, thiabendazole, thiadifluor, thicyofen, thifluzamide, 2-(thiocyanomethylthio) benzothiazole, thiophanate-methyl, thioquinox, thiram, tiadinil, timibenconazole, tioxyimid, tolclofos-methyl, tolylfluanid, triadimefon, triadimenol, triamiphos, triarimol, triazbutil, 10 triazoxide, tricyclazole, tridemorph, trifloxystrobin, triflumazole, triforine, triflumizole, triticonazole, uniconazole, urbacide, validamycin, valifenalate, vapam, vinclozolin, zarilamid, zineb, ziram, and zoxamide.

The compounds of the invention may also be used in combination with anthelmintic agents. 15 Such anthelmintic agents include, compounds selected from the macrocyclic lactone class of compounds such as ivermectin, avermectin, abamectin, emamectin, eprinomectin, doramectin, selamectin, moxidectin, nemadectin and milbemycin derivatives as described in EP- 357460, EP- 444964 and EP-594291. Additional anthelmintic agents include semisynthetic and biosynthetic avermectin/milbemycin derivatives such as those described in US-5015630, WO-9415944 and WO- 20 9522552. Additional anthelmintic agents include the benzimidazoles such as albendazole, cambendazole, fenbendazole, flubendazole, mebendazole, oxfendazole, oxibendazole, parbendazole, and other members of the class. Additional anthelmintic agents include imidazothiazoles and tetrahydropyrimidines such as tetramisole, levamisole, pyrantel pamoate, oxantel or morantel. Additional anthelmintic agents include flukicides, such as triclabendazole and clorsulon and the 25 cestocides, such as praziquantel and epsiprantel.

The compounds of the invention may be used in combination with derivatives and analogues of the paraherquamide/marcfortine class of anthelmintic agents, as well as the antiparasitic oxazolines such as those disclosed in US-5478855, US- 4639771 and DE-1 9520936.

The compounds of the invention may be used in combination with derivatives and analogues 30 of the general class of dioxomorpholine antiparasitic agents as described in WO 96/15121 and also with anthelmintic active cyclic depsipeptides such as those described in WO 96/1 1945, WO 93/19053, WO 93/25543, EP 0 626 375, EP 0 382 173, WO 94/19334, EP 0 382 173, and EP 0 503 538.

The compounds of the invention may be used in combination with other ectoparasiticides; for example, fipronil; pyrethroids; organophosphates; insect growth regulators such as lufenuron; 35 ecdysone agonists such as tebufenozide and the like; neonicotinoids such as imidacloprid and the like.

The compounds of the invention may be used in combination with terpene alkaloids, for example those described in International Patent Application Publication Numbers WO 95/19363 or WO 04/72086, particularly the compounds disclosed therein.

40 Other examples of such biologically active compounds that the compounds of the invention may be used in combination with include but are not restricted to the following:

Organophosphates: acephate, azamethiphos, azinphos-ethyl, azinphos- methyl, bromophos, bromophos-ethyl, cadusafos, chlorethoxyphos, chlorpyrifos, chlorfenvinphos, chlormephos, demeton, demeton-S-methyl, demeton-S-methyl sulphone, dialifos, diazinon, dichlorvos, dicrotophos, dimethoate, disulfoton, ethion, ethoprophos, etrimfos, famphur, fenamiphos, fenitrothion, fensulfothion, 5 fenthion, flupyrazofos, fonofos, formothion, fosthiazate, heptenophos, isazophos, isothioate, isoxathion, malathion, methacriphos, methamidophos, methidathion, methyl- parathion, mevinphos, monocrotophos, naled, omethoate, oxydemeton-methyl, paraoxon, parathion, parathion-methyl, phenthoate, phosalone, phosfolan, phosphocarb, phosmet, phosphamidon, phorate, phoxim, pirimiphos, pirimiphos- methyl, profenofos, propaphos, proetamphos, prothiofos, pyraclofos, 10 pyridapenthion, quinalphos, sulprophos, temephos, terbufos, tebupirimfos, tetrachlorvinphos, thimeton, triazophos, trichlorfon, vamidothion.

Carbamates: alanycarb, aldicarb, 2-sec-butylphenyl methylcarbamate, benfuracarb, carbaryl, carbofuran, carbosulfan, cloethocarb, ethiofencarb, fenoxycarb, fenthioicarb, furathiocarb, HCN-801 , isoprocarb, indoxacarb, methiocarb, methomyl, 5-methyl-m-cumenylbutyryl(methyl)carbamate, 15 oxamyl, pirimicarb, propoxur, thiodicarb, thiofanox, triazamate, UC-51 7 17.

Pyrethroids: acrinathin, allethrin, alphametrin, 5-benzyl-3-furylmethyl (E)-(1 R)-cis-2,2-dimethyl-3-(2-oxothiolan-3-ylidenemethyl)cyclopropanecarboxylate, bifenthrin, beta-cyfluthrin, cyfluthrin, a-cypermethrin, beta-cypermethrin, bioallethrin, bioallethrin((S)-cyclopentylisomer), bioresmethrin, bifenthrin, NCI-851 93, cycloprothrin, cyhalothrin, cythithrin, cyphenothrin, deltamethrin, 20 empenethrin, esfenvalerate, ethofenprox, fenfluthrin, fenpropathrin, fenvalerate, flucythrinate, flumethrin, fluvalinate (D isomer), imiprothrin, cyhalothrin, lambda-cyhalothrin, permethrin, phenothrin, prallethrin, pyrethrins (natural products), resmethrin, tetramethrin, transluthrin, theta-cypermethrin, silafluofen, t-fluvalinate, tefluthrin, tralomethrin, Zeta-cypermethrin.

Arthropod growth regulators: a) chitin synthesis inhibitors: benzoylureas: chlorfluazuron, 25 diflubenzuron, fluazuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, teflubenzuron, triflumuron, buprofezin, diofenolan, hexythiazox, etoxazole, chlorfentazine; b) ecdysone antagonists: halofenozide, methoxyfenozide, tebufenozide; c) juvenoids: pyriproxyfen, methoprene (including S-methoprene), fenoxycarb; d) lipid biosynthesis inhibitors: spiroticlofen.

Other antiparasitics: acequinocyl, amitraz, AKD-1 022, ANS-1 18, azadirachtin, Bacillus 30 thuringiensis, bensultap, bifenazate, binapacryl, bromopropylate, BTG-504, BTG-505, camphechlor, cartap, chlorobenzilate, chlordimeform, chlorfenapyr, chromafenozide, clothianidine, cyromazine, diaclofen, diafenthiuron, DBI-3204, dinactin, dihydroxymethyldihydroxypyrrolidine, dinobuton, dinocap, endosulfan, ethiprole, ethofenprox, fenazaquin, flumite, MTI- 800, fenpyroximate, fluacrypyrim, flubenzimine, flubrocycythrinate, flufenzine, flufenprox, fluproxyfen, halofenprox, 35 hydramethylnon, IKI-220, kanemite, NC-1 96, neem guard , nidinorterfuran, nitenpyram, SD-35651 , WL-1 08477, pirydaryl, propargite, protrifenbute, pymethrozone, pyridaben, pyrimidifen, NC-1 111, R-195,RH-0345, RH-2485, RYI-21 0, S-1 283, S-1 833, SI-8601 , silafluofen, silomadine, spinosad , tebufenpyrad, tetradifon, tetranactin, thiacloprid, thiocyclam, thiamethoxam, tolfenpyrad, triazamate, triethoxyspinosyn, trinactin, verbutin, vertalec, YI-5301 .

40 Biological agents: Bacillus thuringiensis ssp aizawai, kurstaki, Bacillus thuringiensis delta endotoxin, baculovirus, entomopathogenic bacteria, virus and fungi.

Bactericides: chlortetracycline, oxytetracycline, streptomycin.

Other biological agents: enrofloxacin, febantel, penethamate, moloxicam, cefalexin, kanamycin, pimobendan, clenbuterol, omeprazole, tiamulin, benazepril, pyriprole, cefquinome, florfenicol, buserelin, cefovecin, tulathromycin, ceftiour, carprofen, metaflumizone, praziquarantel,
5 triclabendazole.

The following mixtures of the compounds of formula (I) with active ingredients are preferred. The abbreviation "TX" means one compound selected from the group consisting of the compounds described in: Tables 1.1 to 1.12 or Table T1 (below); Tables 2.1 to 2.4 or Table T2 (below); Tables 3.1
10 to 3.6 or Table T3 (below); or Table T4 (below).

an adjuvant selected from the group of substances consisting of petroleum oils (alternative name) (628) + TX,

an acaricide selected from the group of substances consisting of 1,1-bis(4-chlorophenyl)-2-
15 ethoxyethanol (IUPAC name) (910) + TX, 2,4-dichlorophenyl benzenesulfonate (IUPAC/Chemical Abstracts name) (1059) + TX, 2-fluoro-*A*-methyl-*A*'-1-naphthylacetamide (IUPAC name) (1295) + TX, 4-chlorophenyl phenyl sulfone (IUPAC name) (981) + TX, abamectin (1) + TX, acequinocyl (3) + TX, acetoprole [CCN] + TX, acrinathrin (9) + TX, aldicarb (16) + TX, aldoxycarb (863) + TX, alpha-cypermethrin (202) + TX, amidithion (870) + TX, amidoflumet [CCN] + TX, amidothioate (872) + TX,
20 amiton (875) + TX, amiton hydrogen oxalate (875) + TX, amitraz (24) + TX, aramite (881) + TX, arsenous oxide (882) + TX, AVI 382 (compound code) + TX, AZ 60541 (compound code) + TX, azinphos-ethyl (44) + TX, azinphos-methyl (45) + TX, azobenzene (IUPAC name) (888) + TX, azocyclotin (46) + TX, azothoate (889) + TX, benomyl (62) + TX, benoxafos (alternative name) [CCN] + TX, benzoximate (71) + TX, benzyl benzoate (IUPAC name) [CCN] + TX, bifenazate (74) + TX,
25 bifenthrin (76) + TX, binapacryl (907) + TX, brofenvalerate (alternative name) + TX, bromocyclen (918) + TX, bromophos (920) + TX, bromophos-ethyl (921) + TX, bromopropylate (94) + TX, buprofezin (99) + TX, butocarboxim (103) + TX, butoxycarboxim (104) + TX, butylpyridaben (alternative name) + TX, calcium polysulfide (IUPAC name) (111) + TX, camphechlor (941) + TX, carbanolate (943) + TX, carbaryl (115) + TX, carbofuran (118) + TX, carbophenothion (947) + TX, CGA 50'439 (development
30 code) (125) + TX, chinomethionat (126) + TX, chlorbenside (959) + TX, chlordimeform (964) + TX, chlordimeform hydrochloride (964) + TX, chlorfenapyr (130) + TX, chlorfenethol (968) + TX, chlorfenson (970) + TX, chlorfensulfide (971) + TX, chlorfenvinphos (131) + TX, chlorobenzilate (975) + TX, chloromebuform (977) + TX, chloromethiuron (978) + TX, chloropropylate (983) + TX, chlorpyrifos (145) + TX, chlorpyrifos-methyl (146) + TX, chlorthiophos (994) + TX, cinerin I (696) + TX,
35 cinerin II (696) + TX, cinerins (696) + TX, clofentezine (158) + TX, closantel (alternative name) [CCN] + TX, coumaphos (174) + TX, crotamiton (alternative name) [CCN] + TX, crotoxyphos (1010) + TX, cufraneb (1013) + TX, cyanthoate (1020) + TX, cyflumetofen (CAS Reg. No.: 400882-07-7) + TX, cyhalothrin (196) + TX, cyhexatin (199) + TX, cypermethrin (201) + TX, DCPM (1032) + TX, DDT (219) + TX, demephion (1037) + TX, demephion-0 (1037) + TX, demephion-S (1037) + TX, demeton (1038)
40 + TX, demeton-methyl (224) + TX, demeton-0 (1038) + TX, demeton-O-methyl (224) + TX, demeton-S (1038) + TX, demeton-S-methyl (224) + TX, demeton-S-methylsulfon (1039) + TX, diafenthion (226)

+ TX, dialifos (1042) + TX, diazinon (227) + TX, dichlofluanid (230) + TX, dichlorvos (236) + TX, dicliphos (alternative name) + TX, dicofol (242) + TX, dicrotophos (243) + TX, dienochlor (1071) + TX, dimefox (1081) + TX, dimethoate (262) + TX, dinactin (alternative name) (653) + TX, dinex (1089) + TX, dinex-diclexine (1089) + TX, dinobuton (269) + TX, dinocap (270) + TX, dinocap-4 [CCN] + TX, 5 dinocap-6 [CCN] + TX, dinocton (1090) + TX, dinopenton (1092) + TX, dinosulfon (1097) + TX, dinoterbon (1098) + TX, dioxathion (1102) + TX, diphenyl sulfone (IUPAC name) (1103) + TX, disulfiram (alternative name) [CCN] + TX, disulfoton (278) + TX, DNOC (282) + TX, dofenapyn (1113) + TX, doramectin (alternative name) [CCN] + TX, endosulfan (294) + TX, endothion (1121) + TX, EPN (297) + TX, eprinomectin (alternative name) [CCN] + TX, ethion (309) + TX, ethoate-methyl (1134) + 10 TX, etoxazole (320) + TX, etrimfos (1142) + TX, fenazaflor (1147) + TX, fenazaquin (328) + TX, fenbutatin oxide (330) + TX, fenothiocarb (337) + TX, fenpropathrin (342) + TX, fenpyrad (alternative name) + TX, fenpyroximate (345) + TX, fenson (1157) + TX, fentrifanil (1161) + TX, fenvalerate (349) + TX, fipronil (354) + TX, fluacrypyrim (360) + TX, fluazuron (1166) + TX, flubenzimine (1167) + TX, flucycloxuron (366) + TX, flucythrinate (367) + TX, fluenetil (1169) + TX, flufenoxuron (370) + TX, 15 flumethrin (372) + TX, fluorbenside (1174) + TX, fluvalinate (1184) + TX, FMC 1137 (development code) (1185) + TX, formetanate (405) + TX, formetanate hydrochloride (405) + TX, formothion (1192) + TX, formparanate (1193) + TX, gamma-HCH (430) + TX, glyodin (1205) + TX, halfenprox (424) + TX, heptenophos (432) + TX, hexadecyl cyclopropanecarboxylate (IUPAC/Chemical Abstracts name) (1216) + TX, hexythiazox (441) + TX, iodomethane (IUPAC name) (542) + TX, isocarbophos 20 (alternative name) (473) + TX, isopropyl 0-(methoxyaminothiophosphoryl)salicylate (IUPAC name) (473) + TX, ivermectin (alternative name) [CCN] + TX, jasmolin I (696) + TX, jasmolin II (696) + TX, jodfenphos (1248) + TX, lindane (430) + TX, lufenuron (490) + TX, malathion (492) + TX, malonoben (1254) + TX, mecarbarn (502) + TX, mephosfolan (1261) + TX, mesulfen (alternative name) [CCN] + TX, methacrifos (1266) + TX, methamidophos (527) + TX, methidathion (529) + TX, methiocarb (530) 25 + TX, methomyl (531) + TX, methyl bromide (537) + TX, metolcarb (550) + TX, mevinphos (556) + TX, mexacarbate (1290) + TX, milbemectin (557) + TX, milbemycin oxime (alternative name) [CCN] + TX, mipafox (1293) + TX, monocrotophos (561) + TX, morphothion (1300) + TX, moxidectin (alternative name) [CCN] + TX, naled (567) + TX, NC-184 (compound code) + TX, NC-512 (compound code) + TX, nifluridide (1309) + TX, nikkomycins (alternative name) [CCN] + TX, nitrilacarb (1313) + TX, 30 nitrilacarb 1:1 zinc chloride complex (1313) + TX, NNI-0101 (compound code) + TX, NNI-0250 (compound code) + TX, omethoate (594) + TX, oxamyl (602) + TX, oxydeprofos (1324) + TX, oxydisulfoton (1325) + TX, pp'-DDT (219) + TX, parathion (615) + TX, permethrin (626) + TX, petroleum oils (alternative name) (628) + TX, phenkapton (1330) + TX, phenthoate (631) + TX, phorate (636) + TX, phosalone (637) + TX, phosfolan (1338) + TX, phosmet (638) + TX, 35 phosphamidon (639) + TX, phoxim (642) + TX, pirimiphos-methyl (652) + TX, polychloroterpenes (traditional name) (1347) + TX, polynactins (alternative name) (653) + TX, proclonol (1350) + TX, profenofos (662) + TX, promacyl (1354) + TX, propargite (671) + TX, propetamphos (673) + TX, propoxur (678) + TX, prothidathion (1360) + TX, prothoate (1362) + TX, pyrethrin I (696) + TX, pyrethrin II (696) + TX, pyrethrins (696) + TX, pyridaben (699) + TX, pyridaphenthion (701) + TX, 40 pyrimidifen (706) + TX, pyrimitate (1370) + TX, quinalphos (711) + TX, quintiofos (1381) + TX, R-1492 (development code) (1382) + TX, RA-17 (development code) (1383) + TX, rotenone (722) + TX,

schradan (1389) + TX, sebufos (alternative name) + TX, selamectin (alternative name) [CCN] + TX, SI-0009 (compound code) + TX, sophamide (1402) + TX, spirodiclofen (738) + TX, spiromesifen (739) + TX, SSI-121 (development code) (1404) + TX, sulfiram (alternative name) [CCN] + TX, sulfluramid (750) + TX, sulfotep (753) + TX, sulfur (754) + TX, SZI-121 (development code) (757) + TX, tau-
 5 fluvalinate (398) + TX, tebufenpyrad (763) + TX, TEPP (1417) + TX, terbam (alternative name) + TX, tetrachlorvinphos (777) + TX, tetradifon (786) + TX, tetranactin (alternative name) (653) + TX, tetrasul (1425) + TX, thiafenox (alternative name) + TX, thiocarboxime (1431) + TX, thiofanox (800) + TX, thiometon (801) + TX, thioquinox (1436) + TX, thuringiensin (alternative name) [CCN] + TX, triamiphos (1441) + TX, triarathene (1443) + TX, triazophos (820) + TX, triazuron (alternative name) + TX,
 10 trichlorfon (824) + TX, trifenofos (1455) + TX, trinactin (alternative name) (653) + TX, vamidothion (847) + TX, vaniliprole [CCN] and YI-5302 (compound code) + TX,

an algicide selected from the group of substances consisting of bethoxazin [CCN] + TX, copper dioctanoate (IUPAC name) (170) + TX, copper sulfate (172) + TX, cybutryne [CCN] + TX, dichlone (1052) + TX, dichlorophen (232) + TX, endothal (295) + TX, fentin (347) + TX, hydrated lime
 15 [CCN] + TX, nabam (566) + TX, quinochloramine (714) + TX, quinonamid (1379) + TX, simazine (730) + TX, triphenyltin acetate (IUPAC name) (347) and triphenyltin hydroxide (IUPAC name) (347) + TX,

an anthelmintic selected from the group of substances consisting of abamectin (1) + TX, crufomate (1011) + TX, doramectin (alternative name) [CCN] + TX, emamectin (291) + TX, emamectin benzoate (291) + TX, eprinomectin (alternative name) [CCN] + TX, ivermectin (alternative name)
 20 [CCN] + TX, milbemycin oxime (alternative name) [CCN] + TX, moxidectin (alternative name) [CCN] + TX, piperazine [CCN] + TX, selamectin (alternative name) [CCN] + TX, spinosad (737) and thiophanate (1435) + TX,

an avicide selected from the group of substances consisting of chloralose (127) + TX, endrin (1122) + TX, fenthion (346) + TX, pyridin-4-amine (IUPAC name) (23) and strychnine (745) + TX,

a bactericide selected from the group of substances consisting of 1-hydroxy-1-*l*-pyridine-2-thione (IUPAC name) (1222) + TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide (IUPAC name) (748) + TX, 8-hydroxyquinoline sulfate (446) + TX, bronopol (97) + TX, copper dioctanoate (IUPAC name) (170) + TX, copper hydroxide (IUPAC name) (169) + TX, cresol [CCN] + TX, dichlorophen (232) + TX, dipyrithione (1105) + TX, dodicin (1112) + TX, fenaminosulf (1144) + TX, formaldehyde (404) + TX,
 30 hydrargaphen (alternative name) [CCN] + TX, kasugamycin (483) + TX, kasugamycin hydrochloride hydrate (483) + TX, nickel bis(dimethyldithiocarbamate) (IUPAC name) (1308) + TX, nitrapyrin (580) + TX, octhilinone (590) + TX, oxolinic acid (606) + TX, oxytetracycline (611) + TX, potassium hydroxyquinoline sulfate (446) + TX, probenazole (658) + TX, streptomycin (744) + TX, streptomycin sesquisulfate (744) + TX, tecloftalam (766) + TX, and thiomersal (alternative name) [CCN] + TX,

a biological agent selected from the group of substances consisting of *Adoxophyes orana* GV (alternative name) (12) + TX, *Agrobacterium radiobacter* (alternative name) (13) + TX, *Amblyseius* spp. (alternative name) (19) + TX, *Anagrapha falcifera* NPV (alternative name) (28) + TX, *Anagrus atomus* (alternative name) (29) + TX, *Aphelinus abdominalis* (alternative name) (33) + TX, *Aphidius colemani* (alternative name) (34) + TX, *Aphidoletes aphidimyza* (alternative name) (35) + TX,
 40 *Autographa californica* NPV (alternative name) (38) + TX, *Bacillus firmus* (alternative name) (48) + TX, *Bacillus sphaericus* Neide (scientific name) (49) + TX, *Bacillus thuringiensis* Berliner (scientific name)

(51) + TX, *Bacillus thuringiensis* subsp. *aizawai* (scientific name) (51) + TX, *Bacillus thuringiensis* subsp. *israelensis* (scientific name) (51) + TX, *Bacillus thuringiensis* subsp. *japonensis* (scientific name) (51) + TX, *Bacillus thuringiensis* subsp. *kurstaki* (scientific name) (51) + TX, *Bacillus thuringiensis* subsp. *tenebrionis* (scientific name) (51) + TX, *Beauveria bassiana* (alternative name) (53) + TX, *Beauveria brongniartii* (alternative name) (54) + TX, *Chrysoperla carnea* (alternative name) (151) + TX, *Cryptolaemus montrouzieri* (alternative name) (178) + TX, *Cydia pomonella* GV (alternative name) (191) + TX, *Dacnusa sibirica* (alternative name) (212) + TX, *Diglyphus isaea* (alternative name) (254) + TX, *Encarsia formosa* (scientific name) (293) + TX, *Eretmocerus eremicus* (alternative name) (300) + TX, *Helicoverpa zea* NPV (alternative name) (431) + TX, *Heterorhabditis bacteriophora* and *H. megidis* (alternative name) (433) + TX, *Hippodamia convergens* (alternative name) (442) + TX, *Leptomastix dactylopii* (alternative name) (488) + TX, *Macrolophus caliginosus* (alternative name) (491) + TX, *Mamestra brassicae* NPV (alternative name) (494) + TX, *Metaphycus helvolus* (alternative name) (522) + TX, *Metarhizium anisopliae* var. *acridum* (scientific name) (523) + TX, *Metarhizium anisopliae* var. *anisopliae* (scientific name) (523) + TX, *Neodiprion sertifer* NPV and *N. lecontei* NPV (alternative name) (575) + TX, *Orius* spp. (alternative name) (596) + TX, *Paecilomyces fumosoroseus* (alternative name) (613) + TX, *Phytoseiulus persimilis* (alternative name) (644) + TX, *Spodoptera exigua* multicapsid nuclear polyhedrosis virus (scientific name) (741) + TX, *Steinemema bibionis* (alternative name) (742) + TX, *Steinemema carpocapsae* (alternative name) (742) + TX, *Steinemema feltiae* (alternative name) (742) + TX, *Steinemema glaseri* (alternative name) (742) + TX, *Steinemema riobrave* (alternative name) (742) + TX, *Steinemema riobravus* (alternative name) (742) + TX, *Steinemema scapterisci* (alternative name) (742) + TX, *Steinemema* spp. (alternative name) (742) + TX, *Trichogramma* spp. (alternative name) (826) + TX, *Typhlodromus occidentalis* (alternative name) (844) and *Verticillium lecanii* (alternative name) (848) + TX, *bacillus subtilis* var. *amyloliquefaciens* Strain FZB24 (available from Novozymes Biologicals Inc., 5400 Corporate Circle, Salem, VA 24153, U.S.A. and known under the trade name Taegro®) + TX,

a soil sterilant selected from the group of substances consisting of iodomethane (IUPAC name) (542) and methyl bromide (537) + TX,

a chemosterilant selected from the group of substances consisting of apholate [CCN] + TX, bisazir (alternative name) [CCN] + TX, busulfan (alternative name) [CCN] + TX, diflubenzuron (250) + TX, dimatif (alternative name) [CCN] + TX, hemel [CCN] + TX, hempa [CCN] + TX, metepa [CCN] + TX, methiotepa [CCN] + TX, methyl apholate [CCN] + TX, morzid [CCN] + TX, penfluron (alternative name) [CCN] + TX, tepa [CCN] + TX, thiohempa (alternative name) [CCN] + TX, thiotepa (alternative name) [CCN] + TX, tretamine (alternative name) [CCN] and uredepa (alternative name) [CCN] + TX,

an insect pheromone selected from the group of substances consisting of (E)-dec-5-en-1-yl acetate with (E)-dec-5-en-1-ol (IUPAC name) (222) + TX, (E)-tridec-4-en-1-yl acetate (IUPAC name) (829) + TX, (E)-6-methylhept-2-en-4-ol (IUPAC name) (541) + TX, (E,Z)-tetradeca-4, 10-dien-1-yl acetate (IUPAC name) (779) + TX, (Z)-dodec-7-en-1-yl acetate (IUPAC name) (285) + TX, (Z)-hexadec-1-ene-1-yl acetate (IUPAC name) (436) + TX, (Z)-hexadec-1-ene-1-yl acetate (IUPAC name) (437) + TX, (Z)-hexadec-1-ene-1-yl acetate (IUPAC name) (438) + TX, (Z)-icos-13-en-1-one (IUPAC name) (448) + TX, (Z)-tetradec-7-en-1-yl acetate (IUPAC name) (782) + TX, (Z)-tetradec-9-en-1-yl acetate (IUPAC name) (783) + TX, (Z)-tetradec-9-en-1-yl acetate (IUPAC name) (784) + TX, (7E,9Z)-dodeca-7,9-dien-

1-yl acetate (IUPAC name) (283) + TX, (9Z, 11E)-tetradeca-9, 11-dien-1-yl acetate (IUPAC name) (780) + TX, (9Z, 12E)-tetradeca-9, 12-dien-1-yl acetate (IUPAC name) (781) + TX, 14-methyloctadec-1-ene (IUPAC name) (545) + TX, 4-methylnonan-5-ol with 4-methylnonan-5-one (IUPAC name) (544) + TX, alpha-multistriatin (alternative name) [CCN] + TX, brevicomin (alternative name) [CCN] + TX, codlelure
 5 (alternative name) [CCN] + TX, codlemone (alternative name) (167) + TX, cuelure (alternative name) (179) + TX, dispartlure (277) + TX, dodec-8-en-1-yl acetate (IUPAC name) (286) + TX, dodec-9-en-1-yl acetate (IUPAC name) (287) + TX, dodeca-8 + TX, 10-dien-1-yl acetate (IUPAC name) (284) + TX, dominicalure (alternative name) [CCN] + TX, ethyl 4-methyloctanoate (IUPAC name) (317) + TX, eugenol (alternative name) [CCN] + TX, frontalinal (alternative name) [CCN] + TX, gossyplure
 10 (alternative name) (420) + TX, grandlure (421) + TX, grandlure I (alternative name) (421) + TX, grandlure II (alternative name) (421) + TX, grandlure III (alternative name) (421) + TX, grandlure IV (alternative name) (421) + TX, hexalure [CCN] + TX, ipsdienol (alternative name) [CCN] + TX, ipsenol (alternative name) [CCN] + TX, japonilure (alternative name) (481) + TX, lineatin (alternative name) [CCN] + TX, litlure (alternative name) [CCN] + TX, looplure (alternative name) [CCN] + TX, medlure
 15 [CCN] + TX, megatomoic acid (alternative name) [CCN] + TX, methyl eugenol (alternative name) (540) + TX, muscalure (563) + TX, octadeca-2, 13-dien-1-yl acetate (IUPAC name) (588) + TX, octadeca-3, 13-dien-1-yl acetate (IUPAC name) (589) + TX, orfralure (alternative name) [CCN] + TX, oryctalure (alternative name) (317) + TX, ostramone (alternative name) [CCN] + TX, siglure [CCN] + TX, sordidin (alternative name) (736) + TX, sulcatol (alternative name) [CCN] + TX, tetradec-1-ene-1-yl acetate
 20 (IUPAC name) (785) + TX, trimedlure (839) + TX, trimedlure A (alternative name) (839) + TX, trimedlure B₁ (alternative name) (839) + TX, trimedlure B₂ (alternative name) (839) + TX, trimedlure C (alternative name) (839) and trunc-call (alternative name) [CCN] + TX,

an insect repellent selected from the group of substances consisting of 2-(octylthio)ethanol (IUPAC name) (591) + TX, butopyronoxyl (933) + TX, butoxy(polypropylene glycol) (936) + TX, dibutyl
 25 adipate (IUPAC name) (1046) + TX, dibutyl phthalate (1047) + TX, dibutyl succinate (IUPAC name) (1048) + TX, diethyltoluamide [CCN] + TX, dimethyl carbate [CCN] + TX, dimethyl phthalate [CCN] + TX, ethyl hexanediol (1137) + TX, hexamide [CCN] + TX, methoquin-butyl (1276) + TX, methylneodecanamide [CCN] + TX, oxamate [CCN] and picaridin [CCN] + TX,

an insecticide selected from the group of substances consisting of 1-dichloro-1-nitroethane
 30 (IUPAC/Chemical Abstracts name) (1058) + TX, 1,1-dichloro-2,2-bis(4-ethylphenyl)ethane (IUPAC name) (1056), + TX, 1,2-dichloropropane (IUPAC/Chemical Abstracts name) (1062) + TX, 1,2-dichloropropane with 1,3-dichloropropene (IUPAC name) (1063) + TX, 1-bromo-2-chloroethane (IUPAC/Chemical Abstracts name) (916) + TX, 2,2,2-trichloro-1-(3,4-dichlorophenyl)ethyl acetate (IUPAC name) (1451) + TX, 2,2-dichlorovinyl 2-ethylsulfinyethyl methyl phosphate (IUPAC name)
 35 (1066) + TX, 2-(1,3-dithiolan-2-yl)phenyl dimethylcarbamate (IUPAC/ Chemical Abstracts name) (1109) + TX, 2-(2-butoxyethoxy)ethyl thiocyanate (IUPAC/Chemical Abstracts name) (935) + TX, 2-(4,5-dimethyl-1,3-dioxolan-2-yl)phenyl methylcarbamate (IUPAC/ Chemical Abstracts name) (1084) + TX, 2-(4-chloro-3,5-xilyloxy)ethanol (IUPAC name) (986) + TX, 2-chlorovinyl diethyl phosphate (IUPAC name) (984) + TX, 2-imidazolidone (IUPAC name) (1225) + TX, 2-isovalerylindan-1,3-dione
 40 (IUPAC name) (1246) + TX, 2-methyl(prop-2-ynyl)aminophenyl methylcarbamate (IUPAC name) (1284) + TX, 2-thiocyanatoethyl laurate (IUPAC name) (1433) + TX, 3-bromo-1-chloroprop-1-ene

(IUPAC name) (917) + TX, 3-methyl-1-phenylpyrazol-5-yl dimethylcarbamate (IUPAC name) (1283) + TX, 4-methyl(prop-2-ynyl)amino-3,5-xylol methylcarbamate (IUPAC name) (1285) + TX, 5,5-dimethyl-3-oxocyclohex-1-enyl dimethylcarbamate (IUPAC name) (1085) + TX, abamectin (1) + TX, acephate (2) + TX, acetamiprid (4) + TX, acethion (alternative name) [CCN] + TX, acetoprole [CCN] + TX, 5 acrinathrin (9) + TX, acrylonitrile (IUPAC name) (861) + TX, alanycarb (15) + TX, aldicarb (16) + TX, aldoxycarb (863) + TX, aldrin (864) + TX, allethrin (17) + TX, allosamidin (alternative name) [CCN] + TX, allyxycarb (866) + TX, alpha-cypermethrin (202) + TX, alpha-ecdysone (alternative name) [CCN] + TX, aluminium phosphide (640) + TX, amidithion (870) + TX, amidothioate (872) + TX, aminocarb (873) + TX, amiton (875) + TX, amiton hydrogen oxalate (875) + TX, amitraz (24) + TX, anabasine 10 (877) + TX, athidathion (883) + TX, AVI 382 (compound code) + TX, AZ 60541 (compound code) + TX, azadirachtin (alternative name) (41) + TX, azamethiphos (42) + TX, azinphos-ethyl (44) + TX, azinphos-methyl (45) + TX, azothoate (889) + TX, *Bacillus thuringiensis* delta endotoxins (alternative name) (52) + TX, barium hexafluorosilicate (alternative name) [CCN] + TX, barium polysulfide (IUPAC/Chemical Abstracts name) (892) + TX, barthrin [CCN] + TX, Bayer 22/190 (development 15 code) (893) + TX, Bayer 22408 (development code) (894) + TX, bendiocarb (58) + TX, benfuracarb (60) + TX, bensultap (66) + TX, beta-cyfluthrin (194) + TX, beta-cypermethrin (203) + TX, bifenthrin (76) + TX, bioallethrin (78) + TX, bioallethrin S-cyclopentenyl isomer (alternative name) (79) + TX, bioethanomethrin [CCN] + TX, biopermethrin (908) + TX, bioresmethrin (80) + TX, bis(2-chloroethyl) ether (IUPAC name) (909) + TX, bistrifluron (83) + TX, borax (86) + TX, brofenvalerate (alternative 20 name) + TX, bromfenvinfos (914) + TX, bromocyclen (918) + TX, bromo-DDT (alternative name) [CCN] + TX, bromophos (920) + TX, bromophos-ethyl (921) + TX, bufencarb (924) + TX, buprofezin (99) + TX, butacarb (926) + TX, butathiofos (927) + TX, butocarboxim (103) + TX, butonate (932) + TX, butoxycarboxim (104) + TX, butylpyridaben (alternative name) + TX, cadusafos (109) + TX, calcium arsenate [CCN] + TX, calcium cyanide (444) + TX, calcium polysulfide (IUPAC name) (111) + TX, camphechlor (941) + TX, carbanolate (943) + TX, carbaryl (115) + TX, carbofuran (118) + TX, 25 carbon disulfide (IUPAC/Chemical Abstracts name) (945) + TX, carbon tetrachloride (IUPAC name) (946) + TX, carbophenothion (947) + TX, carbosulfan (119) + TX, cartap (123) + TX, cartap hydrochloride (123) + TX, cevadine (alternative name) (725) + TX, chlorbicyclen (960) + TX, chlordane (128) + TX, chlordecone (963) + TX, chlordimeform (964) + TX, chlordimeform hydrochloride (964) + TX, 30 TX, chlorethoxyfos (129) + TX, chlorfenapyr (130) + TX, chlorfenvinphos (131) + TX, chlorfluaazuron (132) + TX, chlormephos (136) + TX, chloroform [CCN] + TX, chloropicrin (141) + TX, chlorphoxim (989) + TX, chlorprazophos (990) + TX, chlorpyrifos (145) + TX, chlorpyrifos-methyl (146) + TX, chlorthiophos (994) + TX, chromafenozide (150) + TX, cinerin I (696) + TX, cinerin II (696) + TX, cinerins (696) + TX, cis-resmethrin (alternative name) + TX, cismethrin (80) + TX, clocythrin 35 (alternative name) + TX, cloethocarb (999) + TX, closantel (alternative name) [CCN] + TX, clothianidin (165) + TX, copper acetoarsenite [CCN] + TX, copper arsenate [CCN] + TX, copper oleate [CCN] + TX, coumaphos (174) + TX, coumithoate (1006) + TX, crotamiton (alternative name) [CCN] + TX, crotoxyphos (1010) + TX, crufomate (1011) + TX, cryolite (alternative name) (177) + TX, CS 708 (development code) (1012) + TX, cyanofenphos (1019) + TX, cyanophos (184) + TX, cyanthoate 40 (1020) + TX, cyclethrin [CCN] + TX, cycloprothrin (188) + TX, cyfluthrin (193) + TX, cyhalothrin (196) + TX, cypermethrin (201) + TX, cyphenothrin (206) + TX, cyromazine (209) + TX, cythioate (alternative

name) [CCN] + TX, cf-limonene (alternative name) [CCN] + TX, cf-tetramethrin (alternative name) (788) + TX, DAEP (1031) + TX, dazomet (216) + TX, DDT (219) + TX, decarbofuran (1034) + TX, deltamethrin (223) + TX, demephion (1037) + TX, demephion-0 (1037) + TX, demephion-S (1037) + TX, demeton (1038) + TX, demeton-methyl (224) + TX, demeton-0 (1038) + TX, demeton-O-methyl
5 (224) + TX, demeton-S (1038) + TX, demeton-S-methyl (224) + TX, demeton-S-methylsulphon (1039) + TX, diafenthuron (226) + TX, dialifos (1042) + TX, diamidafos (1044) + TX, diazinon (227) + TX, dicapthon (1050) + TX, dichlofenthion (1051) + TX, dichlorvos (236) + TX, dicliphos (alternative name) + TX, dicresyl (alternative name) [CCN] + TX, dicrotophos (243) + TX, dicyclanil (244) + TX, dieldrin (1070) + TX, diethyl 5-methylpyrazol-3-yl phosphate (IUPAC name) (1076) + TX, diflubenzuron (250)
10 + TX, dilor (alternative name) [CCN] + TX, dimefluthrin [CCN] + TX, dimefox (1081) + TX, dimetan (1085) + TX, dimethoate (262) + TX, dimethrin (1083) + TX, dimethylvinphos (265) + TX, dimetilan (1086) + TX, dinex (1089) + TX, dinex-diclexine (1089) + TX, dinoprop (1093) + TX, dinosam (1094) + TX, dinoseb (1095) + TX, dinotefuran (271) + TX, diofenolan (1099) + TX, dioxabenzofos (1100) + TX, dioxacarb (1101) + TX, dioxathion (1102) + TX, disulfoton (278) + TX, dithicrofos (1108) + TX, DNOC
15 (282) + TX, doramectin (alternative name) [CCN] + TX, DSP (1115) + TX, ecdysterone (alternative name) [CCN] + TX, EI 1642 (development code) (1118) + TX, emamectin (291) + TX, emamectin benzoate (291) + TX, EMPC (1120) + TX, empenthrin (292) + TX, endosulfan (294) + TX, endothion (1121) + TX, endrin (1122) + TX, EPBP (1123) + TX, EPN (297) + TX, epofenonane (1124) + TX, eprinomectin (alternative name) [CCN] + TX, esfenvalerate (302) + TX, etaphos (alternative name)
20 [CCN] + TX, ethiofencarb (308) + TX, ethion (309) + TX, ethiprole (310) + TX, ethoate-methyl (1134) + TX, ethoprophos (312) + TX, ethyl formate (IUPAC name) [CCN] + TX, ethyl-DDD (alternative name) (1056) + TX, ethylene dibromide (316) + TX, ethylene dichloride (chemical name) (1136) + TX, ethylene oxide [CCN] + TX, etofenprox (319) + TX, etrimfos (1142) + TX, EXD (1143) + TX, famphur (323) + TX, fenamiphos (326) + TX, fenazaflor (1147) + TX, fenchlorphos (1148) + TX, fenethacarb
25 (1149) + TX, fenfluthrin (1150) + TX, fenitrothion (335) + TX, fenobucarb (336) + TX, fenoxacrim (1153) + TX, fenoxycarb (340) + TX, fenpirithrin (1155) + TX, fenpropathrin (342) + TX, fenpyrad (alternative name) + TX, fensulfothion (1158) + TX, fenthion (346) + TX, fenthion-ethyl [CCN] + TX, fenvalerate (349) + TX, fipronil (354) + TX, flonicamid (358) + TX, flubendiamide (CAS. Reg. No.: 272451-65-7) + TX, flucofuron (1168) + TX, flucycloxuron (366) + TX, flucythrinate (367) + TX,
30 fluenetil (1169) + TX, flufenerim [CCN] + TX, flufenoxuron (370) + TX, flufenprox (1171) + TX, flumethrin (372) + TX, fluvalinate (1184) + TX, FMC 1137 (development code) (1185) + TX, fonofos (1191) + TX, formetanate (405) + TX, formetanate hydrochloride (405) + TX, formothion (1192) + TX, formparanate (1193) + TX, fosmethilan (1194) + TX, fospirate (1195) + TX, fosthiazate (408) + TX, fosthietan (1196) + TX, furathiocarb (412) + TX, furethrin (1200) + TX, gamma-cyhalothrin (197) + TX,
35 gamma-HCH (430) + TX, guazatine (422) + TX, guazatine acetates (422) + TX, GY-81 (development code) (423) + TX, halfenprox (424) + TX, halofenozide (425) + TX, HCH (430) + TX, HEOD (1070) + TX, heptachlor (1211) + TX, heptenophos (432) + TX, heterophos [CCN] + TX, hexaflumuron (439) + TX, HHDN (864) + TX, hydramethylnon (443) + TX, hydrogen cyanide (444) + TX, hydroprene (445) + TX, hyquincarb (1223) + TX, imidacloprid (458) + TX, imiprothrin (460) + TX, indoxacarb (465) + TX,
40 iodomethane (IUPAC name) (542) + TX, IPSP (1229) + TX, isazofos (1231) + TX, isobenzan (1232) + TX, isocarbophos (alternative name) (473) + TX, isodrin (1235) + TX, isofenphos (1236) + TX, isolane

(1237) + TX, isoprocarb (472) + TX, isopropyl 0-(methoxyaminothiophosphoryl)salicylate (IUPAC name) (473) + TX, isoprothiolane (474) + TX, isothioate (1244) + TX, isoxathion (480) + TX, ivermectin (alternative name) [CCN] + TX, jasmolin I (696) + TX, jasmolin II (696) + TX, jodfenphos (1248) + TX, juvenile hormone I (alternative name) [CCN] + TX, juvenile hormone II (alternative name) [CCN] + TX, 5 juvenile hormone III (alternative name) [CCN] + TX, kelevan (1249) + TX, kinoprene (484) + TX, lambda-cyhalothrin (198) + TX, lead arsenate [CCN] + TX, lepimectin (CCN) + TX, leptophos (1250) + TX, lindane (430) + TX, lirimfos (1251) + TX, lufenuron (490) + TX, lythidathion (1253) + TX, *m*-cumenyl methylcarbamate (IUPAC name) (1014) + TX, magnesium phosphide (IUPAC name) (640) + TX, malathion (492) + TX, malonoben (1254) + TX, mazidox (1255) + TX, mecarbarn (502) + TX, 10 mecarphon (1258) + TX, menazon (1260) + TX, mephosfolan (1261) + TX, mercurous chloride (513) + TX, mesulfenfos (1263) + TX, metaflumizone (CCN) + TX, metam (519) + TX, metam-potassium (alternative name) (519) + TX, metam-sodium (519) + TX, methacrifos (1266) + TX, methamidophos (527) + TX, methanesulfonyl fluoride (IUPAC/Chemical Abstracts name) (1268) + TX, methidathion (529) + TX, methiocarb (530) + TX, methocrotophos (1273) + TX, methomyl (531) + TX, methoprene 15 (532) + TX, methoquin-butyl (1276) + TX, methothrin (alternative name) (533) + TX, methoxychlor (534) + TX, methoxyfenozide (535) + TX, methyl bromide (537) + TX, methyl isothiocyanate (543) + TX, methylchloroform (alternative name) [CCN] + TX, methylene chloride [CCN] + TX, metofluthrin [CCN] + TX, metolcarb (550) + TX, metoxadiazone (1288) + TX, mevinphos (556) + TX, mexacarbate (1290) + TX, milbemectin (557) + TX, milbemycin oxime (alternative name) [CCN] + TX, mipafox 20 (1293) + TX, mirex (1294) + TX, monocrotophos (561) + TX, morphothion (1300) + TX, moxidectin (alternative name) [CCN] + TX, naftalofos (alternative name) [CCN] + TX, naled (567) + TX, naphthalene (IUPAC/Chemical Abstracts name) (1303) + TX, NC-170 (development code) (1306) + TX, NC-184 (compound code) + TX, nicotine (578) + TX, nicotine sulfate (578) + TX, nifluridide (1309) + TX, nitenpyram (579) + TX, nithiazine (1311) + TX, nitrilacarb (1313) + TX, nitrilacarb 1:1 zinc 25 chloride complex (1313) + TX, NNI-0101 (compound code) + TX, NNI-0250 (compound code) + TX, normicotine (traditional name) (1319) + TX, novaluron (585) + TX, noviflumuron (586) + TX, 0-5-dichloro-4-iodophenyl O-ethyl ethylphosphonothioate (IUPAC name) (1057) + TX, 0,0-diethyl 0-4-methyl-2-oxo-2AY-chromen-7-yl phosphorothioate (IUPAC name) (1074) + TX, 0,0-diethyl O-6-methyl-2-propylpyrimidin-4-yl phosphorothioate (IUPAC name) (1075) + TX, 0,0,0',0'-tetrapropyl 30 dithiopyrophosphate (IUPAC name) (1424) + TX, oleic acid (IUPAC name) (593) + TX, omethoate (594) + TX, oxamyl (602) + TX, oxydemeton-methyl (609) + TX, oxydeprofos (1324) + TX, oxydisulfoton (1325) + TX, pp'-DDT (219) + TX, para-dichlorobenzene [CCN] + TX, parathion (615) + TX, parathion-methyl (616) + TX, penfluron (alternative name) [CCN] + TX, pentachlorophenol (623) + TX, pentachlorophenyl laurate (IUPAC name) (623) + TX, permethrin (626) + TX, petroleum oils 35 (alternative name) (628) + TX, PH 60-38 (development code) (1328) + TX, phenkapton (1330) + TX, phenothrin (630) + TX, phenthoate (631) + TX, phorate (636) + TX, phosalone (637) + TX, phosfolan (1338) + TX, phosmet (638) + TX, phosnichlor (1339) + TX, phosphamidon (639) + TX, phosphine (IUPAC name) (640) + TX, phoxim (642) + TX, phoxim-methyl (1340) + TX, pirimetaphos (1344) + TX, pirimicarb (651) + TX, pirimiphos-ethyl (1345) + TX, pirimiphos-methyl (652) + TX, 40 polychlorodicyclopentadiene isomers (IUPAC name) (1346) + TX, polychloroterpenes (traditional name) (1347) + TX, potassium arsenite [CCN] + TX, potassium thiocyanate [CCN] + TX, prallethrin

(655) + TX, precocene I (alternative name) [CCN] + TX, precocene II (alternative name) [CCN] + TX, precocene III (alternative name) [CCN] + TX, primidophos (1349) + TX, profenofos (662) + TX, profluthrin [CCN] + TX, promacyl (1354) + TX, promecarb (1355) + TX, propaphos (1356) + TX, propetamphos (673) + TX, propoxur (678) + TX, prothidathion (1360) + TX, prothiofos (686) + TX, 5 prothoate (1362) + TX, protrifenbute [CCN] + TX, pymetrozine (688) + TX, pyraclofos (689) + TX, pyrazophos (693) + TX, pyresmethrin (1367) + TX, pyrethrin I (696) + TX, pyrethrin II (696) + TX, pyrethrins (696) + TX, pyridaben (699) + TX, pyridalyl (700) + TX, pyridaphenthion (701) + TX, pyrimidifen (706) + TX, pyrimitate (1370) + TX, pyriproxyfen (708) + TX, quassia (alternative name) [CCN] + TX, quinalphos (711) + TX, quinalphos-methyl (1376) + TX, quinothion (1380) + TX, 10 quintiofos (1381) + TX, R-1492 (development code) (1382) + TX, rafoxanide (alternative name) [CCN] + TX, resmethrin (719) + TX, rotenone (722) + TX, RU 15525 (development code) (723) + TX, RU 25475 (development code) (1386) + TX, ryania (alternative name) (1387) + TX, ryanodine (traditional name) (1387) + TX, sabadilla (alternative name) (725) + TX, schradan (1389) + TX, sebufos (alternative name) + TX, selamectin (alternative name) [CCN] + TX, SI-0009 (compound code) + TX, 15 SI-0205 (compound code) + TX, SI-0404 (compound code) + TX, SI-0405 (compound code) + TX, silafluofen (728) + TX, SN 72129 (development code) (1397) + TX, sodium arsenite [CCN] + TX, sodium cyanide (444) + TX, sodium fluoride (IUPAC/Chemical Abstracts name) (1399) + TX, sodium hexafluorosilicate (1400) + TX, sodium pentachlorophenoxide (623) + TX, sodium selenate (IUPAC name) (1401) + TX, sodium thiocyanate [CCN] + TX, sophamide (1402) + TX, spinosad (737) + TX, 20 spiromesifen (739) + TX, spirotetmat (CCN) + TX, sulcofuron (746) + TX, sulcofuron-sodium (746) + TX, sulfluramid (750) + TX, sulfotep (753) + TX, sulfuryl fluoride (756) + TX, sulprofos (1408) + TX, tar oils (alternative name) (758) + TX, tau-fluvalinate (398) + TX, tazimcarb (1412) + TX, TDE (1414) + TX, tebufenozide (762) + TX, tebufenpyrad (763) + TX, tebupirimfos (764) + TX, teflubenzuron (768) + TX, tefluthrin (769) + TX, temephos (770) + TX, TEPP (1417) + TX, terallethrin (1418) + TX, terbam 25 (alternative name) + TX, terbufos (773) + TX, tetrachloroethane [CCN] + TX, tetrachlorvinphos (777) + TX, tetramethrin (787) + TX, theta-cypermethrin (204) + TX, thiacloprid (791) + TX, thiafenox (alternative name) + TX, thiamethoxam (792) + TX, thicrofos (1428) + TX, thiocarboxime (1431) + TX, thiocyclam (798) + TX, thiocyclam hydrogen oxalate (798) + TX, thiodicarb (799) + TX, thiofanox (800) + TX, thiometon (801) + TX, thionazin (1434) + TX, thiosultap (803) + TX, thiosultap-sodium (803) + TX, 30 TX, thuringiensin (alternative name) [CCN] + TX, tolfenpyrad (809) + TX, tralomethrin (812) + TX, transluthrin (813) + TX, transpermethrin (1440) + TX, triamiphos (1441) + TX, triazamate (818) + TX, triazophos (820) + TX, triazuron (alternative name) + TX, trichlorfon (824) + TX, trichlormetaphos-3 (alternative name) [CCN] + TX, trichloronat (1452) + TX, trifenofos (1455) + TX, triflumuron (835) + TX, trimethacarb (840) + TX, triprene (1459) + TX, vamidothion (847) + TX, vaniliprole [CCN] + TX, 35 veratridine (alternative name) (725) + TX, veratrine (alternative name) (725) + TX, XMC (853) + TX, xylylcarb (854) + TX, YI-5302 (compound code) + TX, zeta-cypermethrin (205) + TX, zetamethrin (alternative name) + TX, zinc phosphide (640) + TX, zolaprofos (1469) and ZXI 8901 (development code) (858) + TX, cyantraniliprole [736994-63-19 + TX, chlorantraniliprole [500008-45-7] + TX, cyenopyrafen [560121-52-0] + TX, cyflumetofen [400882-07-7] + TX, pyrfluquinazon [337458-27-2] + TX, 40 TX, spinetoram [187166-40-1 + 187166-15-0] + TX, spirotetramat [203313-25-1] + TX, sulfoxaflor

[946578-00-3] + TX, flufiprole [704886-18-0] + TX, meperfluthrin [915288-13-0] + TX, tetramethylfluthrin [84937-88-2] + TX, triflumezopyrim (disclosed in WO 2012/092115) + TX,

a molluscicide selected from the group of substances consisting of bis(tributyltin) oxide (IUPAC name) (913) + TX, bromoacetamide [CCN] + TX, calcium arsenate [CCN] + TX, cloethocarb 5 (999) + TX, copper acetoarsenite [CCN] + TX, copper sulfate (172) + TX, fentin (347) + TX, ferric phosphate (IUPAC name) (352) + TX, metaldehyde (518) + TX, methiocarb (530) + TX, niclosamide (576) + TX, niclosamide-olamine (576) + TX, pentachlorophenol (623) + TX, sodium pentachlorophenoxide (623) + TX, tazimcarb (1412) + TX, thiodicarb (799) + TX, tributyltin oxide (913) + TX, trifenmorph (1454) + TX, trimethacarb (840) + TX, triphenyltin acetate (IUPAC name) (347) and 10 triphenyltin hydroxide (IUPAC name) (347) + TX, pyriprole [394730-71-3] + TX,

a nematicide selected from the group of substances consisting of AKD-3088 (compound code) + TX, 1,2-dibromo-3-chloropropane (IUPAC/Chemical Abstracts name) (1045) + TX, 1,2-dichloropropane (IUPAC/Chemical Abstracts name) (1062) + TX, 1,2-dichloropropane with 1,3-dichloropropene (IUPAC name) (1063) + TX, 1,3-dichloropropene (233) + TX, 3,4-15 dichlorotetrahydrothiophene 1,1-dioxide (IUPAC/Chemical Abstracts name) (1065) + TX, 3-(4-chlorophenyl)-5-methylrhodanine (IUPAC name) (980) + TX, 5-methyl-6-thioxo-1,3,5-thiadiazinan-3-ylacetic acid (IUPAC name) (1286) + TX, 6-isopentenylaminopurine (alternative name) (210) + TX, abamectin (1) + TX, acetoprole [CCN] + TX, alanycarb (15) + TX, aldicarb (16) + TX, aldoxycarb (863) + TX, AZ 60541 (compound code) + TX, benclotiaz [CCN] + TX, benomyl (62) + TX, butylpyridaben 20 (alternative name) + TX, cadusafos (109) + TX, carbofuran (118) + TX, carbon disulfide (945) + TX, carbosulfan (119) + TX, chloropicrin (141) + TX, chlorpyrifos (145) + TX, cloethocarb (999) + TX, cytokinins (alternative name) (210) + TX, dazomet (216) + TX, DBCP (1045) + TX, DCIP (218) + TX, diamidafos (1044) + TX, dichlofenthion (1051) + TX, dicliphos (alternative name) + TX, dimethoate (262) + TX, doramectin (alternative name) [CCN] + TX, emamectin (291) + TX, emamectin benzoate 25 (291) + TX, eprinomectin (alternative name) [CCN] + TX, ethoprophos (312) + TX, ethylene dibromide (316) + TX, fenamiphos (326) + TX, fenpyrad (alternative name) + TX, fensulfthion (1158) + TX, fosthiazate (408) + TX, fosthietan (1196) + TX, furfural (alternative name) [CCN] + TX, GY-81 (development code) (423) + TX, heterophos [CCN] + TX, iodomethane (IUPAC name) (542) + TX, isamidofos (1230) + TX, isazofos (1231) + TX, ivermectin (alternative name) [CCN] + TX, kinetin 30 (alternative name) (210) + TX, mecarphon (1258) + TX, metam (519) + TX, metam-potassium (alternative name) (519) + TX, metam-sodium (519) + TX, methyl bromide (537) + TX, methyl isothiocyanate (543) + TX, milbemycin oxime (alternative name) [CCN] + TX, moxidectin (alternative name) [CCN] + TX, *Myrothecium verrucaria* composition (alternative name) (565) + TX, NC-184 (compound code) + TX, oxamyl (602) + TX, phorate (636) + TX, phosphamidon (639) + TX, 35 phosphocarb [CCN] + TX, sebufos (alternative name) + TX, selamectin (alternative name) [CCN] + TX, spinosad (737) + TX, terbam (alternative name) + TX, terbufos (773) + TX, tetrachlorothiophene (IUPAC/Chemical Abstracts name) (1422) + TX, thiafenox (alternative name) + TX, thionazin (1434) + TX, triazophos (820) + TX, triazuron (alternative name) + TX, xylenols [CCN] + TX, YI-5302 (compound code) and zeatin (alternative name) (210) + TX, fluensulfone [318290-98-1] + TX,

40 a nitrification inhibitor selected from the group of substances consisting of potassium ethylxanthate [CCN] and nitrapyrin (580) + TX,

a plant activator selected from the group of substances consisting of acibenzolar (6) + TX, acibenzolar-S-methyl (6) + TX, probenazole (658) and *Reynoutria sachalinensis* extract (alternative name) (720) + TX,

a rodenticide selected from the group of substances consisting of 2-isovalerylindan-1,3-dione (IUPAC name) (1246) + TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide (IUPAC name) (748) + TX, alpha-chlorohydrin [CCN] + TX, aluminium phosphide (640) + TX, antu (880) + TX, arsenous oxide (882) + TX, barium carbonate (891) + TX, bithiosemi (912) + TX, brodifacoum (89) + TX, bromadiolone (91) + TX, bromethalin (92) + TX, calcium cyanide (444) + TX, chloralose (127) + TX, chlorophacinone (140) + TX, cholecalciferol (alternative name) (850) + TX, coumachlor (1004) + TX, coumafuryl (1005) + TX, coumatetralyl (175) + TX, crimidine (1009) + TX, difenacoum (246) + TX, difethialone (249) + TX, diphacinone (273) + TX, ergocalciferol (301) + TX, flocoumafen (357) + TX, fluoroacetamide (379) + TX, flupropradine (1183) + TX, flupropradine hydrochloride (1183) + TX, gamma-HCH (430) + TX, HCH (430) + TX, hydrogen cyanide (444) + TX, iodomethane (IUPAC name) (542) + TX, lindane (430) + TX, magnesium phosphide (IUPAC name) (640) + TX, methyl bromide (537) + TX, norbormide (1318) + TX, phosacetim (1336) + TX, phosphine (IUPAC name) (640) + TX, phosphorus [CCN] + TX, pindone (1341) + TX, potassium arsenite [CCN] + TX, pyrinuron (1371) + TX, scilliroside (1390) + TX, sodium arsenite [CCN] + TX, sodium cyanide (444) + TX, sodium fluoroacetate (735) + TX, strychnine (745) + TX, thallium sulfate [CCN] + TX, warfarin (851) and zinc phosphide (640) + TX,

a synergist selected from the group of substances consisting of 2-(2-butoxyethoxy)ethyl piperonylate (IUPAC name) (934) + TX, 5-(1,3-benzodioxol-5-yl)-3-hexylcyclohex-2-enone (IUPAC name) (903) + TX, farnesol with nerolidol (alternative name) (324) + TX, MB-599 (development code) (498) + TX, MGK 264 (development code) (296) + TX, piperonyl butoxide (649) + TX, piprotal (1343) + TX, propyl isomer (1358) + TX, S421 (development code) (724) + TX, sesamex (1393) + TX, sesasmolin (1394) and sulfoxide (1406) + TX,

an animal repellent selected from the group of substances consisting of anthraquinone (32) + TX, chloralose (127) + TX, copper naphthenate [CCN] + TX, copper oxychloride (171) + TX, diazinon (227) + TX, dicyclopentadiene (chemical name) (1069) + TX, guazatine (422) + TX, guazatine acetates (422) + TX, methiocarb (530) + TX, pyridin-4-amine (IUPAC name) (23) + TX, thiram (804) + TX, trimethacarb (840) + TX, zinc naphthenate [CCN] and ziram (856) + TX,

a virucide selected from the group of substances consisting of imanin (alternative name) [CCN] and ribavirin (alternative name) [CCN] + TX,

a wound protectant selected from the group of substances consisting of mercuric oxide (512) + TX, octhilinone (590) and thiophanate-methyl (802) + TX,

and biologically active compounds selected from the group consisting of ametoctradin [86531 8-97-4] + TX, amisulbrom [348635-87-0] + TX, azaconazole [60207-31-0] + TX, benzovindiflupyr [1072957-71-1] + TX, bitertanol [70585-36-3] + TX, bixafen [581 809-46-3] + TX, bromuconazole [1 16255-48-2] + TX, coumoxystrobin [850881-70-8] + TX, cyproconazole [94361-06-5] + TX, difenoconazole [1 19446-68-3] + TX, diniconazole [83657-24-3] + TX, enoxastrobin [23841 0-11-2] + TX, epoxiconazole [106325-08-0] + TX, fenbuconazole [1 14369-43-6] + TX, fenpyrazamine [473798-59-3] + TX, fluquinconazole [136426-54-5] + TX, flusilazole [85509-1 9-9] + TX, flutriafol


[76674-21-0] + TX, fluxapyroxad [907204-31-3] + TX, fluopyram [658066-35-4] + TX, fenaminstrobin [36681 5-39-6] + TX, isofetamid [87591 5-78-9] + TX, hexaconazole [79983-71-4] + TX, imazalil [35554-44-0] + TX, imibenconazole [86598-92-7] + TX, ipconazole [125225-28-7] + TX, ipfentrifluconazole [1417782-08-1] + TX, isotianil [224049-04-1] + TX, mandestrobin [173662-97-0] (can be prepared
5 according to the procedures described in WO 201 0/093059) + TX, mefentrifluconazole [1417782-03-6] + TX, metconazole [1251 16-23-6] + TX, myclobutanil [88671-89-0] + TX, paclobutrazol [76738-62-0] + TX, pefurazoate [101903-30-4] + TX, penflufen [494793-67-8] + TX, penconazole [66246-88-6] + TX, prothioconazole [178928-70-6] + TX, pyrifenoxy [88283-41-4] + TX, prochloraz [67747-09-5] + TX, propiconazole [60207-90-1] + TX, simeconazole [149508-90-7] + TX, tebuconazole [107534-96-3] +
10 TX, tetraconazole [112281-77-3] + TX, triadimefon [431214-43-3] + TX, triadimenol [55219-65-3] + TX, triflumizole [99387-89-0] + TX, triticonazole [131983-72-7] + TX, ancymidol [12771-68-5] + TX, fenarimol [60168-88-9] + TX, nuarimol [63284-71-9] + TX, bupirimate [41483-43-6] + TX, dimethirimol [5221-53-4] + TX, ethirimol [23947-60-6] + TX, dodemorph [1593-77-7] + TX, fenpropidin [67306-00-7] + TX, fenpropimorph [67564-91-4] + TX, spiroxamine [118134-30-8] + TX, tridemorph [81412-43-3] +
15 TX, cyprodinil [121552-61-2] + TX, mepanipyrim [110235-47-7] + TX, pyrimethanil [53112-28-0] + TX, fenpiclonil [74738-17-3] + TX, fludioxonil [131341-86-1] + TX, fluindapyr [1383809-87-7] + TX, benalaxyl [71626-11-4] + TX, furalaxyl [57646-30-7] + TX, metalaxyl [57837-19-1] + TX, R-metalaxyl [70630-17-0] + TX, ofurace [58810-48-3] + TX, oxadixyl [77732-09-3] + TX, benomyl [17804-35-2] + TX, carbendazim [10605-21-7] + TX, debacarb [62732-91-6] + TX, fuberidazole [3878-19-1] + TX,
20 thiabendazole [148-79-8] + TX, chlozolinate [84332-86-5] + TX, dichlozoline [24201-58-9] + TX, iprodione [36734-19-7] + TX, myclozoline [54864-61-8] + TX, procymidone [32809-16-8] + TX, vinclozoline [50471-44-8] + TX, boscalid [188425-85-6] + TX, carboxin [5234-68-4] + TX, fenfuram [24691-80-3] + TX, flutolanil [66332-96-5] + TX, flutianil [958647-10-4] + TX, mepronil [55814-41-0] + TX, oxycarboxin [5259-88-1] + TX, penthiopyrad [183675-82-3] + TX, thifluzamide [130000-40-7] + TX,
25 guazatine [108173-90-6] + TX, dodine [2439-10-3] [112-65-2] (free base) + TX, iminoctadine [13516-27-3] + TX, azoxystrobin [131860-33-8] + TX, dimoxystrobin [149961-52-4] + TX, enestroburin {Proc. BCPC, Int. Congr., Glasgow, 2003, 1, 93} + TX, fluoxastrobin [361377-29-9] + TX, kresoxim-methyl [143390-89-0] + TX, metominostrobin [133408-50-1] + TX, trifloxystrobin [141517-21-7] + TX, oryastrobin [248593-16-0] + TX, picoxystrobin [117428-22-5] + TX, pyraclostrobin [175013-18-0] +
30 TX, pyraoxystrobin [862588-11-2] + TX, ferbam [14484-64-1] + TX, mancozeb [8018-01-7] + TX, maneb [12427-38-2] + TX, metiram [9006-42-2] + TX, propineb [12071-83-9] + TX, thiram [137-26-8] + TX, zineb [12122-67-7] + TX, ziram [137-30-4] + TX, captafol [2425-06-1] + TX, captan [133-06-2] + TX, dichlofluanid [1085-98-9] + TX, fluoroimide [41205-21-4] + TX, folpet [133-07-3] + TX, tolylfluanid [731-27-1] + TX, bordeaux mixture [8011-63-0] + TX, copperhydroxid [20427-59-2] + TX,
35 copperoxychlorid [1332-40-7] + TX, coppersulfat [7758-98-7] + TX, copperoxid [1317-39-1] + TX, mancopper [53988-93-5] + TX, oxine-copper [10380-28-6] + TX, dinocap [131-72-6] + TX, nitrothal-isopropyl [10552-74-6] + TX, edifenphos [17109-49-8] + TX, iprobenphos [26087-47-8] + TX, isoprothiolane [50512-35-1] + TX, phosdiphen [36519-00-3] + TX, pyrazophos [13457-18-6] + TX, tolclofos-methyl [57018-04-9] + TX, acibenzolar-S-methyl [135158-54-2] + TX, anilazine [101-05-3] +
40 TX, benthialdicarb [413615-35-7] + TX, blasticidin-S [2079-00-7] + TX, chinomethionat [2439-01-2] + TX, chloroneb [2675-77-6] + TX, chlorothalonil [1897-45-6] + TX, cyflufenamid [180409-60-3] + TX,

cymoxanil [57966-95-7] + TX, dichlone [117-80-6] + TX, diclocymet [139920-32-4] + TX, diclomezine [62865-36-5] + TX, dicloran [99-30-9] + TX, diethofencarb [87130-20-9] + TX, dimethomorph [110488-70-5] + TX, SYP-LI90 (Flumorph) [211867-47-9] + TX, dithianon [3347-22-6] + TX, ethaboxam [162650-77-3] + TX, etridiazole [2593-15-9] + TX, famoxadone [131807-57-3] + TX, fenamidone [161326-34-7] + TX, fenoxanil [115852-48-7] + TX, fentin [668-34-8] + TX, ferimzone [89269-64-7] + TX, fluazinam [79622-59-6] + TX, fluopicolide [239110-15-7] + TX, flusulfamide [106917-52-6] + TX, fenhexamid [126833-17-8] + TX, fosetyl-aluminium [39148-24-8] + TX, hymexazol [10004-44-1] + TX, iprovalicarb [140923-17-7] + TX, IKF-916 (Cyazofamid) [120116-88-3] + TX, kasugamycin [6980-18-3] + TX, methasulfocarb [66952-49-6] + TX, metrafenone [220899-03-6] + TX, pencycuron [66063-05-6] + TX, phthalide [27355-22-2] + TX, picarbutrazox [500207-04-5] + TX, polyoxins [11113-80-7] + TX, probenazole [27605-76-1] + TX, propamocarb [25606-41-1] + TX, proquinazid [189278-12-4] + TX, pydiflumetofen [1228284-64-7] + TX, pyrametostrobin [915410-70-7] + TX, pyroquilon [57369-32-1] + TX, pyriofenone [688046-61-9] + TX, pyribencarb [799247-52-2] + TX, pyrisoxazole [847749-37-5] + TX, quinoxifen [124495-18-7] + TX, quintozone [82-68-8] + TX, sulfur [7704-34-9] + TX, Timorex Gold™ (plant extract containing tea tree oil from the Stockton Group) + TX, tebufloquin [376645-78-2] + TX, tiadinil [223580-51-6] + TX, triazoxide [72459-58-6] + TX, tolprocarb [911499-62-2] + TX, triclopyricarb [902760-40-1] + TX, tricyclazole [41814-78-2] + TX, triforine [26644-46-2] + TX, validamycin [37248-47-8] + TX, valifenalate [283159-90-0] + TX, zoxamide (RH7281) [156052-68-5] + TX, mandipropamid [374726-62-2] + TX, isopyrazam [881685-58-1] + TX, phenamacril + TX, sedaxane [874967-67-6] + TX, trinexapac-ethyl [95266-40-3] + TX, 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylene-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-yl)-amide (disclosed in WO 2007/048556) + TX, 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (3',4',5'-trifluoro-biphenyl-2-yl)-amide (disclosed in WO 2006/087343) + TX, [(3S,4R,4aR,6S,6aS,12R,12aS,12bS)-3-[(cyclopropylcarbonyl)oxy]-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-6,12-dihydroxy-4,6a,12b-trimethyl-1-oxo-9-(3-pyridinyl)-2H,11Hnaphtho[2,1-fc]pyrano[3,4-e]pyran-4-yl]methyl-cyclopropanecarboxylate [915972-17-7] + TX and 1,3,5-trimethyl-N-(2-methyl-1-oxopropyl)-N-[3-(2-methylpropyl)-4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]phenyl]-H-pyrazole-4-carboxamide [926914-55-8] + TX,

or a biologically active compound selected from the group consisting of N-[(5-chloro-2-isopropyl-phenyl)methyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-pyrazole-4-carboxamide (can be prepared according to the procedures described in WO 2010/130767) + TX, 2,6-Dimethyl-1H,5H-[1,4]dithiino[2,3-c:5,6-c']dipyrrole-1,3,5,7(2H,6H)-tetrone (can be prepared according to the procedures described in WO 2011/138281) + TX, 6-ethyl-5,7-dioxo-pyrrolo[4,5][1,4]dithiino[1,2-c]isothiazole-3-carbonitrile + TX, 4-(2-bromo-4-fluoro-phenyl)-N-(2-chloro-6-fluoro-phenyl)-2,5-dimethyl-pyrazol-3-amine (can be prepared according to the procedures described in WO 2012/031061) + TX, 3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-indan-4-yl)-1-methyl-pyrazole-4-carboxamide (can be prepared according to the procedures described in WO 2012/084812) + TX, CAS 850881-30-0 + TX, 3-(3,4-dichloro-1,2-thiazol-5-ylmethoxy)-1,2-benzothiazole 1,1-dioxide (can be prepared according to the procedures described in WO 2007/129454) + TX, 2-[2-[(2,5-dimethylphenoxy)methyl]phenyl]-2-methoxy-N-methyl-acetamide + TX, 3-(4,4-difluoro-3,4-dihydro-3,3-dimethylisoquinolin-1-yl)quinolone (can be prepared according to the procedures described in WO

2005/07091 7) + TX, 2-[2-fluoro-6-[(8-fluoro-2-methyl-3-quinolyl)oxy]phenyl]propan-2-ol (can be prepared according to the procedures described in WO 201 1/081 174) + TX, 2-[2-[(7,8-difluoro-2-methyl-3-quinolyl)oxy]-6-fluoro-phenyl]propan-2-ol (can be prepared according to the procedures described in WO 201 1/081 174) + TX, oxathiapiprolin + TX [100331 8-67-9], tert-butyl N-[6-[[[(1-5 methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate + TX, N-[2-(3,4-difluorophenyl)phenyl]-3-(trifluoromethyl)pyrazine-2-carboxamide (can be prepared according to the procedures described in WO 2007/ 072999) + TX, 3-(difluoromethyl)-1 -methyl-N-[(3R)-1 ,1,3-trimethylindan-4-yl]pyrazole-4-carboxamide (can be prepared according to the procedures described in WO 201 4/01 3842) + TX, 2,2,2-trifluoroethyl N-[2-methyl-1 -[[4-10 methylbenzoyl)amino]methyl]propyl]carbamate + TX, (2RS)-2-[4-(4-chlorophenoxy)-a,a,a-trifluoro-o-tolyl]-1 -(1 H-1 ,2,4-triazol-1 -yl)propan-2-ol + TX, (2RS)-2-[4-(4-chlorophenoxy)-a,a,a-trifluoro-o-tolyl]-3-methyl-1 -(1 H-1 ,2,4-triazol-1 -yl)butan-2-ol + TX, 2-(difluoromethyl)-N-[(3R)-3-ethyl-1 ,1-dimethyl-indan-4-yl]pyridine-3-carboxamide + TX, 2-(difluoromethyl)-N-[3-ethyl-1 ,1-dimethyl-indan-4-yl]pyridine-3-carboxamide + TX, N'-(2,5-dimethyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formrianiidine + TX, N'-[4-15 (4,5-dichlorothiazol-2-yl)oxy-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidine (can be prepared according to the procedures described in WO 2007/031 513) + TX, [2-[3-[2-[1 -[2-[3,5-bis(difluoromethyl)pyrazol-1 -yl]acetyl]-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]-3-chloro-phenyl] methanesulfonate (can be prepared according to the procedures described in WO 201 2/025557) + TX, but-3-ynyl N-[6-[[[(Z)-[(1 -methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-20 2-pyridyl]carbamate (can be prepared according to the procedures described in WO 201 0/000841) + TX, 2-[[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl]-4H-1 ,2,4-triazole-3-thione (can be prepared according to the procedures described in WO 201 0/1 46031) + TX, methyl N-[[5-[4-(2,4-dimethylphenyl)triazol-2-yl]-2-methyl-phenyl]nriethyl]carbanriate + TX, 3-chloro-6-methyl-5-phenyl-4-(2,4,6-trifluorophenyl)pyridazine (can be prepared according to the procedures described in WO 25 2005/1 21 104) + TX, 2-[2-chloro-4-(4-chlorophenoxy)phenyl]-1 -(1 ,2,4-triazol-1 -yl)propan-2-ol (can be prepared according to the procedures described in WO 201 3/024082) + TX, 3-chloro-4-(2,6-difluorophenyl)-6-methyl-5-phenyl-pyridazine (can be prepared according to the procedures described in WO 201 2/020774) + TX, 4-(2,6-difluorophenyl)-6-methyl-5-phenyl-pyridazine-3-carbonitrile (can be prepared according to the procedures described in WO 201 2/020774) + TX, (R)-3-(difluoromethyl)-1 -30 methyl-N-[1 ,1,3-trimethylindan-4-yl]pyrazole-4-carboxanriide (can be prepared according to the procedures described in WO 201 1/1 62397) + TX, 3-(difluoromethyl)-N-(7-fluoro-1 ,1,3-trimethyl-indan-4-yl)-1 -methyl-pyrazole-4-carboxamide (can be prepared according to the procedures described in WO 201 2/08481 2) + TX, 1-[2-[[1 -(4-chlorophenyl)pyrazol-3-yl]oxymethyl]-3-methyl-phenyl]-4-methyl-tetrazol-5-one (can be prepared according to the procedures described in WO 2013/1 62072) + TX, 1-35 methyl-4-[3-methyl-2-[[2-methyl-4-(3,4,5-trimethylpyrazol-1 -yl)phenoxy]methyl]phenyl]tetrazol-5-one (can be prepared according to the procedures described in WO 201 4/051 165) + TX, (Z,E)-5-[1 -(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide + TX, (4-phenoxyphenyl)methyl 2-amino-6-methyl-pyridine-3-carboxylate + TX, N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1 -methylpyrazole-4-carboxanriide [1255734-28-1] (can be 40 prepared according to the procedures described in WO 2010/1 30767) + TX, 3-(difluoromethyl)-N-[(R)-2,3-dihydro-1 ,1,3-trimethyl-1 H-inden-4-yl]-1 -methylpyrazole-4-carboxamide [1352994-67-2] + TX, N'-

(2,5-dimethyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine + TX, N'-[4-(4,5-dichloro-thiazol-2-yloxy)-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidine + TX, N'-(2,5-dimethyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine + TX, N'-[4-(4,5-dichloro-thiazol-2-yloxy)-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidine + TX,



5 (fenpicoxamid [51 7875-34-2]) + TX (as described in WO 2003/03561 7), 2-(difluoromethyl)-N-(1,1,3-trimethylindan-4-yl)pyridine-3-carboxamide + TX, 2-(difluoromethyl)-N-(3-ethyl-1,1-dimethyl-indan-4-yl)pyridine-3-carboxamide + TX, 2-(difluoromethyl)-N-(1,1-dimethyl-3-propyl-indan-4-yl)pyridine-3-carboxamide + TX, 2-(difluoromethyl)-N-(3-isobutyl-1,1-dimethyl-indan-4-yl)pyridine-3-carboxamide + TX, 2-(difluoromethyl)-N-[(3R)-1,1,3-trimethylindan-4-yl]pyridine-3-carboxamide + TX, 2-(difluoromethyl)-N-[(3R)-3-ethyl-1,1-dimethyl-indan-4-yl]pyridine-3-carboxamide + TX, and 2-(difluoromethyl)-N-[(3R)-1,1-dimethyl-3-propyl-indan-4-yl]pyridine-3-carboxamide + TX, wherein each of these carboxamide compounds can be prepared according to the procedures described in WO 2014/095675 and/or WO 2016/139189.

15 The references in brackets behind the active ingredients, e.g. [3878-19-1] refer to the Chemical Abstracts Registry number. The above described mixing partners are known. Where the active ingredients are included in "The Pesticide Manual" [The Pesticide Manual - A World Compendium; Thirteenth Edition; Editor: C. D. S. Tomlin; The British Crop Protection Council], they are described therein under the entry number given in round brackets hereinabove for the particular
20 compound; for example, the compound "abamectin" is described under entry number (1). Where "[CCN]" is added hereinabove to the particular compound, the compound in question is included in the "Compendium of Pesticide Common Names", which is accessible on the internet [A. Wood; Compendium of Pesticide Common Names, Copyright © 1995-2004]; for example, the compound "acetoprole" is described under the internet address
25 <http://www.alanwood.net/pesticides/acetoprole.html>.

Most of the active ingredients described above are referred to hereinabove by a so-called "common name", the relevant "ISO common name" or another "common name" being used in individual cases. If the designation is not a "common name", the nature of the designation used instead is given in round brackets for the particular compound; in that case, the IUPAC name, the
30 IUPAC/Chemical Abstracts name, a "chemical name", a "traditional name", a "compound name" or a "development code" is used or, if neither one of those designations nor a "common name" is used, an "alternative name" is employed. "CAS Reg. No" means the Chemical Abstracts Registry Number.

The active ingredient mixture of the compounds of formula (I) selected from a compound 1.1 to 1.27 described in Table T1 (below), a compound 2.1 to 2.3 described in Table T2 (below), a
35 compound 3.1 to 3.11 described in Table T3 (below), or a compound 4.1 to 4.4 described in Table T4

(below), and an active ingredient as described above are preferably in a mixing ratio of from 100:1 to 1:6000, especially from 50:1 to 1:50, more especially in a ratio of from 20:1 to 1:20, even more especially from 10:1 to 1:10, very especially from 5:1 and 1:5, special preference being given to a ratio of from 2:1 to 1:2, and a ratio of from 4:1 to 2:1 being likewise preferred, above all in a ratio of 1:1, or 5:1, or 5:2, or 5:3, or 5:4, or 4:1, or 4:2, or 4:3, or 3:1, or 3:2, or 2:1, or 1:5, or 2:5, or 3:5, or 4:5, or 1:4, or 2:4, or 3:4, or 1:3, or 2:3, or 1:2, or 1:600, or 1:300, or 1:150, or 1:35, or 2:35, or 4:35, or 1:75, or 2:75, or 4:75, or 1:6000, or 1:3000, or 1:1500, or 1:350, or 2:350, or 4:350, or 1:750, or 2:750, or 4:750. Those mixing ratios are by weight.

The mixtures as described above can be used in a method for controlling pests, which comprises applying a composition comprising a mixture as described above to the pests or their environment, with the exception of a method for treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human or animal body.

The mixtures comprising a compound of formula (I) selected from one of Tables 1.1 to 1.12, 2.1 to 2.4, 3.1 to 3.7, (below), or Table T1, T2, T3, or T4 (below), and one or more active ingredients as described above can be applied, for example, in a single "ready-mix" form, in a combined spray mixture composed from separate formulations of the single active ingredient components, such as a "tank-mix", and in a combined use of the single active ingredients when applied in a sequential manner, i.e. one after the other with a reasonably short period, such as a few hours or days. The order of applying the compounds of formula (I) selected from Tables 1.1 to 1.12 or Tables 2.1 to 2.4 or Tables 3.1 to 3.7 (below) or Table T1, T2, T3, or T4 (below), and the active ingredient(s) as described above, is not essential for working the present invention.

The compositions according to the invention can also comprise further solid or liquid auxiliaries, such as stabilizers, for example unepoxidized or epoxidized vegetable oils (for example epoxidized coconut oil, rapeseed oil or soya oil), antifoams, for example silicone oil, preservatives, viscosity regulators, binders and/or tackifiers, fertilizers or other active ingredients for achieving specific effects, for example bactericides, fungicides, nematocides, plant activators, molluscicides or herbicides.

The compositions according to the invention are prepared in a manner known per se, in the absence of auxiliaries for example by grinding, screening and/or compressing a solid active ingredient and in the presence of at least one auxiliary for example by intimately mixing and/or grinding the active ingredient with the auxiliary (auxiliaries). These processes for the preparation of the compositions and the use of the compounds (I) for the preparation of these compositions are also a subject of the invention.

Another aspect of the invention is related to the use of a compound of formula (I) or of a preferred individual compound as defined herein, of a composition comprising at least one compound of formula (I) or at least one preferred individual compound as above-defined, or of a fungicidal or insecticidal mixture comprising at least one compound of formula (I) or at least one preferred individual compound as above-defined, in admixture with other fungicides or insecticides as described above, for controlling or preventing infestation of plants, e.g. useful plants such as crop plants, propagation

material thereof, e.g. seeds, harvested crops, e.g. harvested food crops, or non-living materials by insects or by phytopathogenic microorganisms, preferably fungal organisms.

A further aspect of the invention is related to a method of controlling or preventing an infestation of plants, e.g., useful plants such as crop plants, propagation material thereof, e.g. seeds, harvested
5 crops, e.g., harvested food crops, or of non-living materials by insects or by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, especially fungal organisms, which comprises the application of a compound of formula (I) or of a preferred individual compound as above-defined as active ingredient to the plants, to parts of the plants or to the locus thereof, to the propagation material thereof, or to any part of the non-living materials.

10 Controlling or preventing means reducing infestation by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, especially fungal organisms, to such a level that an improvement is demonstrated.

A preferred method of controlling or preventing an infestation of crop plants by phytopathogenic microorganisms, especially fungal organisms, or insects which comprises the application of a
15 compound of formula (I), or an agrochemical composition which contains at least one of said compounds, is foliar application. The frequency of application and the rate of application will depend on the risk of infestation by the corresponding pathogen or insect. However, the compounds of formula (I) can also penetrate the plant through the roots via the soil (systemic action) by drenching the locus of the plant with a liquid formulation, or by applying the compounds in solid form to the soil, e.g. in
20 granular form (soil application). In crops of water rice such granulates can be applied to the flooded rice field. The compounds of formula I may also be applied to seeds (coating) by impregnating the seeds or tubers either with a liquid formulation of the fungicide or coating them with a solid formulation.

A formulation, e.g. a composition containing the compound of formula (I), and, if desired, a solid
25 or liquid adjuvant or monomers for encapsulating the compound of formula (I), may be prepared in a known manner, typically by intimately mixing and/or grinding the compound with extenders, for example solvents, solid carriers and, optionally, surface active compounds (surfactants).

Advantageous rates of application are normally from 5g to 2kg of active ingredient (a.i.) per hectare (ha), preferably from 10g to 1kg a.i./ha, most preferably from 20g to 600g a.i./ha. When used
30 as seed drenching agent, convenient dosages are from 10mg to 1g of active substance per kg of seeds.

When the combinations of the present invention are used for treating seed, rates of 0.001 to 50 g of a compound of formula I per kg of seed, preferably from 0.01 to 10g per kg of seed are generally sufficient.

35 Suitably, a composition comprising a compound of formula (I) according to the present invention is applied either preventative, meaning prior to disease development or curative, meaning after disease development.

The compositions of the invention may be employed in any conventional form, for example in the form of a twin pack, a powder for dry seed treatment (DS), an emulsion for seed treatment (ES), a
40 flowable concentrate for seed treatment (FS), a solution for seed treatment (LS), a water dispersible powder for seed treatment (WS), a capsule suspension for seed treatment (CF), a gel for seed

treatment (GF), an emulsion concentrate (EC), a suspension concentrate (SC), a suspo-emulsion (SE), a capsule suspension (CS), a water dispersible granule (WG), an emulsifiable granule (EG), an emulsion, water in oil (EO), an emulsion, oil in water (EW), a micro-emulsion (ME), an oil dispersion (OD), an oil miscible flowable (OF), an oil miscible liquid (OL), a soluble concentrate (SL), an ultra-low
 5 volume suspension (SU), an ultra-low volume liquid (UL), a technical concentrate (TK), a dispersible concentrate (DC), a wettable powder (WP) or any technically feasible formulation in combination with agriculturally acceptable adjuvants.


Such compositions may be produced in conventional manner, e.g. by mixing the active ingredients with appropriate formulation inert (diluent, solvent, fillers and optionally other formulating
 10 ingredients such as surfactants, biocides, anti-freeze, stickers, thickeners and compounds that provide adjuvancy effects). Also conventional slow release formulations may be employed where long lasting efficacy is intended. Particularly formulations to be applied in spraying forms, such as water dispersible concentrates (e.g. EC, SC, DC, OD, SE, EW, EO and the like), wettable powders and granules, may contain surfactants such as wetting and dispersing agents and other compounds that
 15 provide adjuvancy effects, e.g. the condensation product of formaldehyde with naphthalene sulphonate, an alkylarylsulphonate, a lignin sulphonate, a fatty alkyl sulphate, and ethoxylated alkylphenol and an ethoxylated fatty alcohol.

A seed dressing formulation is applied in a manner known per se to the seeds employing the combination of the invention and a diluent in suitable seed dressing formulation form, e.g. as an
 20 aqueous suspension or in a dry powder form having good adherence to the seeds. Such seed dressing formulations are known in the art. Seed dressing formulations may contain the single active ingredients or the combination of active ingredients in encapsulated form, e.g. as slow release capsules or microcapsules.

In general, the formulations include from 0.01 to 90% by weight of active agent, from 0 to 20%
 25 agriculturally acceptable surfactant and 10 to 99.99% solid or liquid formulation inert and adjuvant(s), the active agent consisting of at least the compound of formula (I) optionally together with other active agents, particularly microbiocides or conservatives or the like. Concentrated forms of compositions generally contain in between about 2 and 80%, preferably between about 5 and 70% by weight of active agent. Application forms of formulation may for example contain from 0.01 to 20% by weight,
 30 preferably from 0.01 to 5% by weight of active agent. Whereas commercial products will preferably be formulated as concentrates, the end user will normally employ diluted formulations.

Whereas it is preferred to formulate commercial products as concentrates, the end user will normally use dilute formulations.

35 Table 1.1: This table discloses 199 specific compounds of the formula (T-1):



wherein n is 1, A^1 is C-R¹, A^2 is C-R², A^3 is C-R³, A^4 is C-R⁴ and R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 are hydrogen, and R^7 is as defined below in Table 1.

Each of Tables 1.2 to 1.12 (which follow Table 1) make available 199 individual compounds of the formula (T-1) in which n , A^1 , A^2 , A^3 , A^4 , R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 are as specifically defined in Tables 1.2 to 1.12, which refer to Table 1 wherein R^7 is specifically defined.

Table 1

| Compound no. | R ⁷ | Compound no. | R ⁷ |
|--------------|--------------------|--------------|-----------------------------|
| 1.001 | 2-fluorophenyl | 1.101 | 2-chloro-4-pyridyl |
| 1.002 | 3-fluorophenyl | 1.102 | 6-methyl-4-pyridyl |
| 1.003 | 4-fluorophenyl | 1.103 | 5-methyl-4-pyridyl |
| 1.004 | 2-chlorophenyl | 1.104 | 2-methyl-4-pyridyl |
| 1.005 | 3-chlorophenyl | 1.105 | 6-cyano-4-pyridyl |
| 1.006 | 4-chlorophenyl | 1.106 | 5-cyano-4-pyridyl |
| 1.007 | 2-bromophenyl | 1.107 | 2-cyano-4-pyridyl |
| 1.008 | 3-bromophenyl | 1.108 | 3,5-difluoro-4-pyridyl |
| 1.009 | 4-bromophenyl | 1.109 | 3,6-difluoro-4-pyridyl |
| 1.010 | 2-cyanophenyl | 1.110 | 3,5-dichloro-4-pyridyl |
| 1.011 | 3-cyanophenyl | 1.111 | 3,6-dichloro-4-pyridyl |
| 1.012 | 4-cyanophenyl | 1.112 | 6-trifluoromethyl-2-pyridyl |
| 1.013 | 2-methylphenyl | 1.113 | 5-trifluoromethyl-2-pyridyl |
| 1.014 | 3-methylphenyl | 1.114 | 4-trifluoromethyl-2-pyridyl |
| 1.015 | 4-methylphenyl | 1.115 | 3-trifluoromethyl-2-pyridyl |
| 1.016 | 2-trifluorophenyl | 1.116 | 6-difluoromethyl-2-pyridyl |
| 1.017 | 3-trifluorophenyl | 1.117 | 5-difluoromethyl-2-pyridyl |
| 1.018 | 4-trifluorophenyl | 1.118 | 4-difluoromethyl-2-pyridyl |
| 1.019 | 2-difluorophenyl | 1.119 | 3-difluoromethyl-2-pyridyl |
| 1.020 | 3-difluorophenyl | 1.120 | 6-difluoromethoxy-2-pyridyl |
| 1.021 | 4-difluorophenyl | 1.121 | 5-difluoromethoxy-2-pyridyl |
| 1.022 | 2-methoxyphenyl | 1.122 | 4-difluoromethoxy-2-pyridyl |
| 1.023 | 3-methoxyphenyl | 1.123 | 3-difluoromethoxy-2-pyridyl |
| 1.024 | 4-methoxyphenyl | 1.124 | 6-trifluoromethyl-4-pyridyl |
| 1.025 | 2,3-difluorophenyl | 1.125 | 5-trifluoromethyl-4-pyridyl |
| 1.026 | 2,4-difluorophenyl | 1.126 | 2-trifluoromethyl-4-pyridyl |
| 1.027 | 2,5-difluorophenyl | 1.127 | 6-difluoromethyl-4-pyridyl |
| 1.028 | 2,6-difluorophenyl | 1.128 | 5-difluoromethyl-4-pyridyl |
| 1.029 | 3,4-difluorophenyl | 1.129 | 2-difluoromethyl-4-pyridyl |
| 1.030 | 3,5-difluorophenyl | 1.130 | 4-pyrimidinyl |

| | | | |
|-------|--------------------------------------|-------|---------------------------------|
| 1.031 | 2,3-dichlorophenyl | 1.131 | 5-pyrimidinyl |
| 1.032 | 2,4-dichlorophenyl | 1.132 | 5-fluoro-pyrimidinyl |
| 1.033 | 2,5-dichlorophenyl | 1.133 | 5-chloro-pyrimidinyl |
| 1.034 | 2,6-dichlorophenyl | 1.134 | 5-methyl-pyrimidinyl |
| 1.035 | 3,4-dichlorophenyl | 1.135 | 2-thiazolyl |
| 1.036 | 3,5-dichlorophenyl | 1.136 | 4-thiazolyl |
| 1.037 | 2-difluoromethoxyphenyl | 1.137 | 5-thiazolyl |
| 1.038 | 4-difluoromethoxyphenyl | 1.138 | 5-methyl-2-thiazolyl |
| 1.039 | 3-difluoromethoxyphenyl | 1.139 | 4-methyl-2-thiazolyl |
| 1.040 | 2-thienyl | 1.140 | 1H-imidazol-5-yl |
| 1.041 | 3-thienyl | 1.141 | 2-methyl-1 H-imidazol-5-yl |
| 1.042 | 5-fluoro-2-thienyl | 1.142 | 2-cyano-1 H-imidazol-5-yl |
| 1.043 | 3,5-difluoro-2-thienyl | 1.143 | 5-methyl-1 H-imidazol-2-yl |
| 1.044 | 2,5-difluoro-3-thienyl | 1.144 | 5-cyano-1 H-imidazol-2-yl |
| 1.045 | 5-chloro-2-thienyl | 1.145 | 1,2-dimethylimidazol-5-yl |
| 1.046 | 5-methyl-2-thienyl | 1.146 | 2-cyano-1 -methyl-imidazol-5-yl |
| 1.047 | 5-cyano-2-thienyl | 1.147 | 1,5-dimethylimidazol-2-yl |
| 1.048 | 2-pyridyl | 1.148 | 5-cyano-1 -methyl-imidazol-2-yl |
| 1.049 | 3-pyridyl | 1.149 | oxazol-2-yl |
| 1.050 | 4-pyridyl | 1.150 | oxazol-4-yl |
| 1.051 | 6-fluoro-2-pyridyl | 1.151 | oxazol-5-yl |
| 1.052 | 5-fluoro-2-pyridyl | 1.152 | 2-methyloxazol-5-yl |
| 1.053 | 4-fluoro-2-pyridyl | 1.153 | 2-cyanooxazol-5-yl |
| 1.054 | 3-fluoro-2-pyridyl | 1.154 | 5-methyloxazol-2-yl |
| 1.055 | 6-chloro-2-pyridyl | 1.155 | 5-cyanooxazol-5-yl |
| 1.056 | 5-chloro-2-pyridyl | 1.156 | 2-methyl-1 ,2,4-triazol-3-yl |
| 1.057 | 4-chloro-2-pyridyl | 1.157 | oxetan-3-yl |
| 1.058 | 3-chloro-2-pyridyl | 1.158 | thietan-3-yl |
| 1.059 | 6-methyl-2-pyridyl | 1.159 | 1H-azetidin-3-yl |
| 1.060 | 5-methyl-2-pyridyl | 1.160 | 1-acyl-azetidin-3-yl |
| 1.061 | 4-methyl-2-pyridyl | 1.161 | tetrahydropyran-4-yl |
| 1.062 | 3-methyl-2-pyridyl | 1.162 | 4,5-dihydroisoxazol-3-yl |
| 1.063 | 6-cyano-2-pyridyl | 1.163 | 5,5-dimethyl-4H-isoxazol-3-yl |
| 1.064 | 5-cyano-2-pyridyl | 1.164 | 4,4-dimethyl-4H-isoxazol-3-yl |
| 1.065 | 4-cyano-2-pyridyl | 1.165 | 5-methylisoxazol-3-yl |
| 1.066 | 3-cyano-2-pyridyl | 1.166 | 1-methyltetrazol-5-yl |
| 1.067 | 3-chloro-5-fluoro-2-pyridyl | 1.167 | 1H-pyrazol-3-yl |
| 1.068 | 5-chloro-3-fluoro-2-pyridyl | 1.168 | 1-methylpyrazol-3-yl |
| 1.069 | 3-chloro-5-trifluoromethyl-2-pyridyl | 1.169 | 1,5-dimethylpyrazol-3-yl |

| | | | |
|-------|------------------------|-------|--|
| 1.070 | 6-fluoro-3-pyridyl | 1.170 | 1-acylpyrazol-3-yl |
| 1.071 | 5-fluoro-3-pyridyl | 1.171 | 3,4-dihydro-2H-pyrrol-5-yl |
| 1.072 | 4-fluoro-3-pyridyl | 1.172 | 3,3-dimethyl-2,4-dihydropyrrol-5-yl |
| 1.073 | 2-fluoro-3-pyridyl | 1.173 | 2-oxo-3,4-dihydropyrrol-5-yl |
| 1.074 | 6-chloro-3-pyridyl | 1.174 | 1H-pyrrolidin-3-yl |
| 1.075 | 5-chloro-3-pyridyl | 1.175 | 1-acyl-pyrrolidin-4-yl |
| 1.076 | 4-chloro-3-pyridyl | 1.176 | tetrahydrofuran-3-yl |
| 1.077 | 2-chloro-3-pyridyl | 1.177 | 2,3,4,5-tetrahydropyridin-6-yl |
| 1.078 | 6-methyl-3-pyridyl | 1.178 | 2-oxo-4,5-dihydro-3H-pyridin-6-yl |
| 1.079 | 5-methyl-3-pyridyl | 1.179 | 2-oxo-4,4-dimethyl-3,5-dihydropyridin-6-yl |
| 1.080 | 4-methyl-3-pyridyl | 1.180 | 1-methoxy-piperidin-4-yl |
| 1.081 | 2-methyl-3-pyridyl | 1.181 | 1H-piperidin-4-yl |
| 1.082 | 6-cyano-3-pyridyl | 1.182 | 1-acyl-piperidin-4-yl |
| 1.083 | 5-cyano-3-pyridyl | 1.183 | cyclopropyl |
| 1.084 | 4-cyano-3-pyridyl | 1.184 | cyclobutyl |
| 1.085 | 2-cyano-3-pyridyl | 1.185 | cyclopentyl |
| 1.086 | 4,5-difluoro-3-pyridyl | 1.186 | cyclohexyl |
| 1.087 | 4,6-difluoro-3-pyridyl | 1.187 | cyclopent-3-en-1-yl |
| 1.088 | 2,4-difluoro-3-pyridyl | 1.188 | cyclohex-2-en-1-yl |
| 1.089 | 2,5-difluoro-3-pyridyl | 1.189 | methyl |
| 1.090 | 2,6-difluoro-3-pyridyl | 1.190 | ethyl |
| 1.091 | 4,5-dichloro-3-pyridyl | 1.191 | propyl |
| 1.092 | 4,6-dichloro-3-pyridyl | 1.192 | isopropyl |
| 1.093 | 2,4-dichloro-3-pyridyl | 1.193 | butyl |
| 1.094 | 2,5-dichloro-3-pyridyl | 1.194 | pentyl |
| 1.095 | 2,6-dichloro-3-pyridyl | 1.195 | prop-2-en-1-yl |
| 1.096 | 6-fluoro-4-pyridyl | 1.196 | prop-2-yn-1-yl |
| 1.097 | 5-fluoro-4-pyridyl | 1.197 | 2-methoxyethyl |
| 1.098 | 2-fluoro-4-pyridyl | 1.198 | 2-ethoxyethyl |
| 1.099 | 6-chloro-4-pyridyl | 1.199 | 2-isopropoxyethyl |
| 1.100 | 5-chloro-4-pyridyl | | |

Table 1.2: This table discloses 199 specific compounds of formula (T-1) wherein n is 1, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R², R³, R⁴, R⁵, and R⁶ are hydrogen, R¹ is fluorine, and R⁷ is as defined above in Table 1.

5

Table 1.3: This table discloses 199 specific compounds of formula (T-1) wherein n is 1, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R², R³, R⁴, R⁵, and R⁶ are hydrogen, R¹ is chlorine, and R⁷ is as defined above in Table 1.

Table 1.4: This table discloses 199 specific compounds of formula (T-1) wherein n is 1, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R², R³, R⁴, R⁵, and R⁶ are hydrogen, R¹ is methyl, and R⁷ is as defined above in Table 1.

5

Table 1.5: This table discloses 199 specific compounds of formula (T-1) wherein n is 1, A¹ is N, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R², R³, R⁴, R⁵, and R⁶ are hydrogen, and R⁷ is as defined above in Table 1.

10 Table 1.6: This table discloses 199 specific compounds of formula (T-1) wherein n is 1, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R¹, R², R⁴, R⁵, and R⁶ are hydrogen, R³ is fluorine, and R⁷ is as defined above in Table 1.

15 Table 1.7: This table discloses 199 specific compounds of formula (T-1) wherein n is 1, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R², R⁴, R⁵, R⁶, and R⁷ are hydrogen, R¹ and R³ are fluorine, and R⁷ is as defined above in Table 1.

20 Table 1.8: This table discloses 199 specific compounds of formula (T-1) wherein n is 1, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R³, R⁴, R⁵, and R⁶ are hydrogen, R¹ and R² are fluorine, and R⁷ is as defined above in Table 1.

Table 1.9: This table discloses 199 specific compounds of formula (T-1) wherein n is 1, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R¹, R², R³, R⁴, and R⁵ are hydrogen, R⁶ is methyl, and R⁷ is as defined above in Table 1.


25

Table 1.10: This table discloses 199 specific compounds of formula (T-1) wherein n is 1, A¹ is N, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R², R³, R⁴, and R⁵ are hydrogen, R⁶ is methyl, and R⁷ is as defined above in Table 1.

30 Table 1.11: This table discloses 199 specific compounds of formula (T-1) wherein n is 2, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R¹, R², R³, R⁴, R⁵, and R⁶ are hydrogen, and R⁷ is as defined above in Table 1.

35 Table 1.12: This table discloses 199 specific compounds of formula (T-1) wherein n is 2, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R¹, R², R⁴, R⁵, and R⁶ are hydrogen, R³ is fluorine, and R⁷ is as defined above in Table 1.

Table 2.1: This table discloses 117 specific compounds of the formula (T-2):



wherein n is 1, A^1 is C-R¹, A^2 is C-R², A^3 is C-R³, A^4 is C-R⁴ and R¹, R², R³, R⁴, R⁵, and R⁶ are hydrogen, and R⁷ is as defined below in Table 2.

- 5 Each of Tables 2.2 to 2.4 (which follow Table 2) make available 117 individual compounds of the formula (T-2) in which n , A^1 , A^2 , A^3 , A^4 , R¹, R², R³, R⁴, R⁵, and R⁶ are as specifically defined in Tables 2.2 to 2.4, which refer to Table 2 wherein R⁷ is specifically defined.

Table 2

| Compound no. | R ⁷ | Compound no. | R ⁷ |
|--------------|-------------------------|--------------|-----------------------------|
| 2.001 | 2-fluorophenyl | 2.060 | 4-pyrimidinyl |
| 2.002 | 3-fluorophenyl | 2.061 | 5-pyrimidinyl |
| 2.003 | 4-fluorophenyl | 2.062 | 2-thiazolyl |
| 2.004 | 2-chlorophenyl | 2.063 | 4-thiazolyl |
| 2.005 | 3-chlorophenyl | 2.064 | 5-thiazolyl |
| 2.006 | 4-chlorophenyl | 2.065 | 1H-imidazol-5-yl |
| 2.007 | 2-methylphenyl | 2.066 | 2-methyl-1 H-imidazol-5-yl |
| 2.008 | 3-methylphenyl | 2.067 | 5-methyl-1 H-imidazol-2-yl |
| 2.009 | 4-methylphenyl | 2.068 | 1,2-dimethylimidazol-5-yl |
| 2.010 | 2-trifluorophenyl | 2.069 | 1,5-dimethylimidazol-2-yl |
| 2.011 | 3-trifluorophenyl | 2.070 | oxazol-2-yl |
| 2.012 | 4-trifluorophenyl | 2.071 | oxazol-4-yl |
| 2.013 | 2-difluorophenyl | 2.072 | oxazol-5-yl |
| 2.014 | 3-difluorophenyl | 2.073 | 2-methyloxazol-5-yl |
| 2.015 | 4-difluorophenyl | 2.074 | 2-cyanooxazol-5-yl |
| 2.016 | 2-methoxyphenyl | 2.075 | 5-methyloxazol-2-yl |
| 2.017 | 3-methoxyphenyl | 2.076 | 5-cyanooxazol-5-yl |
| 2.018 | 4-methoxyphenyl | 2.077 | 2-methyl-1,2,4-triazol-3-yl |
| 2.019 | 2-difluoromethoxyphenyl | 2.078 | oxetan-3-yl |
| 2.020 | 4-difluoromethoxyphenyl | 2.079 | thietan-3-yl |
| 2.021 | 3-difluoromethoxyphenyl | 2.080 | 1H-azetidin-3-yl |
| 2.022 | 2-pyridyl | 2.081 | 1-acyl-azetidin-3-yl |
| 2.023 | 3-pyridyl | 2.082 | tetrahydrofuran-4-yl |
| 2.024 | 4-pyridyl | 2.083 | 4,5-dihydroisoxazol-3-yl |


| | | | |
|-------|-----------------------------|-------|--------------------------------|
| 2.025 | 6-chloro-3-pyridyl | 2.084 | 5,5-dimethyl-4H-isoxazol-3-yl |
| 2.026 | 5-chloro-3-pyridyl | 2.085 | 4,4-dimethyl-4H-isoxazol-3-yl |
| 2.027 | 4-chloro-3-pyridyl | 2.086 | 5-methylisoxazol-3-yl |
| 2.028 | 2-chloro-3-pyridyl | 2.087 | 1-methyltetrazol-5-yl |
| 2.029 | 6-methyl-3-pyridyl | 2.088 | 1H-pyrazol-3-yl |
| 2.030 | 5-methyl-3-pyridyl | 2.089 | 1-methylpyrazol-3-yl |
| 2.031 | 4-methyl-3-pyridyl | 2.090 | 1,5-dimethylpyrazol-3-yl |
| 2.032 | 2-methyl-3-pyridyl | 2.091 | 1-acylpyrazol-3-yl |
| 2.033 | 6-cyano-3-pyridyl | 2.092 | 3,4-dihydro-2H-pyrrol-5-yl |
| 2.034 | 5-cyano-3-pyridyl | 2.093 | 1H-pyrrolidin-3-yl |
| 2.035 | 4-cyano-3-pyridyl | 2.094 | 1-acyl-pyrrolidin-4-yl |
| 2.036 | 2-cyano-3-pyridyl | 2.095 | tetrahydrofuran-3-yl |
| 2.037 | 6-fluoro-4-pyridyl | 2.096 | 2,3,4,5-tetrahydropyridin-6-yl |
| 2.038 | 5-fluoro-4-pyridyl | 2.097 | 1-methoxypiperidin-4-yl |
| 2.039 | 2-fluoro-4-pyridyl | 2.098 | 1H-piperidin-4-yl |
| 2.040 | 6-chloro-4-pyridyl | 2.099 | 1-acyl-piperidin-4-yl |
| 2.041 | 5-chloro-4-pyridyl | 2.100 | cyclopropyl |
| 2.042 | 6-trifluoromethyl-2-pyridyl | 2.101 | cyclobutyl |
| 2.043 | 5-trifluoromethyl-2-pyridyl | 2.102 | cyclopentyl |
| 2.044 | 4-trifluoromethyl-2-pyridyl | 2.103 | cyclohexyl |
| 2.045 | 3-trifluoromethyl-2-pyridyl | 2.104 | cyclopent-3-en-1-yl |
| 2.046 | 6-difluoromethyl-2-pyridyl | 2.105 | cyclohex-2-en-1-yl |
| 2.047 | 5-difluoromethyl-2-pyridyl | 2.106 | methyl |
| 2.048 | 4-difluoromethyl-2-pyridyl | 2.107 | ethyl |
| 2.049 | 3-difluoromethyl-2-pyridyl | 2.108 | propyl |
| 2.050 | 6-difluoromethoxy-2-pyridyl | 2.109 | isopropyl |
| 2.051 | 5-difluoromethoxy-2-pyridyl | 2.110 | butyl |
| 2.052 | 4-difluoromethoxy-2-pyridyl | 2.111 | pentyl |
| 2.053 | 3-difluoromethoxy-2-pyridyl | 2.112 | prop-2-en-1-yl |
| 2.054 | 6-trifluoromethyl-4-pyridyl | 2.113 | prop-2-yn-1-yl |
| 2.055 | 5-trifluoromethyl-4-pyridyl | 2.114 | 2-methoxyethyl |
| 2.056 | 2-trifluoromethyl-4-pyridyl | 2.115 | 2-ethoxyethyl |
| 2.057 | 6-difluoromethyl-4-pyridyl | 2.116 | 2-isopropoxyethyl |
| 2.058 | 5-difluoromethyl-4-pyridyl | 2.117 | 2-difluoromethoxyethyl |
| 2.059 | 2-difluoromethyl-4-pyridyl | | |

Table 2.2: This table discloses 117 specific compounds of formula (T-2) wherein n is 1, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R¹, R², R⁴, R⁵, and R⁶ are hydrogen, R³ is fluorine, and R⁷ is as defined above in Table 2.

Table 2.3: This table discloses 117 specific compounds of formula (T-2) wherein n is 2, A^1 is C-R¹, A^2 is C-R², A^3 is C-R³, A^4 is C-R⁴ and R¹, R², R³, R⁴, R⁵, and R⁶ are hydrogen, and R⁷ is as defined above in Table 2.

- 5 Table 2.4: This table discloses 117 specific compounds of formula (T-2) wherein n is 2, A^1 is C-R¹, A^2 is C-R², A^3 is C-R³, A^4 is C-R⁴ and R¹, R², R⁴, R⁵, and R⁶ are hydrogen, R³ is fluorine, and R⁷ is as defined above in Table 2.

Table 3.1: This table discloses 122 specific compounds of the formula (T-3):



10

wherein n is 1, A^1 is C-R¹, A^2 is C-R², A^3 is C-R³, A^4 is C-R⁴ and R¹, R², R³, R⁴, R⁵, R⁶ and R⁸ are hydrogen, and R⁷ is as defined below in Table 3.

- Each of Tables 3.2 to 3.7 (which follow Table 3) make available 122 individual compounds of the formula (T-3) in which n , A^1 , A^2 , A^3 , A^4 , R¹, R², R³, R⁴, R⁵, R⁶, and R⁸ are as specifically defined in Tables 3.2 to 3.7, which refer to Table 3 wherein R⁷ is specifically defined.

Table 3

| Compound no. | R ⁷ | Compound no. | R ⁷ |
|--------------|-------------------|--------------|----------------------------|
| 3.001 | 2-fluorophenyl | 3.062 | 2-thiazolyl |
| 3.002 | 3-fluorophenyl | 3.063 | 4-thiazolyl |
| 3.003 | 4-fluorophenyl | 3.064 | 5-thiazolyl |
| 3.004 | 2-chlorophenyl | 3.065 | 1H-imidazol-5-yl |
| 3.005 | 3-chlorophenyl | 3.066 | 2-methyl-1 H-imidazol-5-yl |
| 3.006 | 4-chlorophenyl | 3.067 | 5-methyl-1 H-imidazol-2-yl |
| 3.007 | 2-methylphenyl | 3.068 | 1,2-dimethylimidazol-5-yl |
| 3.008 | 3-methylphenyl | 3.069 | 1,5-dimethylimidazol-2-yl |
| 3.009 | 4-methylphenyl | 3.070 | oxazol-2-yl |
| 3.010 | 2-trifluorophenyl | 3.071 | oxazol-4-yl |
| 3.011 | 3-trifluorophenyl | 3.072 | oxazol-5-yl |
| 3.012 | 4-trifluorophenyl | 3.073 | 2-methyloxazol-5-yl |
| 3.013 | 2-difluorophenyl | 3.074 | 2-cyanooxazol-5-yl |
| 3.014 | 3-difluorophenyl | 3.075 | 5-methyloxazol-2-yl |

| | | | |
|-------|-----------------------------|-------|------------------------------------|
| 3.015 | 4-difluorophenyl | 3.076 | 5-cyanooxazol-5-yl |
| 3.016 | 2-methoxyphenyl | 3.077 | 2-methyl-1,2,4-triazol-3-yl |
| 3.017 | 3-methoxyphenyl | 3.078 | oxetan-3-yl |
| 3.018 | 4-methoxyphenyl | 3.079 | thietan-3-yl |
| 3.019 | 2-difluoromethoxyphenyl | 3.080 | 1H-azetidin-3-yl |
| 3.020 | 4-difluoromethoxyphenyl | 3.081 | 1-acyl-azetidin-3-yl |
| 3.021 | 3-difluoromethoxyphenyl | 3.082 | tetrahydro-4H-pyran-4-yl |
| 3.022 | 2-pyridyl | 3.083 | 4,5-dihydroisoxazol-3-yl |
| 3.023 | 3-pyridyl | 3.084 | 5,5-dimethyl-4H-isoxazol-3-yl |
| 3.024 | 4-pyridyl | 3.085 | 4,4-dimethyl-4H-isoxazol-3-yl |
| 3.025 | 6-chloro-3-pyridyl | 3.086 | 5-methylisoxazol-3-yl |
| 3.026 | 5-chloro-3-pyridyl | 3.087 | 1-methyltetrazol-5-yl |
| 3.027 | 4-chloro-3-pyridyl | 3.088 | 1H-pyrazol-3-yl |
| 3.028 | 2-chloro-3-pyridyl | 3.089 | 1-methylpyrazol-3-yl |
| 3.029 | 6-methyl-3-pyridyl | 3.090 | 1,5-dimethylpyrazol-3-yl |
| 3.030 | 5-methyl-3-pyridyl | 3.091 | 1-acylpyrazol-3-yl |
| 3.031 | 4-methyl-3-pyridyl | 3.092 | 3,4-dihydro-2H-pyrrol-5-yl |
| 3.032 | 2-methyl-3-pyridyl | 3.093 | 1H-pyrolidin-3-yl |
| 3.033 | 6-cyano-3-pyridyl | 3.094 | 1-acyl-pyrolidin-4-yl |
| 3.034 | 5-cyano-3-pyridyl | 3.095 | tetrahydrofuran-3-yl |
| 3.035 | 4-cyano-3-pyridyl | 3.096 | 2,3,4,5-tetrahydro-6H-pyridin-6-yl |
| 3.036 | 2-cyano-3-pyridyl | 3.097 | 1-methoxy-6H-pyridin-4-yl |
| 3.037 | 6-fluoro-4-pyridyl | 3.098 | 1H-piperidin-4-yl |
| 3.038 | 5-fluoro-4-pyridyl | 3.099 | 1-acyl-piperidin-4-yl |
| 3.039 | 2-fluoro-4-pyridyl | 3.100 | cyclopropyl |
| 3.040 | 6-chloro-4-pyridyl | 3.101 | cyclobutyl |
| 3.041 | 5-chloro-4-pyridyl | 3.102 | cyclopentyl |
| 3.042 | 6-trifluoromethyl-2-pyridyl | 3.103 | cyclohexyl |
| 3.043 | 5-trifluoromethyl-2-pyridyl | 3.104 | cyclopent-3-en-1-yl |
| 3.044 | 4-trifluoromethyl-2-pyridyl | 3.105 | cyclohex-2-en-1-yl |
| 3.045 | 3-trifluoromethyl-2-pyridyl | 3.106 | methyl |
| 3.046 | 6-difluoromethyl-2-pyridyl | 3.107 | ethyl |
| 3.047 | 5-difluoromethyl-2-pyridyl | 3.108 | propyl |
| 3.048 | 4-difluoromethyl-2-pyridyl | 3.109 | isopropyl |
| 3.049 | 3-difluoromethyl-2-pyridyl | 3.110 | butyl |
| 3.050 | 6-difluoromethoxy-2-pyridyl | 3.111 | pentyl |
| 3.051 | 5-difluoromethoxy-2-pyridyl | 3.112 | prop-2-en-1-yl |
| 3.052 | 4-difluoromethoxy-2-pyridyl | 3.113 | prop-2-yn-1-yl |
| 3.053 | 3-difluoromethoxy-2-pyridyl | 3.114 | 2-methoxyethyl |
| 3.054 | 6-trifluoromethyl-4-pyridyl | 3.115 | 2-ethoxyethyl |

| | | | |
|-------|-----------------------------|-------|------------------------|
| 3.055 | 5-trifluoromethyl-4-pyridyl | 3.116 | 2-isopropoxyethyl |
| 3.056 | 2-trifluoromethyl-4-pyridyl | 3.117 | 2-difluoromethoxyethyl |
| 3.057 | 6-difluoromethyl-4-pyridyl | 3.118 | 2-chlorophenyl |
| 3.058 | 5-difluoromethyl-4-pyridyl | 3.119 | methylcarbonyl |
| 3.059 | 2-difluoromethyl-4-pyridyl | 3.120 | pyridin-2-yl |
| 3.060 | 4-pyrimidinyl | 3.121 | (2-thienyl)methyl |
| 3.061 | 5-pyrimidinyl | 3.122 | 2,2,2-trifluoroethyl |

Table 3.2: This table discloses 122 specific compounds of formula (T-3) wherein n is 1, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R¹, R², R⁴, R⁵, R⁶ and R⁸ are hydrogen, R³ is fluorine, and R⁷ is as defined above in Table 3.

5

Table 3.3: This table discloses 122 specific compounds of formula (T-3) wherein n is 2, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R¹, R², R³, R⁴, R⁵, R⁶ and R⁸ are hydrogen, and R⁷ is as defined above in Table 3.

10 Table 3.4: This table discloses 122 specific compounds of formula (T-3) wherein n is 2, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R¹, R², R⁴, R⁵, R⁶ and R⁸ are hydrogen, R³ is fluorine, and R⁷ is as defined above in Table 3.

15 Table 3.5: This table discloses 122 specific compounds of formula (T-3) wherein n is 1, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R¹, R², R⁴, R⁵, and R⁶ are hydrogen, R⁸ is methoxy, and R⁷ is as defined above in Table 3.

20 Table 3.6: This table discloses 122 specific compounds of formula (T-3) wherein n is 1, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R², R³, R⁴, R⁵, and R⁶ are hydrogen, R³ is fluorine, R⁸ is methoxy, and R⁷ is as defined above in Table 3.

Table 3.7: This table discloses 122 specific compounds of formula (T-3) wherein n is 1, A¹ is C-R¹, A² is C-R², A³ is C-R³, A⁴ is C-R⁴ and R¹, R², R⁴, R⁵, and R⁶ are hydrogen, R⁸ is methyl, and R⁷ is as defined above in Table 3.

25

EXAMPLES

The Examples which follow serve to illustrate the invention. The compounds of the invention can be distinguished from known compounds by virtue of greater efficacy at low application rates, which can be verified by the person skilled in the art using the experimental procedures outlined in the

30 Examples, using lower application rates if necessary, for example 50 ppm, 12.5 ppm, 6 ppm, 3 ppm, 1.5 ppm, 0.8 ppm or 0.2 ppm.

Compounds of Formula (I) may possess any number of benefits including, *inter alia*, advantageous levels of biological activity for protecting plants against diseases that are caused by fungi or superior properties for use as agrochemical active ingredients (for example, greater biological

activity, an advantageous spectrum of activity, an increased safety profile (including improved crop tolerance), improved physico-chemical properties, or increased biodegradability).

Throughout this description, temperatures are given in degrees Celsius (°C) and "mp." means melting point. LC/MS means Liquid Chromatography Mass Spectrometry and the description of the apparatus and the method (Methods A, B and C) is as follows:

The description of the LC/MS apparatus and the method A is:

SQ Detector 2 from Waters

10 Ionisation method: Electrospray

Polarity: positive and negative ions

Capillary (kV) 3.0, Cone (V) 30.00, Extractor (V) 2.00, Source Temperature (°C) 150, Desolvation Temperature (°C) 350, Cone Gas Flow (L/Hr) 0, Desolvation Gas Flow (L/Hr) 650

Mass range: 100 to 900 Da

15 DAD Wavelength range (nm): 210 to 500

Method Waters ACQUITY UPLC with the following HPLC gradient conditions:

(Solvent A: Water/Methanol 20:1 + 0.05% formic acid and Solvent B: Acetonitrile+ 0.05% formic acid)

20

| Time (minutes) | A (%) | B (%) | Flow rate (ml/min) |
|----------------|-------|-------|--------------------|
| 0 | 100 | 0 | 0.85 |
| 1.2 | 0 | 100 | 0.85 |
| 1.5 | 0 | 100 | 0.85 |

25

Type of column: Waters ACQUITY UPLC HSS T3; Column length: 30 mm; Internal diameter of column: 2.1 mm; Particle Size: 1.8 micron; Temperature: 60°C.

The description of the LC/MS apparatus and the method B is:

30

SQ Detector 2 from Waters

Ionisation method: Electrospray

Polarity: positive ions

Capillary (kV) 3.5, Cone (V) 30.00, Extractor (V) 3.00, Source Temperature (°C) 150, Desolvation

35 Temperature (°C) 400, Cone Gas Flow (L/Hr) 60, Desolvation Gas Flow (L/Hr) 700

Mass range: 140 to 800 Da

DAD Wavelength range (nm): 210 to 400

Method Waters ACQUITY UPLC with the following HPLC gradient conditions

40 (Solvent A: Water/Methanol 9:1 + 0.1% formic acid and Solvent B: Acetonitrile + 0.1% formic acid)

| | Time (minutes) | A (%) | B (%) | Flow rate (ml/min) |
|---|----------------|-------|-------|--------------------|
| | 0 | 100 | 0 | 0.75 |
| | 2.5 | 0 | 100 | 0.75 |
| | 2.8 | 0 | 100 | 0.75 |
| 5 | 3.0 | 100 | 0 | 0.75 |

Type of column: Waters ACQUITY UPLC HSS T3; Column length: 30 mm; Internal diameter of column: 2.1 mm; Particle Size: 1.8 micron; Temperature: 60°C.

The description of the LC/MS apparatus and the method C is:

10 SQ Detector 2 from Waters

Ionisation method: Electrospray

ACQUITY H Class UPLC, Mass Spectrometer from Waters

Polarity: positive and Negative Polarity Switch

Scan Type MS1 Scan

15 Capillary (kV) 3.00, Cone (V) 40.00, Desolvation Temperature (°C) 500, Cone Gas Flow (L/Hr) 50,

Desolvation Gas Flow (L/Hr) 1000

Mass range: 0 to 2000 Da

DAD Wavelength range (nm): 200 to 350

20 Method Waters ACQUITY UPLC with the following HPLC gradient conditions

(Solvent A: Water +,0.1% formic acid and Solvent B: Acetonitrile)

| | Time (minutes) | A (%) | B (%) | Flow rate (ml/min) |
|----|----------------|-------|-------|--------------------|
| | 0 | 70 | 30 | 0.5 |
| | 0.05 | 70 | 30 | 0.5 |
| 25 | 0.8 | 5 | 95 | 0.5 |
| | 1.8 | 5 | 95 | 0.5 |
| | 2.45 | 70 | 30 | 0.5 |
| | 2.50 | 70 | 30 | 0.5 |

30 Type of column: Waters ACQUITY UPLC BEH C 18; Column length: 50 mm; Internal diameter of column: 2.1 mm; Particle Size: 1.7 micron; Temperature: 35°C.

Where necessary, enantiomerically pure final compounds may be obtained from racemic materials as appropriate via standard physical separation techniques, such as reverse phase chiral chromatography, or through stereoselective synthetic techniques, eg, by using chiral starting materials.

Formulation Examples

Wettable powders

| | a) | b) | c) |
|---|------|------|------|
| active ingredient [compound of formula (I)] | 25 % | 50 % | 75 % |
| sodium lignosulfonate | 5 % | 5 % | - |

| | | | |
|---|------|------|------|
| sodium lauryl sulfate | 3 % | - | 5 % |
| sodium diisobutylphenathalenesulfonate | - | 6 % | 10 % |
| phenol polyethylene glycol ether (7-8 mol of ethylene oxide) | - | 2 % | - |
| highly dispersed silicic acid | 5 % | 10 % | 10 % |
| Kaolin | 62 % | 27 % | - |

The active ingredient is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording wettable powders that can be diluted with water to give suspensions of the desired concentration.

5

| <u>Powders for dry seed treatment</u> | a) | b) | c) |
|---|------|------|------|
| active ingredient [compound of formula (I)] | 25 % | 50 % | 75 % |
| light mineral oil | 5 % | 5 % | 5 % |
| highly dispersed silicic acid | 5 % | 5 % | - |
| Kaolin | 65 % | 40 % | - |
| Talcum | - | | 20 % |

The active ingredient is thoroughly mixed with the adjuvants and the mixture is thoroughly ground in a suitable mill, affording powders that can be used directly for seed treatment.

Emulsifiable concentrate

| | |
|--|------|
| active ingredient [compound of formula (I)] | 10 % |
| octylphenol polyethylene glycol ether (4-5 mol of ethylene oxide) | 3 % |
| calcium dodecylbenzenesulfonate | 3 % |
| castor oil polyglycol ether (35 mol of ethylene oxide) | 4 % |
| Cyclohexanone | 30 % |
| xylene mixture | 50 % |

10

Emulsions of any required dilution, which can be used in plant protection, can be obtained from this concentrate by dilution with water.

| <u>Dusts</u> | a) | b) | c) |
|---|------|------|------|
| Active ingredient [compound of formula (I)] | 5 % | 6 % | 4 % |
| Talcum | 95 % | - | - |
| Kaolin | - | 94 % | - |
| mineral filler | - | - | 96 % |

15

Ready-for-use dusts are obtained by mixing the active ingredient with the carrier and grinding the mixture in a suitable mill. Such powders can also be used for dry dressings for seed.

Extruder granules

| | |
|---|------|
| Active ingredient [compound of formula (I)] | 15 % |
| sodium lignosulfonate | 2 % |
| Carboxymethylcellulose | 1 % |
| Kaolin | 82 % |

The active ingredient is mixed and ground with the adjuvants, and the mixture is moistened with water. The mixture is extruded and then dried in a stream of air.

5

Coated granules

| | |
|---|------|
| Active ingredient [compound of formula (I)] | 8 % |
| polyethylene glycol (mol. wt. 200) | 3 % |
| Kaolin | 89 % |

The finely ground active ingredient is uniformly applied, in a mixer, to the kaolin moistened with polyethylene glycol. Non-dusty coated granules are obtained in this manner.

10 Suspension concentrate

| | |
|--|------|
| active ingredient [compound of formula (I)] | 40 % |
| propylene glycol | 10 % |
| nonylphenol polyethylene glycol ether (15 mol of ethylene oxide) | 6 % |
| Sodium lignosulfonate | 10 % |
| Carboxymethylcellulose | 1 % |
| silicone oil (in the form of a 75 % emulsion in water) | 1 % |
| Water | 32 % |

The finely ground active ingredient is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water. Using such dilutions, living plants as well as plant propagation material can be treated and protected

15 against infestation by microorganisms, by spraying, pouring or immersion.

Flowable concentrate for seed treatment

| | |
|---|--------|
| active ingredient [compound of formula (I)] | 40 % |
| propylene glycol | 5 % |
| copolymer butanol PO/EO | 2 % |
| tristyrenephenole with 10-20 moles EO | 2 % |
| 1,2-benzisothiazolin-3-one (in the form of a 20% solution in water) | 0.5 % |
| monoazo-pigment calcium salt | 5 % |
| Silicone oil (in the form of a 75 % emulsion in water) | 0.2 % |
| Water | 45.3 % |

The finely ground active ingredient is intimately mixed with the adjuvants, giving a suspension concentrate from which suspensions of any desired dilution can be obtained by dilution with water. Using such dilutions, living plants as well as plant propagation material can be treated and protected
5 against infestation by microorganisms, by spraying, pouring or immersion.

Slow-Release Capsule Suspension

28 parts of a combination of the compound of formula (I) are mixed with 2 parts of an aromatic solvent and 7 parts of toluene diisocyanate/polymethylene-polyphenylisocyanate-mixture (8:1). This
10 mixture is emulsified in a mixture of 1.2 parts of polyvinylalcohol, 0.05 parts of a defoamer and 51.6 parts of water until the desired particle size is achieved. To this emulsion a mixture of 2.8 parts 1,6-diaminohexane in 5.3 parts of water is added. The mixture is agitated until the polymerization reaction is completed.

15 The obtained capsule suspension is stabilized by adding 0.25 parts of a thickener and 3 parts of a dispersing agent. The capsule suspension formulation contains 28% of the active ingredients. The medium capsule diameter is 8-15 microns.

The resulting formulation is applied to seeds as an aqueous suspension in an apparatus suitable
20 for that purpose.

List of Abbreviations:

| | |
|----------|------------------------------|
| AIBN | = azobisisobutyronitrile |
| brs | = broad singlet |
| 25 CDCI3 | = chloroform-d |
| °C | = degrees Celsius |
| DIPEA | = N,N-di-isopropylethylamine |
| d | = doublet |
| EtOAc | = ethyl acetate |
| 30 h | = hour(s) |
| HCl | = hydrochloric acid |
| NBS | = N-bromosuccinimide |
| M | = molar |
| min | = minutes |
| 35 MHz | = mega hertz |
| mp | = melting point |
| N | = normal |
| ppm | = parts per million |
| Rt | = retention time |
| 40 RT | = room temperature |
| s | = singlet |


t = triplet

TFAA = trifluoroacetic acid anhydride

LC/MS = Liquid Chromatography Mass Spectrometry (description of the apparatus and the methods used for LC/MS analysis are given above)


5

Example 1: This example illustrates the preparation 3-[4-(4,5-dihydroisoxazol-3-yloxymethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (Compound 1.2 of Table T 1)



Step 1: Preparation of N'-hydroxy-4-methyl-benzamidine


10



To a suspension of 4-methylbenzamide (35 g, 0.29 mol) in ethanol (220 mL) and water (440 mL) at RT was added hydroxylamine hydrochloride (41.1 g, 0.58 mol), potassium carbonate (65.4 g, 0.47 mol) and 8-hydroxyquinoline (0.22 g, 1.5 mmol). The reaction mixture was heated at 80°C for 4 h. The mixture was cooled to RT, diluted with 2N HCl until pH 8 and the ethanol was removed under reduced pressure. The resultant mixture was filtered, washed with water and dried under vacuum to afford the title compound which was used without further purification. LC/MS (Method A) retention time = 0.23 minutes, 151.0 (M+H).

20

Step 2: Preparation of 3-(p-tolyl)-5-(trifluoromethyl)-1,2,4-oxadiazole



To a stirred solution of N'-hydroxy-4-methylbenzamide (38.7 g, 0.25 mol) in 2-methyltetrahydrofuran (750 mL) was added TFAA (49 mL, 0.35 mol) at 0°C. The reaction mixture was stirred for 2 h at 15°C and then diluted with water. The organic layer was separated, washed successively with sodium bicarbonate solution, saturated aqueous ammonium chloride solution, then water and dried over sodium sulfate, filtered, and evaporated to dryness. The crude product was subjected to flash chromatography over silica gel (750g pre-packed column) with heptane/EtOAc 99:1 to 90:10 to afford the title compound as a clear oil, which solidified after storage. LC/MS (Method A) retention time = 1.15 minutes, mass not detected.


30

¹H NMR (400 MHz, CDCl₃) δ ppm: 8.00 (d, 2H), 7.32 (d, 2H), 2.45 (s, 3H).

¹⁹F NMR (400 MHz, CDCl₃) δ ppm: -65.41 (s).

Step 3a: Preparation of 3-[4-(bromomethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole

5



A stirred mixture of 3-(p-tolyl)-5-(trifluoromethyl)-1,2,4-oxadiazole (56.0 g, 0.24 mol) and NBS (45.4 g, 0.25 mol) in tetrachloromethane (480 mL) under argon was heated to 70°C. AIBN (4.03 g, 24 mmol) was added and the reaction mixture stirred at 65°C for 18 h. The mixture was cooled to RT and diluted with dichloromethane and water and the layers were separated. The organic layer was washed with sodium bicarbonate solution, dried over sodium sulfate, filtered and evaporated to dryness. The crude residue was subjected to flash chromatography over silica gel (750g pre-packed column) with cyclohexane/EtOAc 100:0 to 95:5 to afford the title compound as a white solid (44.7 g, 57% yield). mp: 58-63°C. LC/MS (Method A) retention time = 1.16 minutes, 308 (M+H).

15

¹H NMR (400 MHz, CDCl₃) δ ppm: 8.11 (d, 2H), 7.55 (d, 2H), 4.53 (s, 2H).

¹⁹F NMR (400 MHz, CDCl₃) δ ppm: -65.32 (s).


3-[4-(dibromomethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole was isolated as by-product as a white solid (1.7g, 1.5% yield). mp: 61-66°C.

20

¹H NMR (400 MHz, CDCl₃) δ ppm: 8.15 (d, 2H), 7.73 (d, 2H), 6.68 (s, 1H).

¹⁹F NMR (400 MHz, CDCl₃) δ ppm: -65.34 (s).

25 Step 3b: Preparation of 3-[4-(bromomethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole from 3-[4-(dibromomethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole



To a stirred 1:9 ratio mixture of 3-[4-(bromomethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole and 3-[4-(dibromomethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (10.2 g) in acetonitrile (95 mL), water (1.9 mL) and DIPEA (6.20 mL, 35.7 mmol) was added diethylphosphite (4.7 mL, 35.7 mmol) at 5°C. The mixture was stirred for 2 h at 5-10 °C then water and 1M HCl was added. Volatiles were removed under reduced pressure and the resultant white slurry was extracted three times with dichloromethane. The combined organic layers were dried over sodium sulfate and filtered. The

30

solvent was removed under reduced pressure and the crude residue was subjected to flash chromatography over silica gel (40 g pre-packed column) with cyclohexane/EtOAc 99:1 to 9:1 to afford 3-[4-(bromomethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole as a white solid (7.1 g, 95% yield). mp: 58-63°C. LC/MS (Method A) retention time = 1.16 minutes, 308 (M+H).

5

^1H NMR (400 MHz, CDCl_3) δ ppm: 8.11 (d, 2H), 7.55 (d, 2H), 4.53 (s, 2H).

^{19}F NMR (400 MHz, CDCl_3) δ ppm: -65.32 (s).


Step 4: Preparation of 3-[4-(4,5-dihydroisoxazol-3-yl)oxymethyl]phenyl]-5-(trifluoromethyl)-1,2,4-

10 oxadiazole

A heterogeneous solution of 3-[4-(bromomethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (150 mg, 0.46 mmol), isoxazolidin-3-one (61 mg, 0.7 mmol), and potassium carbonate (130 mg, 0.93 mmol) in acetonitrile (4.7 mL) was irradiated with microwaves at 120°C for 30 min. Then, solids were removed by filtration, washed with ethyl acetate, and the mother liquor was concentrated under reduced pressure. The resultant residue was purified by flash chromatography over silica gel (cyclohexane/EtOAc eluent gradient 1:0 to 1:1) to afford the title compound as a yellow solid (19 mg, 13% yield). LC/MS (Method A) retention time = 0.96 minutes, 314 (M+H). mp: 97.0-101°C

15
20 ^1H NMR (400 MHz, CDCl_3) δ ppm: 8.10 (d, 2H), 7.48 (d, 2H), 4.75 (s, 2H), 4.34 (t, 2H), 2.84 (t, 2H)

Example 2: This example illustrates the preparation 3-[4-[(2-fluorophenoxy)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (Compound 1.11 of Table T 1).




25

To a solution of 2-fluorophenol (0.17 g, 1.5 mmol) in acetonitrile (10 mL) was added potassium carbonate (0.275 g, 1.99 mmol) and 3-[4-(bromomethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (0.31 g, 0.10 mmol) and the reaction mixture was stirred at room temperature overnight. The reaction mass was diluted with water and the resulting aqueous solution was extracted with ethyl acetate. The combined organic layers were washed with water and brine then dried over sodium sulfate. Volatiles were removed under reduced pressure and the crude mass was purified using flash chromatography over silica gel with (cyclohexane/EtOAc eluent gradient) to obtain the titled compound (302 mg, 90% yield) as a white solid. LC/MS (Method A) retention time = 1.08 minutes, 337 (M-H). mp: 108-110°C.

35

^1H NMR (400 MHz, CDCl_3) δ ppm: 8.16 (m, 2H), 7.64 (d, 2H), 7.05 (m, 4H), 5.25 (s, 2H).


Example 3: This example illustrates the preparation [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl acetate (Compound 2.1 of Table T2)




- 5 To a solution of 3-[4-(bromomethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (1.2 g, 4.0 mmol, in dimethylformamide (10 mL) was added potassium acetate (1.06 g, 5.98 mmol) and the reaction mixture was stirred for overnight. Water was introduced, the layers were separated, and the aqueous layer was extracted with ethyl acetate. Solvent was removed under reduced pressure and the resultant crude residue was purified by flash chromatography over silica gel (cyclohexane/EtOAc
- 10 eluent gradient 1:0 to 15:1) to afford the title compound as a clear oil (1.14 g, 92% yield). LC/MS (Method A) retention time = 0.94 minutes, 285 (M-H).

¹H NMR (400 MHz, CDCl₃) δ ppm: 8.05 (d, 2H), 7.44 (d, 2H), 5.10 (s, 2H), 2.07 (t, 3H).

- 15 Example 4: This example illustrates the preparation 3-[4-(4,5-dihydroisoxazol-3-yloxymethyl)-2-fluorophenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (Compound 1.13 of Table T1)



Step 1: Preparation of 2-fluoro-N'-hydroxy-4-methyl-benzamidine




- 20 To a suspension of 2-fluoro-4-methylbenzamide (5 g, 37.0 mmol) in ethanol (125 mL) at 25°C was added hydroxylamine hydrochloride (7.7 g, 111 mmol). The reaction mixture was heated at 80°C for 2 h. After cooling to room temperature the volatiles were removed under reduced pressure thus affording a white solid that was used in the next step without any purification. LC/MS (Method A) retention time = 1.14 minutes, 169.2 (M+H).

25

¹H NMR (400 MHz, CDCl₃) δ ppm: 7.96 (t, 1H), 7.11 (m, 2H), 2.45 (s, 3H).


Step 2: Preparation of 3-(2-fluoro-4-methyl-phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole



To a solution of 2-fluoro-N'-hydroxy-4-methyl-benzimidine (37 mmol) in tetrahydrofuran (122 mL) cooled via an ice bath was added TFAA (7.71 mL, 55.5 mmol). The reaction mixture was stirred at 25°C overnight and then diluted with water. The organic layer was separated, washed successively
5 with sodium bicarbonate solution, ammonium chloride solution, and water then dried over sodium sulfate, filtered and evaporated to dryness. The crude product was subjected to flash chromatography over silica gel with cyclohexane/EtOAc 99:1 to 1:1 to afford the title compound (6.6 g, 72% yield) as an amorphous white solid. LC/MS (Method A) retention time = 1.14 minutes, 247 (M+H).

10 ¹H NMR (400 MHz, CDCl₃) δ ppm: 8.00 (d, 1H), 7.32 (d, 2H), 2.45 (s, 3H).
¹⁹F NMR (400 MHz, CDCl₃) δ ppm: -65.3 (s), 108.1 (s).

Step 3a: Preparation of 3-[4-(bromomethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole




15 A stirred mixture of 3-(2-fluoro-4-methylphenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole (4.2 g, 17.1 mmol) and NBS (3.11 g, 17.1 mmol) in tetrachloromethane (34.3 mL) under argon was heated to 70°C. AIBN (0.29 g, 1.71 mmol) was added and the reaction mixture stirred at 65°C for 18 h. The mixture was cooled to 25°C then diluted with dichloromethane and water after which the layers were
20 separated. The succinimide by-product was filtrated off, and the solvent was removed under reduced pressure to afford a brown gum. This crude residue was subjected to flash chromatography over silica gel (with cyclohexane/EtOAc 100:0 to 4:1 to afford the title compound as a white solid (1.7 g, 31% yield). LC/MS (Method A) retention time = 1.13 minutes, (M+H) not detected.

25 ¹H NMR (400 MHz, CDCl₃) δ ppm: 8.09 (t, 1H), 7.34 (m, 2H), 4.49 (s, 2H).
¹⁹F NMR (400 MHz, CDCl₃) δ ppm: -65.18 (s), -106.2 (s).

3-[4-(dibromomethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole was isolated as by-product in the form of a beige solid (4.0 g, 58% yield) LC/MS (Method A) retention time = 1.20 minutes, (M+H)
30 not detected.

¹H NMR (400 MHz, CDCl₃) δ ppm: 8.14 (d, 1H), 7.52 (dd, 2H), 6.63 (s, 1H).

Step 3b: Preparation of 3-[4-(bromomethyl)-2-fluoro-phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole from 33-[4-(dibromomethyl)-2-fluoro-phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole



To a 1:20 ratio mixture of 3-[4-(bromomethyl)-2-fluoro-phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole and 3-[4-(dibromomethyl)-2-fluoro-phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (4.0 g, 9.9 mmol) in acetonitrile (37 mL), water (0.8 mL) and DIPEA (2.59 mL, 14.8 mmol) at 5°C was added diethylphosphite (2.0 mL, 14.8 mmol). The mixture was stirred at 5-10°C for 2 h, water and 1M HCl were added, and volatiles were removed under reduced pressure. The white slurry was extracted three times with dichloromethane and the combined organic layers were dried over sodium sulfate and filtered. The solvent was removed under reduced pressure and the resultant light orange colored crude residue was subjected to flash chromatography over silica gel with cyclohexane/EtOAc 99:1 to 1:1 to afford 3-[4-(bromomethyl)-2-fluoro-phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (2.2 g, 68% yield). LC/MS (Method A) retention time = 1.13 minutes, (M+H) not detected.

¹H NMR (400 MHz, CDCl₃) δ ppm: 8.09 (t, 1H), 7.34 (m, 2H), 4.49 (s, 2H).

¹⁹F NMR (400 MHz, CDCl₃) δ ppm: -65.18 (s), -106.2 (s).


Step 4: Preparation of 3-[4-(4,5-dihydroisoxazol-3-ylomethyl)-2-fluoro-phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole

20


A solution of 3-[4-(bromomethyl)-2-fluorophenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (100 mg, 0.31 mmol), isoxazolidin-3-one (41 mg, 0.45 mmol), and potassium carbonate (95 mg, 0.93 mmol) in acetonitrile (3.6 mL) was irradiated with microwaves at 120°C for 30 min. Then, solids were removed by filtration, washed with ethyl acetate, and the mother liquor was concentrated under reduced pressure. The resultant residue was purified by flash chromatography over silica gel (cyclohexane/EtOAc eluent gradient 1:0 to 1:1) to afford the title compound as a yellow solid (7 mg, 7% yield). LC/MS (Method A) retention time = 1.04 minutes, 332 (M+H).

Example 5: This example illustrates the preparation 3-[2,3-difluoro-4-(phenoxy)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (Compound 1.12 of Table T 1)

30




Step 1: Preparation of 2,3-difluoro-N'-hydroxy-4-methyl-benzamidine



To a suspension of 2,3-difluoro-4-methylbenzamide (5.0 g, 32.6 mmol) in ethanol (111 mL) at 25°C was added hydroxylamine hydrochloride (4.5 g, 65.3 mmol). The reaction mixture was heated at 80°C for 2 h. After cooling to RT the volatiles were removed under reduced pressure thus affording a white solid that was used in the next step without purification.

¹H NMR (400 MHz, CDCl₃) δ ppm: 7.30 (m, 1H), 6.95 (m, 1H), 6.50 (brs, 1H), 5.05 (brs, 2H), 2.30 (s, 3H).

10 Step 2: Preparation of 3-(2,3-difluoro-4-methyl-phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole




To a solution of 2,3-difluoro-N'-hydroxy-4-methyl-benzamide (2.6 mmol) in tetrahydrofuran (108 mL) cooled using an ice bath was added TFAA (6.9 mL, 49 mmol). The reaction mixture was stirred at 25°C overnight and then diluted with water. The organic layer was separated, washed successively with sodium bicarbonate solution, ammonium chloride solution, and water and then dried over sodium sulfate, filtered and evaporated to dryness. The crude title compound (6.6 g, 72% yield) was isolated as a light brown solid that was used in the next transformation without further purification. LC/MS (Method A) retention time = 1.16 minutes, 265 (M+H).

20 ¹H NMR (400 MHz, CDCl₃) δ ppm: 7.76 (d, 1H), 7.12 (d, 1H), 2.41 (s, 3H).

¹⁹F NMR (400 MHz, CDCl₃) δ ppm: -65.41 (s), -133.3 (s), -140.1 (s).

Step 3: Preparation of 3-[4-(bromomethyl)-2,3-difluoro-phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole



25

A mixture of 3-(2,3-difluoro-4-methyl-phenyl)-5-(trifluoromethyl)-1,2,4-oxadiazole (6.0 g, 22.6 mmol) and NBS (7.17 g, 10.0 mmol) in tetrachloromethane (79 mL) under argon was heated to 70°C. AIBN (0.68 g, 3.95 mmol) was added and the reaction mixture stirred at 65°C for 36 h. The mixture was cooled to 25°C, diluted with dichloromethane and water, and the layers were separated. The succinimide by-product was filtered off, and the solvent was removed under vacuum, to afford a brown

30

gum. This crude residue was subjected to flash chromatography over silica gel (cyclohexane/EtOAc eluent gradient 100:0 to 4:1) to afford the title compound as a white solid (4.8 g, 72% yield). LC/MS (Method A) retention time = 1.16 minutes, 344 (M+H).


- 5 ^1H NMR (400 MHz, CDCl_3) δ ppm: 7.80 (m, 1H), 7.37 (m, 1H), 4.55 (s, 2H).
 ^{19}F NMR (400 MHz, CDCl_3) δ ppm: -65.1 (s), -131.2 (s), -139.1 (s).

Step 4: Preparation of 3-[2,3-difluoro-4-(phenoxy)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole

- 10 To a solution of phenol (0.03 g, 0.33 mmol) in acetonitrile (5 mL) was added potassium carbonate (0.06 g, 0.44 mmol) then 3-[4-(bromomethyl)-2,3-difluoro-phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole (75 mg, 0.22 mmol) and reaction mixture was stirred at RT overnight. The reaction mixture was diluted with water and the resulting aqueous solution was extracted with EtOAc. The combined organic layers were washed with water, followed by brine, dried over sodium sulfate and concentrated
15 under reduced pressure. The crude mass was subjected to flash chromatography over silica gel (cyclohexane/EtOAc eluent gradient) to obtain the title compound (50 mg, 64% yield) as a white solid LC/MS (Method A) retention time = 1.09 minutes, 355 (M+H). mp: 113-115°C.

- ^1H NMR (400 MHz, CDCl_3) δ ppm: 7.90 (m, 1H), 7.52 (t, 1H), 7.35 (t, 2H), 7.03 (m, 3H), 5.26
20 (s, 2H).

Example 6: This example illustrates the preparation of [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl N-(4-chlorophenyl)carbamate (Compound 3.10 of Table T3)




- 25 To a solution of [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanol (0.08 g, 0.3 mmol) in dichloromethane (2 mL) was added pyridine (0.08 g, 1.0 mmol) and 1-chloro-4-isocyanato-benzene (0.05 g, 0.3 mmol). The reaction mixture was stirred at 40°C for 12 h. The reaction mixture was then cooled to ambient temperature and poured into water (10 mL) extracted twice with dichloromethane. The combined organic layer was washed with brine, dried over sodium sulfate, and filtered. The
30 solvent was removed under reduced pressure and the resultant crude residue was subjected to flash chromatography over silica gel (heptane: EtOAc eluent gradient 9:1 to 8:2) to afford the title compound (0.075 g) as white solid. LC/MS (Method A) retention time = 1.629 minutes, 395.6 (M-H).

¹H NMR (400 MHz, DMSO-c/6) δ ppm: 10.02 (brs, 1H), 8.09 (m, 2H), 7.65 (d, 2H), 7.49 (d, 2H), 7.34 (d, 2H), 5.26 (s, 2H).

¹⁹F NMR (376 MHz, DMSO-c/6) δ ppm: -64.74 (s)

5








Example 7: This example illustrates the preparation of [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl N-cyclopropylcarbamate (Compound 3.2 of Table T3)



To a solution of cyclopropanamine (0.03 g, 0.5 mmol) in dichloromethane (2 mL) was added
10 bis(trichloromethyl) carbonate (0.05 g, 0.2 mmol) and stirred at ambient temperature. After 30 minutes,
pyridine (0.04 g, 0.5 mmol) and [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methanol (0.1 g, 0.4
mmol) was added to the reaction mass and the reaction mixture was stirred at ambient temperature
for another 12 hours. The reaction mixture was cooled to ambient temperature, poured into water, and
15 extracted with dichloromethane. The combined organic layer was washed with brine, dried over
sodium sulfate, and filtered. The solvent was removed under reduced pressure and the resultant crude
residue was subjected to flash chromatography over silica gel (heptane: EtOAc eluent gradient 9:1 to
8:2) to afford 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl N-cyclopropylcarbamate (0.03 g,
20% Yield of theoretical yield) as off white solid.

20 ¹H NMR (400 MHz, CDCl₃) δ ppm: 8.04 (d, 2H), 7.44 (d, 2H), 5.11 (s, 2H), 4.93 (brs, 1H), 2.56
(m, 1H), 0.68 (m, 2H), 0.48 (m, 2H).

Table T 1: Melting point (mp) data and/or retention times (Rt) for the compounds of Formula (I):

| Entry | Compound name | Structure | R _t (mins) | Mass charge (M+H) ⁺ | Method | mp (°C) |
|-------|---|--|--------------------------|--------------------------------------|--------|--------------------------|
| 1.1 | 3-[4-[(4,4-dimethyl-5H-isoxazol-3-yl)oxymethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole |  | | | | 50.2 - 51.8 |
| 1.2 | 3-[4-(4,5-dihydroisoxazol-3-yloxymethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole |  | | | | 97 - 100. 9 |
| 1.3 | 3-[4-[(5,5-dimethyl-4H-isoxazol-3-yl)oxymethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole |  | | | | 107. 9 - 108. 6 |
| 1.4 | 3-[4-(isoxazol-3-yloxymethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole |  | | | | 61.8 - 64.4 |
| 1.5 | 3-[4-[(5-methylisoxazol-3-yl)oxymethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole |  | | | | 81.2 - 82.6 |
| 1.6 | 3-[4-[(4-fluorophenoxy)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole |  | | | | 174 - 176 |
| 1.7 | 3-[4-(phenoxy)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole |  | | | | 105 - 107 |

| Entry | Compound name | Structure | R _t (mins) | Mass charge (M+H) ⁺ | Method | mp (°C) |
|-------|---|-----------|--------------------------|--------------------------------------|--------|----------------------------|
| 1.8 | 3-[4-[(1-methyltetrazol-5-yl)oxymethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | | | | 113 - 3 - 114 - 2 |
| 1.9 | 3-[4-(2-pyridyloxymethyl)phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | | | | 86 - 88 |
| 1.10 | 3-[4-[(2,6-difluorophenoxy)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | | | | 66 - 68 |
| 1.11 | 3-[4-[(2-fluorophenoxy)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | | | | 108 - 110 |
| 1.12 | 3-[2,3-difluoro-4-(phenoxy)methyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | | | | 113 - 115 |

| Entry | Compound name | Structure | R _t (mins) | Mass charge (M+H) ⁺ | Method | mp (°C) |
|-------|---|-----------|--------------------------|--------------------------------------|--------|-------------------|
| 1.13 | 3-[4-(4,5-dihydroisoxazol-3-yloxymethyl)-2-fluorophenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | 1.04 | 332 | | |
| 1.14 | 6-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methoxy]pyridine-3-carbonitrile | | | | | 156 - 158 |
| 1.15 | 3-[4-[(5-methyl-2-pyridyl)oxymethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | | | | 141 - 143 |
| 1.16 | 3-[4-[(5-fluoro-2-pyridyl)oxymethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | | | | 84 - 86 |
| 1.17 | 3-[4-[(1-methylpyrazol-3-yl)oxymethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | | | | 84.9 - 87.8 |
| 1.18 | 1-[3-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methoxy]pyrazol-1-yl]ethanone | | | | | 86.1 - 87.3 |





| Entry | Compound name | Structure | R _t (mins) | Mass charge (M+H) ⁺ | Method | mp (°C) |
|-------|---|-----------|--------------------------|--------------------------------------|--------|---------------|
| 1.19 | 3-[4-[(5-methyl-1 <i>H</i> -pyrazol-3-yl)oxymethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | | | | 137.4 - 141.8 |
| 1.20 | 2-methyl-5-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methoxy]-1,3,4-oxadiazole | | | | | |
| 1.21 | 3-[4-[(6-bromopyridazin-3-yl)oxymethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | | | | |
| 1.22 | 3-[4-[1-(1-methyltetrazol-5-yl)oxyethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | | | | 104 - 106 |
| 1.23 | [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl <i>N</i> -methoxymethanimidate | | | | | |
| 1.24 | 3-[4-[1-[(6-methyl-2-pyridyl)oxy]ethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | | | | |
| 1.25 | 3-[2,6-difluoro-4-[(6-methyl-2-pyridyl)oxymethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | | | | 64 - 66 |





| Entry | Compound name | Structure | R _t (mins) | Mass charge (M+H) ⁺ | Method | mp (°C) |
|-------|---|-----------|--------------------------|--------------------------------------|--------|------------|
| 1.26 | 3-[4-[(5,5-dimethyl-4H-isoxazol-3-yl)oxymethyl]-2,6-difluoro-phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | 1.05 | 378.3 | | |
| 1.27 | 3-[2,5-difluoro-4-[(6-methyl-2-pyridyl)oxymethyl]phenyl]-5-(trifluoromethyl)-1,2,4-oxadiazole | | | | | 91 - 94 |

Table T2: Melting point (mp) data and/or retention times (R_t) for the compounds of Formula (I):

| Entry | Compound name | Structure | R _t (mins) | Mass charge (M+H) ⁺ | Method | mp (°C) |
|-------|---|-----------|--------------------------|--------------------------------------|--------|------------|
| 2.1 | [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl acetate | | 1.04 | 285 (M-H) | C | |
| 2.2 | [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl 2-methylpropanoate | | | | | 48 - 50 |
| 2.3 | [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl 2,2-dimethylpropanoate | | 1.09 | 327 (M-H) | C | |

Table T3: Melting point (mp) data and/or retention times (Rt) for the compounds of Formula (I):




| Entry | Compound name | Structure | R _t (mins) | Mass charge (M+H) ⁺ | Method | mp (°C) |
|-------|---|--|--------------------------|--------------------------------------|--------|------------|
| 3.1 | [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl <i>N,N</i> -dimethylcarbamate |  | 1.509 | 315.8 | C | 95 - 97 |
| 3.2 | [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl <i>N</i> -cyclopropylcarbamate |  | 1.567 | 353.9 | C | 98 - 100 |
| 3.3 | [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl <i>N</i> -(2,2,2-trifluoroethyl)carbamate |  | 1.479 | (M+H) not observed | C | 84 - 86 |
| 3.4 | [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl <i>N</i> -methoxy- <i>N</i> -methylcarbamate |  | 1.567 | 353.9 | C | |

| Entry | Compound name | Structure | R _t (mins) | Mass charge (M+H) ⁺ | Method | mp (°C) |
|-------|---|--|--------------------------|--------------------------------------|--------|-------------|
| 3.5 | 1-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]ethyl <i>N,N</i> -dimethylcarbamate |  | 1.62 | (M+H) not observed | C | |
| 3.6 | [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl <i>N</i> -methyl- <i>N</i> -(2-pyridyl)carbamate |  | | | C | 110- 112 |
| 3.7 | [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl <i>N</i> -methylcarbamate |  | 1.493 | 301 | C | 100- 102 |
| 3.8 | [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl <i>N</i> -acetyl- <i>N</i> -methylcarbamate |  | 1.567 | 344 | C | |

| Entry | Compound name | Structure | R _t (mins) | Mass charge (M+H) ⁺ | Method | mp (°C) |
|-------|--|-----------|--------------------------|--------------------------------------|--------|------------|
| 3.9 | [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl morpholine-4-carboxylate | | 1.533 | M+H) not observed | C | 71 - 74 |
| 3.10 | [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl N-(4-chlorophenyl)carbamate | | 1.629 | 395.6 | C | |
| 3.11 | [4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methyl N-(2-chlorophenyl)carbamate | | 1.707 | 395.5 | C | |

Table T4: Melting point (mp) data and/or retention times (R_t) for the compounds of Formula (I):

| Entry | Compound name | Structure | R _t (mins) | Mass charge (M+H) ⁺ | Method | mp (°C) |
|-------|---|-----------|--------------------------|--------------------------------------|--------|------------|
| 4.1 | N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methoxy]propan-2-imine | | | | | 48 - 52 |

| Entry | Compound name | Structure | R _t (mins) | Mass charge (M+H) ⁺ | Method | mp (°C) |
|-------|--|---|--------------------------|--------------------------------------|--------|------------|
| 4.2 | (Z)-1-imidazol-1-yl-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methoxy]ethanimine |  | | | | 51 - 53 |
| 4.3 | (Z)-1-morpholino-N-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methoxy]ethanimine |  | Not observed | | | |
| 4.4 | 2,5-dimethyl-4-[[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]methoxyimino]pyrazol-3-one |  | | | | 110 - 111 |

BIOLOGICAL EXAMPLES:

General examples of leaf disk tests in well plates:

5

Leaf disks or leaf segments of various plant species are cut from plants grown in a greenhouse. The cut leaf disks or segments are placed in multiwell plates (24-well format) onto water agar. The leaf disks are sprayed with a test solution before (preventative) or after (curative) inoculation. Compounds to be tested are prepared as DMSO solutions (max. 10 mg/ml) which are diluted to the appropriate concentration with 0.025% Tween20 just before spraying. The inoculated leaf disks or segments are incubated under defined conditions (temperature, relative humidity, light, etc.) according to the respective test system. A single evaluation of disease level is carried out 3 to 14 days after inoculation, depending on the pathosystem. Percent disease control relative to the untreated check leaf disks or segments is then calculated.

15

General examples of liquid culture tests in well plates:

Mycelia fragments or conidia suspensions of a fungus prepared either freshly from liquid cultures of the fungus or from cryogenic storage, are directly mixed into nutrient broth. DMSO solutions of the

test compound (max. 10 mg/ml) are diluted with 0.025% Tween20 by a factor of 50 and 10 μ l of this solution is pipetted into a microtiter plate (96-well format). The nutrient broth containing the fungal spores/mycelia fragments is then added to give an end concentration of the tested compound. The test plates are incubated in the dark at 24°C and 96% relative humidity. The inhibition of fungal growth is determined photometrically after 2 to 7 days, depending on the pathosystem, and percent antifungal activity relative to the untreated check is calculated.

Example 1: Fungicidal activity against *Puccinia recondita* f. sp. *tritici* / wheat / leaf disc preventative (Brown rust)

10

Wheat leaf segments cv. Kanzler were placed on agar in multiwell plates (24-well format) and sprayed with the formulated test compound diluted in water. The leaf disks were inoculated with a spore suspension of the fungus 1 day after application. The inoculated leaf segments were incubated at 19°C and 75% relative humidity (rh) under a light regime of 12 hours light / 12 hours darkness in a climate cabinet and the activity of a compound was assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf segments (7 to 9 days after application).

The following compounds at 200 ppm in the applied formulation give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.

Compounds (from Table T1) 1.1, 1.2, 1.4, 1.5, 1.8, 1.9, 1.11, 1.13, 1.14, 1.17, 1.18, 1.19, 1.22, 1.23, and 1.26.

Compounds (from Table T2) 2.1.

Compounds (from Table T3) 3.1, 3.2, 3.3, and 3.5.

Compounds (from Table T4) 4.2 and 4.3.

Example 2: Fungicidal activity against *Puccinia recondita* f. sp. *tritici* / wheat / leaf disc curative (Brown rust)

30

Wheat leaf segments cv. Kanzler are placed on agar in multiwell plates (24-well format). The leaf segments are then inoculated with a spore suspension of the fungus. Plates were stored in darkness at 19°C and 75% relative humidity. The formulated test compound diluted in water was applied 1 day after inoculation. The leaf segments were incubated at 19°C and 75% relative humidity under a light regime of 12 hours light / 12 hours darkness in a climate cabinet and the activity of a compound was assessed as percent disease control compared to untreated when an appropriate level of disease damage appears in untreated check leaf segments (6 to 8 days after application).

The following compounds at 200 ppm in the applied formulation give at least 80% disease control in this test when compared to untreated control leaf disks under the same conditions, which show extensive disease development.

Compounds (from Table T1) 1.1, 1.2, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 1.10, 1.11, 1.13, 1.15, 1.17, 1.18, 1.19, 1.22, 1.23, and 1.26.

Compounds (from Table T3) 3.1, 3.2, 3.3, and 3.5.

Compounds (from Table T4) 4.1 and 4.2.

5

Example 3: Fungicidal activity against *Phakopsora pachyrhizi* / soybean / leaf disc preventative (Asian soybean rust)

Soybean leaf disks are placed on water agar in multiwell plates (24-well format) and sprayed
10 with the formulated test compound diluted in water. One day after application leaf discs are inoculated
by spraying a spore suspension on the lower leaf surface. After an incubation period in a climate
cabinet of 24-36 hours in darkness at 20°C and 75% rh leaf disc are kept at 20°C with 12 h light/day
and 75% rh. The activity of a compound is assessed as percent disease control compared to
untreated when an appropriate level of disease damage appears in untreated check leaf disks (12 to
15 14 days after application).

The following compounds at 200 ppm in the applied formulation give at least 80% disease
control in this test when compared to untreated control leaf disks under the same conditions, which
show extensive disease development.

20 Compounds (from Table T1) 1.1, 1.2, 1.3, 1.4, 1.5, 1.8, 1.11, 1.13, 1.16, 1.17, 1.18, 1.19, 1.22,
and 1.23.

Compounds (from Table T3) 3.1 and 3.2.

Compounds (from Table T4) 4.2 and 4.3.

25 Example 4: Fungicidal activity against *Glomerella lagenarium* (*Colletotrichum lagenarium*)
liquid culture / cucumber / preventative (Anthracnose)

Conidia of the fungus from cryogenic storage are directly mixed into nutrient broth (PDB -
potato dextrose broth). After placing a (DMSO) solution of test compound into a microtiter plate (96-
30 well format), the nutrient broth containing the fungal spores is added. The test plates are incubated at
24°C and the inhibition of growth is measured photometrically 3 to 4 days after application.

The following compounds at 20 ppm in the applied formulation give at least 80% disease
control in this test when compared to untreated control under the same conditions, which show
extensive disease development.

35

Compounds (from Table T1) 1.1, 1.2, 1.3, 1.4, 1.5, 1.8, 1.9, 1.11, 1.13, 1.14, 1.17, 1.18, 1.19,
1.20, 1.21, 1.22, 1.23, 1.24, 1.25, and 1.26.


Compounds (from Table T2) 2.1, 2.2, and 2.3.

Compounds (from Table T3) 3.1, 3.2, 3.3, 3.4, and 3.5.

40 Compounds (from Table T4) 4.2, 4.3, and 4.4.

CLAIMS:

1. A compound of formula (I):



- 5 wherein

A^1 represents N or CR^1 , wherein R^1 represents hydrogen, halogen, methyl, ethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, or difluoromethoxy;

- 10 A^2 represents N or CR^2 , wherein R^2 represents hydrogen, halogen, methyl, ethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, or difluoromethoxy;

A^3 represents N or CR^3 , wherein R^3 represents hydrogen or fluoro;

- 15 A^4 represents N or CR^4 , wherein R^4 represents hydrogen or fluoro; and

wherein no more than two of A^1 to A^4 are N;

- R^5 and R^6 are independently selected from hydrogen, halogen, cyano, methyl, ethyl, methoxy or
20 Ci-2haloalkyl; or

R^5 and R^6 together with the carbon atom to which they are attached form a C3-6cycloalkyl ring;

n is 1 or 2;

- 25

L^1 represents -O-, -C(O)O-, $-(R^8)NC(O)O-$ or $-(R^{10})C=N-O-$;

- R^7 represents C_1 -ealkyl, C_3 -ealkenyl, C_3 -ealkynyl, cyanoCi-ealkyl, C_1 -ehaloalkyl, C_3 -ehaloalkenyl, hydroxyCi-ealkyl, Ci-4alkoxyCi-6alkyl, Ci-4alkoxyCi-6alkoxy, Ci-2haloalkoxyCi-6alkyl or $-CH=N-O-C_1$ -
30 4alkyl; or

- R^7 represents C3-scycloalkyl wherein the cycloalkyl moiety is optionally partially unsaturated, phenyl, heteroaryl bonded to L^1 through a carbon atom wherein the heteroaryl moiety is a 5- or 6-membered monocyclic aromatic ring which comprises 1, 2, 3 or 4 heteroatoms individually selected
35 from N, O and S, heterocyclyl bonded to L^1 through a carbon atom wherein the heterocyclyl moiety is

a 4- to 6-membered non-aromatic ring which comprises 1, 2 or 3 heteroatoms individually selected from N, O and S, and wherein C₃-cycloalkyl, phenyl, heteroaryl, and heterocyclyl are optionally substituted by 1, 2, or 3 substituents, which may be the same or different, selected from R⁹;

5 or wherein when R⁷ represents C₃-cycloalkyl or heterocyclyl, the C₃-cycloalkyl moiety or the heterocyclyl moiety is optionally substituted by 1 or 2 oxo groups;

R⁸ represents hydrogen, Ci-4alkyl, Ci-4alkoxy or methylcarbonyl;

10 R⁹ represents cyano, halogen, hydroxy, Ci-4alkyl, Ci-4haloalkyl, Ci-4alkoxy, Ci-4haloalkoxy, Ci-4alkylcarbonyl, Ci-4alkoxycarbonyl, aminocarbonyl, dialkylaminocarbonyl, diCi-4alkylaminocarbonyl; and

R¹⁰ is C₁₋₄alkyl; or

15

when L¹ is -C(O)O- or -(R¹⁰)C=N-O-, R⁷ may be a heterocyclyl ring comprising a nitrogen atom, wherein the heterocyclyl is bonded to L¹ through the nitrogen atom, and wherein the heterocyclyl moiety is a 4- to 6-membered non-aromatic ring which optionally comprises an additional heteroatom selected from N, O or S, and wherein the heterocyclyl is optionally substituted by 1, 2, or 3
20 substituents, which may be the same or different, selected from R⁹; or

when L¹ is -(R¹⁰)C=N-O-, R⁷ may be a heteroaryl ring comprising a nitrogen atom, wherein the heteroaryl is bonded to L¹ through the nitrogen atom, and wherein the heteroaryl moiety is a 5- or 6-membered monocyclic aromatic ring which optionally comprises an additional 1 or 2 nitrogen atoms,
25 and wherein the heteroaryl is optionally substituted by 1, 2, or 3 substituents, which may be the same or different, selected from R⁹; or

when L¹ is -(R¹⁰)C=N-O-, R⁷ and R¹⁰, together with the carbon atom to which they are bonded, may form a 4-, 5- or 6-membered cycle, optionally partially unsaturated or fully unsaturated, and
30 optionally containing 1 or 2 nitrogen atoms, wherein the the cycle is optionally substituted by 1, 2, or 3 substituents, which may be the same or different, selected from R⁹ and may optionally further contain 1 group selected from C(O) or S(O)₂; or

a salt or an N-oxide thereof.

35

2. A compound according to claim 1, wherein A¹ represents N or CR¹, wherein R¹ is selected from hydrogen, halogen, or methyl.

3. A compound according to claim 1 or claim 2, wherein A² represents N or CR², wherein R² is
40 selected from hydrogen, halogen or methyl.

4. A compound according to any one of claims 1 to 3, wherein A¹, A², A³, and A⁴ are C-H.
5. A compound according to any one of claims 1 to 4, wherein R⁵ and R⁶ each independently represent hydrogen, methoxy or Ci-2haloalkyl.
- 5
6. A compound according to any one of claims 1 to 5, wherein R⁷ represents:
- (i) C₁-ealkyl or Ci-4haloalkyl; or
- (ii) C₃₋₆cycloalkyl, phenyl, heteroaryl, or heterocyclyl optionally substituted by 1, 2, or 3 substituents, which may be the same or different, selected from R⁹.
- 10
7. A compound according to any one of claims 1 to 6, wherein R⁷ represents methyl, ethyl, isopropyl, i-butyl, 2,2,2-trifluoroethyl, cyclopropyl, phenyl, pyridinyl, pyridazinyl, isoxazolyl, dihydroisoxazolyl, tetrazolyl, pyrazolyl, oxadiazolyl, or morpholinyl, wherein phenyl, pyridinyl, pyridazinyl, isoxazolyl, dihydroisoxazolyl, tetrazolyl, pyrazolyl, and oxadiazolyl are optionally substituted by 1, 2, or 3 substituents, which may be the same or different, selected from R⁹.
- 15
8. A compound according to any one of claims 1 to 7, wherein L¹ represents -O- or -C(O)O-.
- 20
9. A compound according to any one of claims 1 to 8, wherein R⁹ represents cyano, halogen, Ci-4alkyl, or Ci-4haloalkyl.
10. A compound according to any one of claims 1 to 9, wherein R⁹ represents cyano, fluoro, methyl, or trifluoromethyl.
- 25
11. A compound according to any one of claims 1 to 10, wherein n is 1.
12. An agrochemical composition comprising a fungicidally effective amount of a compound of formula (I) according to any one of claims 1 to 11.
- 30
13. The composition according to claim 12, further comprising at least one additional active ingredient and/or an agrochemically-acceptable diluent or carrier.
14. A method of controlling or preventing infestation of useful plants by phytopathogenic microorganisms, wherein a fungicidally effective amount of a compound of formula (I) according to any of claims 1 to 11, or a composition comprising this compound as active ingredient, is applied to the plants, to parts thereof or the locus thereof.
- 35
15. Use of a compound of formula (I) according to any one of claims 1 to 11 as a fungicide.
- 40

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/058839

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D413/12 C07D271/06
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal , CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|-----------------------|
| A | wo 2015/185485 AI (BASF SE [DE]) 10 December 2015 (2015-12-10) cited in the applicati on page 1, line 3 - line 9 page 1; compound I page 52 - page 55; tabl e I page 56; tabl e A page 56 - page 64; tabl e W page 64 - page 67 claims ----- | 1-15 |

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

| | |
|--|--|
| Date of the actual completion of the international search 12 May 2017 | Date of mailing of the international search report 24/05/2017 |
|--|--|

| | |
|--|--|
| Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016 | Authorized officer Hoepfner, Wolfgang |
|--|--|

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2017/058839

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|-------------------------|------------------|
| WO 2015185485 AI | 10-12-2015 | AU 2015270651 AI | 22-12-2016 |
| | | CA 2950084 AI | 10-12-2015 |
| | | CN 106455572 A | 22-02-2017 |
| | | EP 3151669 AI | 12-04-2017 |
| | | WO 2015185485 AI | 10-12-2015 |
| ----- | | | |